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The implementation of new biocatalytic processes can be a very challenging procedure, 
which can require several stages of screening, characterization and evaluation prior to 
scale-up. Indeed, several process parameters, with different weights on the final process 
costs, need to be considered side-by-side. Process design and economic evaluation 
represent a very important part of the early process development stage. However, often 
the parameters set at these initial stages are based on assumptions. Therefore, a 
laboratory scale characterization of the biocatalyst and different process options are 
important in order to eliminate infeasible routes. This work illustrates the laboratory 
scale characterization of different process options for the asymmetric synthesis of chiral 
amines catalysed by ω-transaminase (ω –TAm). The studied process options include: (i) 
the immobilization of the biocatalyst to improve its stability and allow recycling and easy 
separation; (ii) the use of controlled release of substrate (fed-batch) or in situ substrate 
supply – (ISSS) to decrease substrate inhibition and deal with the substrate low solubility; 
and (iii) the use of in situ product (ISPR) and co-product removal (IScPR) to respectively 
alleviate product inhibition and shift the reaction equilibrium.  
From an academic point of view, more important than the implementation of these 
technologies to a specific example, is the development of a general methodology that can 
be later applied in other cases. Hence, this work has also focused on development of 
comprehensive screening methodologies and guidelines to aid (i) the selection and 
characterization of suitable biocatalysts for the process; (ii) the selection and 
characterization of suitable carriers for immobilization of (S)- and (R)-selective ω-TAm; 
and (iii) the selection of suitable polymeric resins for product removal. The work has 
been performed in collaboration with c-LEcta GmbH (Leipzig, Germany) and DSM 
Innovative Synthesis (Geleen, The Netherlands) who supplied the enzymes for the case 
study, making possible the successful demonstration of the screening methodologies 
developed. Furthermore, the work addresses several practical questions regarding to the 
implementation of the process strategies mentioned above. 
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Implementeringen af nye biokatalytiske processer kan være en meget udfordrende 
procedure, hvor det kan være nødvendigt med flere omgange af screening, karakterisering 
og evaluering før opskalering. Faktisk er det nødvendigt sideløbende at overveje adskillige 
proces-parametre, der har forskellig indflydelse på de endelige omkostninger.  Procesdesign 
og økonomisk evaluering repræsenterer en meget vigtig del af de første udviklingstrin. 
Parametrene der er brugt på disse tidlige trin er dog ofte baseret på antagelser. Derfor er 
karakteriseringen af biokatalysatoren og forskellige procesløsninger på laboratorieskala 
vigtige for at være i stand til at eliminerer ikke levedygtige muligheder. Denne afhandling 
omhandler karakteriseringen af forskellige procesteknologier for den asymmetriske 
produktion af chirale aminer katalyseret af ω-transaminase på laboratorieskala. De 
undersøgte procesteknologier  inkluderer: (i) Immobiliseringen af biokatalysatoren for at 
forbedre dens stabilitet og for at  tillade genbrug og nem separation; (ii) Brugen af 
kontrolleret substrat frigivelse (fed-batch) eller in-situ substrat forsyning ( in-situ substate 
supply - ISSS) for at nedsætte substrat inhiberingen og håndterer den lave opløselighed af 
substratet; og (iii) Bortskaffelse af produkt og co-produkt in situ (in situ product og in situ 
co-product removal – ISPR og IScPR) for  at mindske produkt inhiberingen og forskyde 
reaktionsligevægten.  
Fra et akademisk synspunkt  er udviklingen af en generel metodik, der kan anvendes i mange 
tilfælde, vigtigere end implementeringen af teknologien i et specifik eksempel.  Som følge af 
dette synspunkt har arbejdet, der danner grundlag for denne afhandling, fokuseret på 
udviklingen af omfattende screeningsmetodikker og retningslinjer for at hjælpe  med (i) 
udvælgelsen og karakteriseringen af passende biokatalysator til processen; (ii) udvælgelse 
og karaktering af passende bærere til at immobiliserer (S) and (R) selektive ω-transaminase 
og (iii) udvælgelse af passende polymer resiner til produktbortskaffelse. Arbejdet har været 
udført i samarbejde med c-LEcta GmbH (Leipzig, Tyskland) og DSM innovative Syntesis 
(Geleen, Holland) som leverede enzymerne til case studiet, hvilke muliggjorte en succesfuld 
demonstrering af den udviklede screeningsmetodik. Derudover adresserer denne afhandling 
adskillelige praktiske spørgsmål angående implementeringen af ovenstående 
processtrategierne.
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Abbreviation Description 
α-KG Alpha-Ketoglutaric acid 
AAO Amino acid oxidase 
ACE Acetone 
ATP Adenosine triphosphate 
ALS Acetolactate synthase 
ButA 2-butyl amine 
YADH Yeast alcohol dehydrogenase 
ADXs Amine donor excess 
ALA Alanine 
APB 3-amino-1-phenylbutane 
APH Acetophenone 
BA Benzylacetone 
CAL-B  Candida antarctica lipase B 
CFE Cell-free extract 
CO2 Carbon dioxide 
D/A  Amine donor-amine acceptor ratio 
DCM Dichloromethane 
DHG  Dehydrogenase 
DKR  Dynamic kinetic resolution 
DMSO Dimethyl sulfoxide 
DSP Downstream processing 
E Pyridoxal form of ω-TAm 
ee Enantiomeric excess 
F Pyridoxamine form of ω-TAm 
GDH  glucose dehydrogenase 
GRAS  Generally Regarded As Safe 
GMOs Genetically modified microorganism 
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 ix 
Abbreviation Description 
HIC Hydrophobic interaction chromatography 
HPLC High-performance liquid chromatography 
Imm-CFE Immobilized cell free extract 
IPA Isopropylamine 
ISPR In situ product removal 
ISSS In situ substrate supply 
IScPR In situ co-product removal 
k-PBS Potassium phosphate buffer solution 
KR Kinetic resolution 
KsACE Substrate inhibition constant for ACE 
KsAPH Substrate inhibition constant for APH 
KsIPA Substrate inhibition constant for IPA 
LDH Lactose dehydrogenase 
MAN-N Monoamine Oxidase N 
MBA Methylbenzylamine 
NADH  Nicotinamide adenine dinucleotide 
NLR Non-linear regression 
pKa Acid dissociation constant 
SEM Scanning electron microscope 
TCl4 Titanium tetrachloride 
THF Tetrahydrofuran 
PLP Pyridoxal 5-phosphate 
PMP Pyridoxamine 5-phosphate 
PE Purified enzymes  
PYR Pyruvate/Pyruvic acid 
(R)- Rectus, Latin for right 
(S)- Sinister, Latin for left 
STR Stirred-tank reactor 
VOC Volatile organic compound 
WC Whole-cells 
ω-TAm  ω-Transaminase 
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Nomenclature                     Description Unit 
ΔG Variation of Gibbs free energy J.mol-1 
A0 enzyme’s initial activity or concentration  mmol.L-1.min-1 
A enzyme’s activity or concentration at time t  mmol.L-1.min-1 
[A] concentration of substrate A mmol.L-1 
Ccrit Critical concentration for the cell g.L-1; mol.L-1 
[I] concentration of inhibitor mmol.L-1 
k reaction rate constant min-1 
KA Dissociation constant for compound A mmol.L-1 
KB Dissociation constant for compound B mmol.L-1 
Keq Thermodynamic equilibrium constant No units 
Ki Inhibition constant mmol.L-1 
Km Michaelis–Menten constant mmol.L-1 
LogP Partition coefficient No units 
Mw Molecular weight g.mol-1 
pi* Vapour pressure of pure compound i mmHG 
pH Power of hydrogen No units 
pKa Acid dissociation constant No units 
Pvap Vapour pressure mmHG 
Saq Aqueous solubility g.L-1; mol.L-1 
T Temperature ˚C 
t Time min 
Tb Boiling temperature ˚C 
Tm Melting temperature ˚C 
v reaction rate mmol.L-1.min-1 
Vmax Maximum velocity mmol.L-1.min-1 
xil Molar fraction of compound i in liquid phase No units 
xivap Molar fraction of compound i in vapour phase No units 
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Optically active amines are highly valuable functionalized molecules with a wide range of 
applications. These include being (i) intermediates for the synthesis of pharmaceutical 
and agrochemical active ingredients (APIs), (ii) resolving agents for the separation of 
enantiomers via diastereomeric salt formation, and (iii) ligands for asymmetric synthesis 
using either transition metal catalysis or organocatalysis [1] . 
Chiral amines integrate the backbone of several APIs used in modern medicine for 
treatment of a vast range of diseases and conditions [2] such as pain relievers, obesity 
control, treatment of cancer and diabetes as well as tuberculosis (Table 1.1). Thus, the 
market for these compounds is vast and their need has historically increased in the past 
few decades [2]. Chiral compounds have been estimated in 2000 to have a 15% fraction 
of the €20 billion market (total revenues from sales of pharmaceutical and agrochemical 
industries) [3], and it can be expected that this number has increased since then. 
However, despite the historical increase in demand for these compounds, their synthesis 
remains challenging and several laboratories around the world have ongoing research 
projects targeted at their efficient preparation [2-4].  
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Table 1.1: Examples of active pharmaceutical ingredients containing a chiral amine in their structure. Adapted from [2]. i  
these can be direcly obtained using ω-TAm. 
 
   
   
   
 
 
Lopinavir  
(Abbot, HIV-protease inhbitor) 
 
Sitagliptin/Januviai 
(Merck, antihyperglycemic) 
 
Dextroamphetaminei 
(Generic, ADHD and 
narcolepsy) 
 
Ephedrine  
(Generic, Psychostimulant,  
appetite suppressant) 
 
AZD1480 (in clinical trial) 
(Astra Zeneca, leukemia treatment) 
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Chiral amines can be produced both by chemo- and bio-catalytic processes [2-4]. The 
option of preparing them using biocatalytic approaches has gained much attention from 
both industry and academia as a result of recent developments in biocatalyst availability, 
methods for improving biocatalyst stability, and the potentially high selectivity and 
catalytic activity that can be obtained through enzyme catalysis [1, 5]. These methods will 
briefly be reviewed in the following sections.  
1.1.1. Chemo-catalytic processes  
 Crystallization with chiral carboxylic acids  
One of the most conventional and widely used strategies consists of the crystallization of 
diastomeric salts of chiral carboxylic acids with chiral amines as depicted in Figure 1.1 
[3]. This allows the isolation of (S) or (R) chiral amines as well as (S) or (R) carboxylic 
acids on an industrial scale [3]. For instance, (S)- or (R)-methylbenzylamine (MBA) can 
be obtained by crystallization either with (S)-malic acid or (R)-mandelic acid or even with 
(R, R)-tartaric acid.  [3]. The main drawbacks are associated with the screening and/or 
selection of suitable resolving agents (carboxylic acid) for the amine, which can be a time 
consuming procedure, and the limited 50% of maximum yield that is possible to achieve.  
 
  
Figure 1.1: Racemate resolution through fraction crystallization of salts of racemic amines and enantiomerically pure 
carboxylic acids. Adapted from [3]. 
A prominent approach, commonly denoted as “Dutch resolution” or “The family 
approach” (developed by researchers at DSM and Syncom BV) [6], attempted to shorten 
the screening procedure for selection of a suitable resolving agent by implementing a 
combinatorial approach of a mixture of several optically active acids. This results in 
immediate precipitation of the amine in nearly pure enantiomeric form, avoiding the 
need for a screening for a suitable chiral carboxylic acid. This has allowed establishment 
of standard mixtures for resolution of amines and carboxylic acids [3]. 
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 Reduction of C=N bonds 
Another option to chemically access chiral amines is through the reduction of a C=N 
double bond from a prochiral precursor, and the subsequent cleavage of the auxiliary 
group (X) to form the chiral amine (Figure 1.2). The major challenges related with this 
approach are the preparation of the prochiral imine precursor itself and the consecutive 
cleavage of the auxiliary group to give the free amine, as reviewed in several articles [2, 
3, 7]. Also the screening effort for selection of a reducing agents and the use of precious 
metals (which increases the catalysts cost) are important disadvantages. 
 
Figure 1.2: Prochiral precursor with a C=N double bond for the enantioselective synthesis of amines (X= aryl, alkyl, OR, NHR, 
PR2). Adapted from [3]. 
1.1.2. Bio-catalytic processes 
A promising and much acclaimed approach to prepare chiral amines makes use of 
biocatalysis to selectively yield the enantiopure amine from a wide range of precursors 
[1]. Biocatalytic processes have developed as an environmentally benign alternative to 
chemo-catalaytic methods, because the bio-catalytic process usually operates under mild 
conditions and avoids the need for highly flammable metal-organic reagents or heavy 
metal contamination [8].  
Several biocatalytic routes can be employed for the synthesis of optically active amines 
as depicted in Figure 1.3. Some of these options employ existing and well described 
technologies such as the (i) kinetic resolution (KR) of racemic amines (using for instance 
hydrolases); (ii) dynamic kinetic resolution (DKR) of racemic mixtures using hydrolases, 
oxidases or transaminases; and (iii) asymmetric synthesis using transaminases [1, 4, 5]. 
In addition, emerging technologies such as the asymmetric reduction of imines using 
imine reductases or the use of decarboxylases to cleave carboxylic groups are being 
considered as attractive options [1]. These technologies will briefly be reviewed in the 
following sections.  
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Figure 1.3: Biocatalytic approaches for the synthesis of chiral amines. Adapted from [1]. 
 
 (Dynamic) kinetic resolution of racemic amines  
Enzymatic kinetic resolution (KR) is the term used to refer to differentiation of two 
enantiomers in a racemic mixture using a biocatalyst. The two enantiomers react with 
different reaction rates in a chemical reaction with a chiral (bio)catalyst or reagent, 
resulting in an optically enriched sample of the less reactive enantiomer [9]. The classical 
kinetic resolution approach has a maximum theoretical yield of 50%. This is however, 
overcome if a racemization step is included to return the undesired product to its racemic 
initial form, in an approach designated as dynamic kinetic resolution (DKR). Several 
enzymes can be used for deracemization of racemic mixtures, as will be briefly reviewed 
in the following sections. 
1.1.2.1.1. Hydrolytic enzymes 
Hydrolytic enzymes have recently received attention for their possible application in 
resolution of racemic amines [10, 11]. Most of the reported examples are run under low 
water conditions, with Candida antarctica lipase B (CAL-B) (EC 3.1.1.3) as the most 
commonly employed hydrolase, as depicted in Figure 1.4 [1].  
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Figure 1.4: Hydrolysis of racemic N-1-phenylethylacetamide using lipase. Adapted [1] 
This process is implemented at industrial scale for instance at BASF AG (Germany) for 
production of optically pure aliphatic amines, benzylic amines and amino alcohols [12]. 
Although the process is highly optimized and performed at multiton scale for a variety of 
amines, the yield of this kinetic resolution is limited to less than 50% [4]. As an alternative 
to overcome this limitation, a racemization step can be included to convert the chiral N-
1-phenylethylacetamide back to its racemic form, allowing the hydrolysis to proceed. 
This strategy, depicted in Figure 1.5 is known as DKR. By including a racemization step, 
the theoretical yield could potentially reach 100%. However, it has been reported that 
often very harsh conditions involving metal-organic reagents are required in order to 
enable the racemization of the amines [13] as well as a large number of cycles, and yet it 
does not guarantee 100% yield. 
 
 
Figure 1.5: Hydrolysis of racemic N-1-phenylethylacetamide using lipase. Adapted from [1, 4] 
For instance, the first DKR of amines employing CAL-B and palladium on charcoal as a 
racemization catalyst, was reported to yield 64% (R)-N-(1-phenylethyl)acetamide after 
eight days [14].  
1.1.2.1.2. Amine oxidases  
Another biocatalytic route to chiral amines employs the use of monoamine oxidase N 
(MAO-N) (EC 1.4.3.4). The method, as shown in Figure 1.6, was developed by Turner et 
al. [1, 4, 15]. In this catalytic cycle, (MAO-N) from Aspergillus niger catalyzes 
enantioselective oxidation of one enantiomer of a racemic amine to the corresponding 
Lipase 
Racemization catalyst 
Lipase 
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imine. Rather than allow the imine to simply hydrolyze to the corresponding ketone, a 
chemical reducing agent (e.g., ammonia borane) is added to the reaction resulting in in 
situ reduction of the imine back to the racemic amine that then undergoes another round 
of enantioselective oxidation to the imine. Provided that the enzyme is highly 
enantioselective, eventually complete deracemization of the racemate occurs yielding 
one enantiomer of the amine in high yield and 100% theoretical ee after repeated cycles 
[1, 4, 15].  
This method allows both reactions to take place in one-pot which brings advantages in 
terms of reaction design. Furthermore, Turner and co-workers improved the enzyme 
performance by directed evolution, obtaining a MAO-N with 50-fold higher activity [16, 
17].  However, the major challenges seem to be the identification or creation of an (R)-
selective MAO to allow access to the (S)-enantiomer of the amine and also the limited 
range of substrate for (S)- and (R)- selective MAO [4]. 
 
Figure 1.6: Deracemization of racemic amines by repeated cycles of enzyme-catalysed enantioselective oxidation followed 
by nonselective chemical reduction. Adapted from [1, 4] 
1.1.2.1.3. Transaminases  
The past years have been marked by an increased prevalence of biocatalytic 
transamination reactions for the synthesis of chiral amines from prochiral ketones, as a 
result of the increased availability of transaminase enzymes (also named 
aminotransferases, EC 2.6.1.18). ω-Transaminases (ω –TAm) can be applied to kinetic 
resolution and deracemisation [18] as depicted in Figure 1.7, but also in the asymmetric 
synthesis of chiral amines, as will be discussed later.  
23
Chapter 1 – Thesis Introduction
 
8 
 
Figure 1.7: Kinetic resolution of racemic amines using transaminases (PLP= pyridoxal-5'-phosphate, PMP= Pyridoxamine 5-
phosphate). Adapted from [1, 4] 
ω-TAm were identified more than 50 years ago [19, 20], but only in the late 1990s they 
have been employed as an alternative methodology for enzymatic kinetic resolution of 
racemic mixtures [5].  The first significant advances for organic synthesis were achieved 
by Celgene Corporation (USA) [21, 22] which employed ω-TAm for the enantioselective 
preparation of chiral amines, via kinetic resolution of racemic amines. This process has 
been used on a 2.5 m3 scale and has been demonstrated on several different aliphatic and 
aromatic amines.  The main advantage of employing ω-TAm is that the reaction is highly 
enantioselective and several recombinant enzymes are readily available, most of them 
showing (S)-selectivity [5]. The lack of (R)-selective enzymes is however one of the major 
disadvantages. Furthermore, this approach is often associated with relatively low 
product concentrations attainable in an all-aqueous reaction system with hydrophobic 
compounds (since the starting pro-chiral ketone substrate often shows low solubility in 
water). Another disadvantage is the significant inhibition of the ω-TAm caused both by 
the amine products and the ketone substrates [1, 5, 22, 23]. Nevertheless, the use of ω-
TAm remains a very attractive approach to access chiral amines.  The main contribution 
for making ω-TAm so attractive for industrial application, despite these bottlenecks, is 
the possibility of using low-cost amine donor compounds, in conjunction with the pro-
chiral ketone of interest. In particular, the broad substrate specificity [24] and the 
increasing availability of (R)-specific ω-TAm are further enabling factors.  
ω-TAm 
PLP 
PMP 
ω-TAm 
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 Asymmetric synthesis 
 In the asymmetric synthesis, enzymes are used to yield exclusively the enantiomer of 
interest with a theoretical yield of 100%. Chiral amines have been reported to be 
obtained asymmetrically, using amine dehydrogenase (DHG) and more attractively, using   
ω-TAm. [1, 4]. These two technologies are relatively well known in the scientific 
community. Two less explored options to asymmetrically access chiral amines are the use 
of ketimine reductase to carry out the asymmetric reduction of prochiral imines and the 
use of decarboxylases to remove the carboxylic group from amino acids, yielding amines. 
These technologies will briefly be described in the following sections.  
1.1.2.2.1. Ketimine reductase  
The reduction of ketimines, as depicted in Figure 1.8, to access enantiomerically pure 
amines employing ketimine reductases (EC 1.5.1.25) has been rarely investigated, when 
compared to various chemical methods [1]. Vaijayanthi and Chadha reported that 
ketimines formed by the condensation of benzylamine with substituted acetophenone 
derivatives could selectively be reduced by applying Candida parapsilosis whole cells 
[25]. The authors reported yields of 55–80 % for the R-enantiomer, with high 
enantiomeric purities (95–99% ee). At the time of this study (2008), the enzyme was 
neither overexpressed nor purified and further investigations were thus required to 
render this approach versatile for organic synthesis. Nevertheless, the enzymatic 
asymmetric reduction of imines represents a potentially attractive route to chiral amines 
which certainly enriches the list of available technologies. 
 
 
Figure 1.8 Asymmetric reduction of imines. Adapted from [1, 4] 
 
  
25
Chapter 1 – Thesis Introduction 
 
10 
1.1.2.2.2. Decarboxylase 
Another emerging possibility makes use of decarboxylases (EC 1.4.4.X) to remove the 
carboxylic groups from amino-acids. This have been developed by researchers at the 
University of Graz, in collaboration with scientists from DSM, for the synthesis of β-amino 
alcohols using two different enzymes in one pot (Figure 1.9). For example, a threonine 
aldolase-catalysed reaction was initially used to prepare an intermediate from glycine 
and benzaldehyde. The intermediate was then converted to an (R)-amino alcohol in high 
ee by an irreversible decarboxylation catalysed by L-tyrosine decarboxylase [26]. 
 
Figure 1.9: Combined use of threonine aldolase and L-tyrosine decarboxylase. Adapted from [1]. 
 
1.1.2.2.3. Amine dehydrogenase (DHG) 
Similarly to MAO-N, DHG (EC 1.4.99.3) are able to oxidize amines into ketones and 
ammonia (Figure 1.10). This process requires the use of other redox cofactors such as 
copper proteins or artificial redox mediators to act as electron acceptors [27]. The main 
disadvantages of this process (limiting its application), is the fact that NADH-dependent 
enzymes cannot be widely employed. This would allow an efficient cofactor recycling by 
using formate and formate DGH, for example [4]. This is due to the fact that most NADH-
dependent enzymes exclusively convert α-ketoacids with the exception of one amine-
DHG recently isolated from Streptomyces virginiae which was reported to accept NADH 
as cofactor [28]. The authors reported that the enzyme was able to convert a wide range 
of substrates such as amino-alcohols, aliphatic amines, benzylic amines (although only 
MBA was reported) and α-amino acids. Unfortunately, the enzyme also showed very poor 
enantioselectivity. 
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Figure 1.10: Asymmetric synthesis using amine dehydrogenase. Adapted from [4] 
1.1.2.2.4. Transaminase  
In turn, the use of ω-TAm eliminates the cofactor regeneration issues. The enzyme 
requires pyridoxal 5-phosphate (PLP) as cofactor for the transfer of the amino group. 
During the transamination, PLP alternates between its aldehyde form (PLP) and amino 
form pyridoxamine 5-phosphate (PMP) [29] as depicted in Figure 1.7 and Figure 1.11.  
 
Figure 1.11: Asymmetric synthesis of chiral amines using transaminases. (PLP= pyridoxal-5'-phosphate; PMP= Pyridoxamine 
5-phosphate). Adapted from [1, 4] 
Briefly, the PLP dependent enzymes are reported to exist in their resting state as a Schiﬀ 
base with the PLP bond with the active site lysine, forming an internal aldimine. The 
incoming, amine-containing substrate (the amine donor) displaces the lysine ε-amino 
group from the internal aldimine, and in the process the cofactor forms a new aldimine 
with the substrate, which is referred to as external aldimine [29], as depicted in Figure 
1.12. After this step the mechanism proceeds in several different ways, depending on the 
enzyme employed.  
ω-TAm 
PLP 
Amine 
donor 
Amine 
acceptor 
PMP 
ω-TAm 
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Figure 1.12: Scheme of reactions enabled by PLP. The first step of all PLP dependent reactions is the formation of an 
aldimine intermediate with the amine-containing substrate. Thereafter, the reactions diverge. Adapted from [29] 
 
Although the asymmetric synthesis approach using ω-TAm theoretically allows a 100% 
yield of the desired optically pure product, it has been favoured less in comparison with 
the kinetic resolution options in past years because of the difficulties concerning reaction 
equilibrium and stereoselectivity and also due to intellectual property restrictions. The 
challenge in asymmetric syntheses that employ ω-TAm is to shift the equilibrium to the 
product side, especially when using an amino acid like alanine. In this case, the 
equilibrium is on the side of the substrates (ketone and alanine) and not on the side of 
the products (amine and pyruvate) [5]. Also inhibition by substrate and product, as 
mentioned will be discussed further in the following sections, has a strong contribution 
limiting its wide application at industrial scale for asymmetric synthesis today. 
Table 1.2 summarizes the most important published examples of asymmetric synthesis 
of chiral amines using ω-TAm, where it can be seen that, with exception for cases where 
cascade reactions (using isolated enzymes) or large excess of amine donor (high D/A 
ratio) are used, the yields achieved are far from 100%.  Furthermore, in most of these 
studies, the initial substrate concentration was beneath the solubility limit, which in turn 
yields low product concentrations, with a few exceptions [30, 31].  
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Transaminases, in general, are highly versatile for the synthesis of optically active amines 
or α-amino acids [42]. While α-TAm require the presence of a carboxylic group in the α 
position to the keto or amine functionality, and hence only allow formation of α-amino 
acids, ω-TAm are much more useful as they, in principle, accept any ketone or amine [4].  
The mechanism is however the same for both α- and ω-TAm. They operate by 
transferring an amine group from a donor substrate to an acceptor compound utilizing 
the cofactor pyridoxal-5'-phosphate (PLP) [32]. This can be performed either as kinetic 
resolution of racemic amines (as depicted in Figure 1.7) or as asymmetric synthesis 
starting from a prostereogenic ketone (Figure 1.11).  
The enzyme is known to follow the Ping-Pong Bi Bi mechanism [43], where the first 
product (the keto-product, P) is released before the second substrate (the prochiral 
ketone/amine acceptor, B) binds to the enzyme, as depicted in Figure 1.13.  
 
Figure 1.13 – Ping pong Bi Bi mechanism. Adapted from [43, 44] 
This is common for all transaminases and for both kinetic resolution or asymmetric 
synthesis [43]. Interestingly, by employing the same ω-TAm in a kinetic resolution or in 
an asymmetric synthesis, amines with opposite absolute configurations are accessible; 
for example, if the ω-TAm leads to the (S)-enantiomer product during asymmetric 
synthesis, the (R)-enantiomer can be obtained in the kinetic resolution [5]. 
While the use of ω-TAm to access chiral amines is very attractive to industry, the 
limitations inherent with the whole process development, makes it very challenging.  
These include strong inhibition caused by substrates and products, potential 
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unfavourable thermodynamic equilibrium in the direction of interest and low water 
solubility of the ketone substrates [32]. Hence, several factors need to be considered and 
several strategies need to be applied in order to obtain high product concentrations 
(gProduct/L).  
Protein engineering tools such as directed evolution and/or rational design, have the 
potential to enable wild-type enzymes to be used outside their natural environment 
(where the substrate concentrations and reaction rates are low), as demonstrated by 
several authors [31, 45-47]. On the other hand, process engineering tools can help to 
overcome some of the limitations that protein engineering cannot, e.g. the unfavourable 
thermodynamic equilibrium, as mentioned before. It is thus evident that the two 
technologies can be used in a smart manner, allowing high productivity to be achieved by 
balancing the contribution of each.   Table 1.3 summarizes the different methodologies 
that can be used to improve biocatalytic process.  These include process, reactor, reaction 
and biocatalyst engineering. For simplicity, the term “process engineering” is used 
throughout this thesis to refer to any manipulation in the process which does not cause 
alteration to the biocatalyst, hence, this includes for instance: reaction and reactor 
engineering strategies. These will be further developed in Chapter 5. 
Driven by the attractiveness of accessing chiral amines using ω-TAm, several research 
works (as shown in Table 1.2) have been carried out aiming at understanding and 
overcoming the various bottlenecks limiting the industrial implementation of ω-TAm 
catalysed reactions. While some of these works have focused on the enzyme discovery 
and/or development (biocatalyst engineering), others have focused on process 
engineering strategies to overcome the above mentioned disadvantages [1, 32]. The 
latter, is of particular interest since it has the potential to overcome several limitations 
without altering the enzyme structure, hence avoiding the need to change multiple amino 
acids in the protein and screening among various mutants for the different features which 
can be a very labour (and cost) intensive task [48, 49]. Furthermore, limitations such as 
unfavourable equilibrium or low solubility of the substrates cannot be directly solved by 
protein engineering strategies, hence the solution, at least to some extent, relies on 
process engineering strategies. It is however important, to mention that protein 
engineering can be used to indirectly solve the equilibrium related issues. 
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For instance, the enzyme can be engineered to operate at a higher temperature which 
would influence the thermodynamic equilibrium. 
 Table 1.3 Description of potential methodologies, tools and the respective technologies for use in biocatalysis 
 
  
Eng. Methodologies Options (tools) Example of Technologies 
Process Engineering 
In situ product removal (ISPR) 
- Resins 
- Solvents 
- Membrane 
- Distillation 
In situ substrate supply (ISSS) - Resins - Solvents 
In situ co-product removal 
(IScPR) 
- Resins 
- Solvents 
- Membrane 
- Distillation/evaporation 
- Enzymatic cascade 
Immobilization 
- Binding to carrier 
- Crosslinking 
- Encapsulation 
Biocatalyst formulation 
- Whole-cell (WC) 
- Cell-free extract (CFE) 
- Purified enzymes (PE) 
- Immobilized biocatalyst 
Reactor Engineering 
Selection of operating mode 
- Batch 
- Fed-batch 
- Continuous 
Hydrodynamic - STR - Plug-flow 
Optimization of stirring speed - Optim. of stirring speed 
Reaction Engineering Optimization  reaction  condition 
- Optim. pH, T and P 
- Optim. of [Biocatalyst] 
- Stoichiometry/Molar ratio 
- Substrate selection 
- Co-solvent  
Biocatalyst Engineering 
Protein improvement - Rational design - Directed evolution 
Optimization of expression 
- Enhance expression level 
- Co-expression of enzymes 
- Host selection 
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This strategy has been explored and demonstrated, for instance, by Shin and Kim who 
developed various methods aimed at increasing the product concentrations of ω-TAm 
catalysed amine resolutions, through the continuous removal of product ketone from the 
reaction using an aqueous/organic two-phase system. This was applied to the resolution 
of racemic MBA and was found to yield superior product concentration than those 
obtained in an single aqueous-phase system [50, 51]. However, a drawback of the 
biphasic system was found to be the increased enzyme deactivation rate compared to the 
aqueous-only system due to the aqueous/organic interface, which is expected if the 
enzyme is not developed to operate at such conditions. Another reported disadvantage 
was the significant inhibition of the ω-TAm by the amine acceptor substrate (pyruvate) 
used [18], suggesting the need for further strategies to fully enable the reaction potential. 
These bottlenecks, as mentioned before, are well known to affect this enzyme when used 
in both kinetic resolution and asymmetric synthesis at process condition [32]. This 
suggests the need for further work in the field to help understanding the potential of the 
different methodology in the process development for ω-TAm catalysed reactions. 
This thesis was motivated by the lack of a work where these different methodologies 
were considered in parallel. Focusing mainly on Process and Protein engineering 
methodologies and the integration of the two, using ω-TAm as case study, this work aims 
at bringing up the discussion on the role of process and protein engineering in the 
biocatalysis. In 2011, we published a review summarizing the state of the art of ω-TAm 
catalysed reactions where this discussion was initiated [32]. This thesis aims at becoming 
an experimental extension of that work, focusing on the early process development 
stages where various screenings and characterizations at lab scale are required in order 
to both gather information regarding the reaction parameters (e.g. biocatalyst data, 
reaction conditions and separation options) and to eliminate infeasible process options.  
In summary, it is part of the objective of this thesis to support the process development 
for ω-TAm catalysed as well as other similar biocatalytic processes which can also benefit 
from this work. 
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In this thesis, 4 main reaction systems are used to characterize the process at the different 
stages. These include two amine donors (Isopropylamine - IPA and Alanine -ALA) and 
two prochiral ketones/amine acceptors (Acetophenone-APH and Benzylacetone-BA), 
yielding Methylbenzylamine (MBA) and 3-amino-1-phenyl butane (APB), as depicted in 
Figure 1.14. Throughout the experimental work in this thesis at least one of these 
reactions systems will be used. These systems were selected because they deal with non-
toxic and inexpensive compounds and these compounds’ properties fairly represent the 
main challenges faced in the asymmetric synthesis of chiral amines catalysed by ω-TAm 
(low solubility, potentially unfavourable thermodynamic equilibrium and enzyme 
inhibition) [32]. Furthermore, the similarity in properties between the substrates and 
products (which is very common in transamination) brings several challenges to 
downstream processing (which is also represented by the choice of these reaction 
systems). Two different amine donors were selected to demonstrate their importance to 
process. The choice of amine donor affects not only the thermodynamic equilibrium but 
also enables different product removal and DSP options, since different co-products are 
formed depending on the donor.  
For instance, the use of IPA as amine donor is often reported, mostly due to its low cost 
[32]. In this case acetone (ACE) is formed as the co-product, which can potentially be 
evaporated by stripping using an inert gas such as nitrogen [52] allowing, in principle at 
least, an equilibrium shift as will be discussed later. 
On the other hand, the use of ALA as the amine donor opens the possibility of carrying 
out cascade reactions to remove the formed pyruvate co-product [30], which is a great 
advantage since the thermodynamic equilibrium for reactions featuring ALA as amine 
donor are very low in comparison to those featuring IPA (for example: Keq for synthesis 
of MBA is 4.03E-05 and 3.33E-02 for ALA and IPA as amine donors, respectively [53]).  
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Figure 1.14 Overview of the model reactions catalysed by ω-TAm. APH – Acetophenone, BA – Benzylacetone, IPA – 
Isopropylamine, ALA – Alanine, MBA – Methylbenzylamine, APB – 3-amino-1-phenyl butane. Keq. obtained from [53] 
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This thesis aims at developing strategies to improve the production process of chiral amines 
through the asymmetric synthesis using ω-TAm. The thesis identifies the main challenges 
inherent with different stages of the process development and gives a theoretical as well as 
experimental overview of the possible solutions for the different challenges as well as their 
limitations. Process engineering strategies such as in situ product and co-product removal 
(ISPR and IScPR) were used to overcome the product inhibition and unfavourable 
thermodynamic equilibrium limitations.  
Several screening methodologies were developed and implemented with the objective of 
aiding the selection of: i) a suitable biocatalyst for the process; ii) a suitable carrier for 
enzyme immobilization; and iii) a suitable support for product removal. The work follows a 
comprehensive approach throughout these screening methodologies, defining several 
criteria that can potentially be used at the different stages.  
In summary, the goals established for this thesis were: 
 to overview the integration of process engineering strategies in biocatalysis; 
 to integrate these with protein engineering and identify the role of each of these two 
technologies as well as their limitations;  
 to establish guidelines and develop screening methodologies to aid the selection of a 
suitable biocatalyst to be used in process; 
 to overview the different biocatalyst formulations that can be used in biocatalysis 
and study their influence in the process; 
 to overview the main bottleneck affecting the development of biocatalytic processes; 
 study the influence of these on the process (e.g. the influence of (i) amine donor, (ii) 
catalyst formulation on the inhibition);  
 to review the downstream processing challenges and the different options, and; 
 to overview and implement strategies to improve yield of the asymmetric production 
of chiral amines.  
 to summarize in one work the all the important considerations for the entire 
biocatalytic process development for the asymmetric synthesis of chiral amines. 
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This thesis is divided in seven main chapters, four of them being theoretical and serving 
as introduction and conclusion for the experimental chapters. In that regard, the 
chapter’s title and content are as follows: 
Chapter 1: Thesis introduction  
x Introduction to chiral amines and ω-transaminase; 
x Definition of model reactions systems used in the thesis; 
x Identification of the challenges and research motivation; 
x Identification of the thesis goals. 
Chapter 2: Biocatalyst considerations  
x Overview of the challenges inherent with biocatalysis in general and ω-TAm 
catalysed reactions in particular; 
x Overview of the potential of protein and process engineering tools and the 
integration of both; 
x Overview of the different biocatalyst formulations. 
Chapter 3: Screening and characterization of biocatalyst  
x Development of screening methodology for selection and characterization of ω-
TAm enzymes based on the inhibition and stability profile of the enzymes; 
x Study of the influence of the catalyst formulation on inhibition; 
x Study of the influence of the amine donor choice on inhibition; 
Chapter 4: Immobilization of ω-TAm  
x Development of screening methodology for immobilization carriers; 
x Characterization of free and immobilized ω-Tam; 
x Economical evaluation of immobilization. 
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Chapter 5: Process considerations  
x Overview of the main challenges affecting the ω-TAm catalysed reactions: 
unfavourable thermodynamic equilibrium, substrate and product inhibition; 
x Overview of the process engineering tools used to overcome these limitations; 
x Overview of the challenges inherent with downstream processing. 
Chapter 6: Implementation of process engineering strategies 
x Overview of the different technologies used as auxiliary phase (polymeric resins 
and organic solvents); 
x Screening of auxiliary phase (polymeric resins) for in situ product removal;  
x Development of rapid screening mythology for process strategies at  small scale; 
x Implementation of process engineering tools to attain high product concentration.  
Chapter 7: Conclusions and future perspectives  
 Concluding remarks and future perspective.
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This project was greatly enriched by feedback obtained at different conferences and 
seminars attended and also the collaborations established. All these events resulted in 
important contributions for the conclusion of this work. The list of the most relevant 
contributions follows, divided in journals papers, oral presentations and poster 
presentations. 
1.6.1. Journal papers 
The following submitted publications have resulted from work presented in this thesis. 
Parts or these have been reproduced in Chapters 2 and 5. Copy of these publications are 
presented in the Appendixes 1A, B and C. References to more recent studies were 
included when suitable. 
Tufvesson, P., Lima-Ramos J., Jensen J. S., Al-Haque N., Neto, W., Woodley, M. J. (2011). 
Process considerations for the asymmetric synthesis of chiral amines using 
transaminases. Biotechnology and Bioengineering. 108 (7), 1479-1493. 
Cárdenas-Fernández, M., Neto, W., López, C., Álvaro, G., Tufvesson, P., Woodley, J. M. 
(2012) Immobilization of Escherichia coli containing ω-transaminase activity in 
LentiKats®; Biotechnology Progress. 28 (3), 693-698. 
Al-Haque, N., Santacoloma, P. A., Neto, W., Tufvesson, P., Gani, R., Woodley, J. M. (2012) A 
Robust Methodology for Kinetic Model Parameter Estimation for Biocatalytic Reactions. 
Biotechnology Progress. 28(5), 1186-1196 
1.6.2. Conference oral presentations 
Neto, W., Al-Haque, N., Tufvesson, P. and Woodley, J. M., “Integrated downstream 
processing for biocatalytic reactions.” Presented at BIOTRAINS biannual scientific 
meeting, December 2010. Basel, Switzerland. 
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Neto, W., Tufvesson, P. and Woodley, J. M., “Strategies for integrated product removal 
applied to production of chiral amines.” Presented at Frontiers in White Biotechnology, 
June 2011. Delft, The Netherlands 
Neto, W., Al-Haque, N., Tufvesson, P. and Woodley, J. M., “Process considerations when 
implementing two-liquid phase biocatalytic reactions.” Presented at BIOTRAINS biannual 
scientific meeting. February 2012, York, United Kingdom  
Neto, W., Anderssen, M., Schwarze, D., Tufvesson, P., Vogel, A. and Woodley, J. M. “Process 
considerations for ω-transaminase: Towards integrating process and protein engineering.” 
Presented at ANQUE ICCE 2012. June 2012, Seville, Spain 
Neto, W., Tufvesson, P. and Woodley, J. M. “Process considerations for ω-transaminase” 
Presented at BIOTRAINS biannual scientific meeting. September 2012, Copenhagen, 
Denmark  
1.6.3. Conference poster presentations 
Neto, W., Al-Haque, N., Tufvesson, P., Woodley, J. M. “Study of the inhibitory effect present 
in the ω-Transaminase catalysed processes.” Presented at EFB BEC 2010, September 2010, 
Brac, Croatia. 
Neto, W., Al-Haque, N., Tufvesson, P., Woodley, J. M. “Evaluation of the inhibitory effect 
present in the ω-Transaminase catalysed processes – The importance of in situ product 
removal.” Presented at ESOF 2010, July 2010. Torino, Italy. 
Neto, W., Al-Haque, N., Tufvesson, P., Woodley, J. M. “Evaluation of the inhibitory effect 
present in the Transaminase catalysed processes – The importance of in situ product 
removal.” Presented at biannual scientific meeting, December 2010. Basel, Switzerland. 
Neto, W., Tufvesson, P., Woodley, J. M. “Strategies for integrated product removal applied 
to production of chiral amines.” Presented at CAPEC-PROCESS Annual Meeting, June 2011, 
Borupgaard, Denmark. 
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Neto, W., Tufvesson, P., Woodley, J. M. “Strategies for integrated product removal applied 
to production of chiral amines”. Frontiers in White Biotechnology. June 2011, Delft, The 
Netherlands 
Neto, W., Tufvesson, P., Woodley, J. M. “Polymeric resins as strategy for Removal of Chiral 
amines, Produced using omega-Transaminase.” Presented at BIOTRANS 2011, October 
2011. Sicily, Italy. 
Neto, W., Pirrung, S., Tufvesson, P., Woodley, J. M. “Process strategies for implementing ω-
transaminase catalysed reactions.”; Presented at 1st International Symposium on 
Transaminase Biocatalysis. Feb 2013, Stockholm, Sweden. 
Neto, W, Schwarze, D., Vogel, A., Panella, L., Schürmann, M., Tufvesson, P. Woodley, J. M.  
“Process strategies for implementing ω-transaminase catalysed reactions.” Presented at 
BIOTRANS 2013, July, Manchester, United Kingdom. 
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In this chapter, a brief overview of the most important considerations regarding the 
biocatalyst are discussed.  The chapter serves as the introduction to Chapter 3, where the 
screening and characterization of a suitable biocatalyst will be carried out following a 
methodology developed for that purpose. Hence, this chapter overviews the main 
challenges associated with biocatalysis in general and ω-TAm catalysed reactions in 
particular.  These challenges include for instance the stability issues faced by many 
enzymes and the inhibition caused by substrates and/or product, which as mentioned 
before, greatly affects the ω-TAm catalysed reactions. In addition, the role of both protein 
and process engineering to address these issues is discussed. 
The chapter gives an overview of the most important considerations regarding to the 
biocatalyst, from the estimation of the kinetic parameters to the choice of biocatalyst 
formulation as well as the influence of each of these on the process design. 
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Over the past decades, the use of biocatalysis to produce fine chemicals and 
pharmaceutical intermediates has increased significantly. It is believed that several 
hundred biocatalytic processes operate at an industrial scale, which is testament to the 
interest (both economic and environmental) for the implementation of such processes 
[54, 55]. A major contribution to this trend has been the continuous discovery and 
isolation of new enzymes from a variety of different biological sources. This has 
broadened the scope of biocatalysis which nowadays allows the regio- and enantio-
selective synthesis of many compounds, through processes with potentially green 
credentials [56-59]. The technology therefore has many potential advantages over 
classical chemical synthesis to prepare fine chemical and pharmaceutical intermediates. 
The list of advantages includes, for instance, lower energy demand since biocatalytic 
processes often run at mild temperatures and pressures, reduced number of side 
products and increased stereo-selectivity, among others [60]. 
2.1.1. Challenges in biocatalytic processes  
Despite these advantages, there are several challenges associated with this technology. 
First it is necessary to find a suitable enzyme or group of enzymes that are able to catalyse 
the synthesis of the desired compound. Secondly, often the naturally occurring enzyme 
does not meet the requirements of the process conditions, where high substrate and 
product concentrations as well as high stereoselectivity and biocatalytic yield 
(gproduct/gbiocatalyst), are key to economic feasibility at an industrial/commercial level [32]. 
Table 2.1 summarizes the most common advantages and disadvantages associated with 
the use of enzyme and cells as biocatalysts.  
ω-TAm are well known to be affected by several of these issues, as introduced in Chapter 
1. Inhibition caused both by substrates and products, unfavourable equilibrium and low 
stability under process conditions are the most commonly reported in the scientific 
literature [47, 61, 62].   
In a recent work, we have reviewed all the bottlenecks affecting the process development 
of ω-TAm catalysed reactions and suggested solutions for these different limitations [32]. 
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These were divided into those which are related to the biocatalyst itself and those related 
to the process, as illustrated in Table 2.2.  
This chapter and chapter 3 focus on the biocatalyst related challenges (with the exception 
of enzyme immobilization/separation which will be addressed in Chapter 4) while the 
process related challenges will be addressed in Chapters 5 and 6. 
Table 2.1- Advantages and disadvantages of cell and enzymes in biocatalysis, Adapted from [60].  
Advantages 
 Stereo and regio-selective 
 Ambient temperatures required 
 Low energy consumption 
 Fewer side products 
 Can be potentially re-used 
 Can be degraded biologically i 
 Nontoxic (when correctly used) i 
Disadvantages 
 Wild type enzymes are often ii: 
- unstable at high temperature iii 
- unstable at extreme pH values iii 
- unstable to aggressive solvents iii 
- hydrolysed by proteases 
- low activity in non-natural environment 
- unstable in non-natural environment 
- exhibit poor ee in process conditions 
 Some enzymes ii:  
- are very expensive 
- require expensive cofactors 
- are inhibited by substrates and/or products 
i  in comparison with organo-metals used as catalyst in classical chemical approach. Although GMOs also 
require special handling. 
ii often the wild type enzyme needs to be engineered to overcome these limitations 
iii  these are only disadvantages in the rare cases where these conditions are required in the process
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 Stability related issues 
When enzymes are used outside of their natural environment (where the conditions are 
mild and operation is at low substrate concentrations and for a short period of time) their 
activity is often compromised by the process or media conditions. This is due to a loss of 
their native quaternary stable structures (denaturation) which are sensitive to 
conditions which are not similar to the ones in their biological environment [60]. Table 
2.3 summarizes the most common causes of denaturation of enzymes in biocatalysis as 
well the most common strategies used to minimize these. 
Table 2.3: Most common enzyme denaturation factors and solutions often implemented (Adapted from [60] ) 
Factor  / (Objective) Cause of denaturation Alleviated by 
Temperature increase / 
(increase rates an yields) 
Unfolding or chemical 
modification 
Use enzyme’s optimum 
temperature or use improved 
enzyme 
Shear stress caused by agitation / 
(increase mass transfer) 
Unfolding Immobilize the enzyme 
pH increase or decrease / 
(Increase rates and yields) 
Unfolding when pH>>or<<pI 
Immobilized enzyme or use 
improved enzyme 
O2  / 
(increase rates with oxidases) 
Oxidations of –SH or 
methionine 
Use improved enzymes 
Higher substrate concentration/ 
(increase yields, reduce DSP costs) 
Chemical modification Use improved enzyme 
Organic solvents / 
(increase substrate/product solubility) 
Unfolding Immobilize enzyme 
The deactivation/denaturation by temperature and pH of several enzymes has been 
reported to follow a first-order process [63, 64] as described by Equation 2.1: 
ܣ
ܣ଴
ൌ ݁ݔ݌ି௞௧ሺʹǤͳሻ 
where, A and A0 are the enzyme’s activity or concentrations at time t and initial activity 
or concentrations, respectively,  A/A0 represents residual enzymatic activity at time t 
(min), and k (min-1) is the reaction rate constant at a given temperature, pH or other 
condition. By estimating k one can in theory create models to estimate the deactivation 
under different conditions. 
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 Inhibition by substrates and products 
Inhibition is an issue in several enzyme catalysed reactions and as mentioned before, this 
is one of the most discussed issues inherent to transaminase catalysed reactions. 
Enzyme inhibition occurs when a compound, the inhibitor, reversibly binds to the 
enzyme slowing down the reaction rate. The higher the concentration of the inhibitor the 
slower the rate becomes [65]. There are three types of reversible enzyme inhibition 
defined in scientific literature [66, 67]: 
i. Competitive: where the inhibiting molecule is competing with the substrate to 
bind the enzyme. It occupies the active site and forms a complex with the enzyme, 
preventing the substrate from binding to the enzyme itself. This results in an 
apparent increase in the enzyme–substrate dissociation constant (Km) (i.e., an 
apparent decrease in the affinity of the enzyme for the substrate) without affecting 
the enzyme’s maximum velocity (Vmax);  
ii. Uncompetitive: the inhibitor binds to the enzyme on a site distinct from the site 
which binds the substrate. This, results in an apparent decrease in both Vmax and 
Km. The apparent increase in affinity of the enzyme for the substrate (i.e. a 
decrease in Km) is due to unproductive substrate binding, resulting in a decrease 
in free enzyme concentration. Half-maximum velocity, or half-maximum 
saturation, will therefore be attained at a relatively lower substrate concentration; 
iii. Non-competitive (or linear mixed): the inhibitor binds to the enzyme, either to the 
free enzyme or to a complex, on a site distinct from the active site. Substrate can 
still bind; however, the enzyme is inactivated. This results in an apparent decrease 
in Vmax and an apparent increase in Km. 
 
These three types of inhibition can be graphically distinguished using the linear form of 
Michaelis–Menten expression (Equation 2.2), commonly designated as Lineweaver–Burk 
equation (Equation 2.3), where v represents reaction rate, Km Michaelis–Menten 
constant, [A] is the concentration of substrate and Vmax the maximum velocity.  
ݒ ൌ ܸ݉ܽݔ ൈ ሾܣሿܭ௠ ൅ ሾܣሿ
ሺʹǤʹሻ 
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ͳ
ݒ ൌ
ܭ௠
ܸ݉ܽݔ ൬
ͳ
ሾܣሿ൰ ൅
ͳ
ܸ݉ܽݔ ሺʹǤ͵ሻ 
Adding the factor ቀͳ ൅ ሾூሿ௄௜ቁ to the slope, or to the intercept or to both terms in Equation 
2.3, equations can be obtained describing the competitive, the uncompetitive and non-
competitive inhibitions respectively, as depicted in equations 2.4, 2.5 and 2.6. 
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ሾܫሿ
ܭ݅൰ሺʹǤ͸ሻ 
Where [I] represents the inhibitor concentration, which can be a molecule which is not 
part of the reaction or one of the reaction substrates or products and Ki represents its 
dissociation constant [65, 67].  
2.1.1.2.1. Substrate inhibition 
Substrate inhibition is observed when the initial rates do not increase asymptotically 
with higher substrate concentrations to a specific maximum value but instead decrease 
after reaching a certain substrate concentration. 
There are several possible causes for this [44]: 
i) the substrate can combine as a dead-end inhibitor with an enzyme form with 
which it is not supposed to react; 
ii) high levels of substrate can cause an altered order of addition of reactants, or in 
any other way generate an altered reaction pathway;  
iii) the substrate may combine at an allosteric site and cause either total or partial 
substrate inhibition;  
iv) higher levels of substrate may cause nonspecific inhibition as a result of increased 
ionic strength to a toxic level; 
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More specifically, in the case of ω-TAm which follows a Ping-Pong Bi Bi mechanism [43] 
as represented in Figure 2.1. During the reaction, the enzyme oscillates between two 
main forms represented by E and F (where E represents the pyridoxal form and F, the 
pyridoxamine form of the enzyme) as also described in Chapter 1.  
 
Figure 2.1 – Ping pong Bi Bi mechanism. Adapted from [43, 44] 
The substrate A is meant to react with the E form of the enzyme and B with the F form. 
However, considering the similarity between the two forms, it is reasonable to expect 
that B has also some affinity for the form E and likewise A for F (if the active site is able 
to accommodate A). These unconventional combinations will result in lower reaction 
rates at a certain substrate level caused by competitive substrate inhibition (where B 
competes with A for the active site of the F form and less commonly, A competing with B 
for the active site of E). Other type of substrate inhibition are unlikely to be expected for 
transaminase [44].  This can be kinetically represented by multiplying Michaelis–Menten 
constant for substrate A and B (KA and KB) terms in the denominator of the rate equation 
by ቀͳ ൅ ሾ஺ሿ௄௜஺ቁ and ቀͳ ൅
ሾ஻ሿ
௄௜஻ቁ respectively [43, 65, 68], as previously explained for Equation 
2.3.  
2.1.1.2.2. Product inhibition 
For similar reasons, product inhibition occurs as the result of the interaction of substrate 
in the reverse reaction with the wrong enzyme form (i.e. Q interacting with F instead of 
E). This leads to formation of a complex that cannot further react [65, 69].  
 Kinetics of ω-transaminase (parameter estimations) 
Knowing the kinetic parameters of an enzyme allows accurate quantification of the 
biocatalyst effectiveness and provides guidance for biocatalyst improvement [70]. The 
kinetic parameters can also be used in a process model to describe the dynamic behaviour 
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of the reaction and in this way be used to evaluate opportunities for process integration 
(e.g. in situ product removal) [71], process control and operational optimization [72] and 
derive the reaction equilibrium [32]. 
Several methods have been developed that allow estimation of dissociation and 
inhibition constants. Graphical methods using reciprocal plots have been used for several 
decades now and several books and publications have detailed the stepwise procedure 
allowing its implementation, as well as details of the experiments (initial rate 
measurements) needed [43, 44, 65-67, 69]. Although relatively easy to implement, this 
method requires a large amount of experimental data. Furthermore, this method is 
known to be inaccurate as small experimental errors will drastically affect the estimated 
parameters [73, 74].   Furthermore, where there is significant inhibition of the substrates, 
the plots are no longer linear and therefore assumptions of linear regions are not valid 
[67]. Another often used methodology is non-linear regression (NLR). It relies on 
minimizing the margin of error between the model outputs (or model predictions) and 
the corresponding experimentally measured values. Often, this procedure is carried out 
using an optimization routine such as the least squares method. This is clearly an 
improvement on the graphical method since no model linearization is required, although 
usually mathematical software with curve fitting or an optimization toolbox is needed as 
well as expertise on using these. The major advantage of the NLR method is that it can be 
applied for both initial rate data (as the graphical method) and a set of reaction progress 
curves. However, a difficulty in using the NLR method is the necessity of good initial 
guesses for the kinetic parameters [75]. In a recent publication [76], these issues have 
been minimized by combining both methodologies, i.e. using the graphical method to 
obtain a good initial guess of the parameters and using non-linear regression to fit the 
reaction rate equations to the experimental data (both initial rates measurements at 
different substrates and product concentrations and multiple reaction progress curves). 
Regardless of the method used to estimate the parameters, it is important to know the 
kinetic mechanism followed by the enzyme and to derive the reaction rate expression. In 
the cited work the kinetic model was derived based on the King–Altman method [43, 66] 
using the reaction system featuring IPA as amine donor and APH as the amine acceptor 
(Figure 2.2). The mechanism includes the formation of four non-productive complexes E-
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PLP-APH, E-PMP-IPA, E-PMP-MBA, and E-PLP-ACE, which are characterized by a 
substrate inhibition constant KsAPH and KsIPA in the forward direction and KsMBA and 
KsACE in the reverse direction.  
E-PMP-IPA
E-PLP-ACE
K15[IPA]
K11[ACE]
K16
K12
K4[ACE]
E-PLP
E-PLP-IPA
E-PMP-ACE
K1[IPA]
K2
K3
E-PMP
K6
K5[APH]
E-PLP-MBA
E-PMP-APH
E-PMP-MBA
K13[MBA]
K14
E-PLP-APH
K10
K9[APH]
K8[PEA]K7
 
Figure 2.2 King-Altman representation of Ping Pong Bi Bi mechanism for transamination of isopropylamine (IPA) and 
acetophenone (APH) to form methylbenzylamine (MBA) and acetone (ACE). Adapted from [43]. 
Estimating the full list of kinetic parameters involves a large set of experiments. In the above 
work, approximately 60 experiments were performed, while for graphical methods and non-
linear regression, an average of 130 experiments are required [76]. In order to estimate the 
kinetic parameters for different enzyme mutants or for different reaction system, these numbers 
of experiments are multiplied by the number of variables (mutants or reactions systems). For 
this reason this will not be pursued in this thesis. Here, the inhibition profile for different 
mutants and different reaction system will be compared based on primary Michaelis-
Menten plots and its calculated constants (for substrate inhibition) and the direct result 
(reaction rate) of increased initial product concentration in the system (for product 
inhibition), rather than using the full list of parameters. Regardless of the inaccuracy that 
might be associated with this methodology, it considerably reduces the number of 
experiments required while giving a fair overview of the differences between the 
compared variables, as will be demonstrated and discussed in Chapter 3. 
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2.1.2. Protein engineering  
As discussed in the previous section (see Table 2.2), several of the biocatalyst limitations 
(i.e. inhibition, low stability, low activity and poor enantioselectivity) can be alleviated or 
improved by  engineering the biocatalyst and this is often (or even nearly always) 
necessary in order to meet process requirements[49]. Throughout the history of protein 
engineering, three main approaches have been pursued to obtain improved biocatalysts 
[55]. Early work was focused on rational design and thereby restricted to enzymes where 
there was a considerable knowledge of structure. In the following generation, the 
emphasis was on the development of diversity via random mutagenesis to create large 
libraries. Whilst in the last decade this type of library has developed such that a greater 
diversity is used as the starting point, also using natural diversity [77, 78]. The libraries 
are screened and, via repeated cycles, evolution is directed at the required properties [49, 
79-82]. This has allowed several improved catalysts to be obtained showing remarkable 
new features, such as higher stability, higher activity and even the inversion of the 
enantioselectivity has been demonstrated [83-85].  A well-known example in the context 
of ω-TAm, has been achieved by Merck and Co (Rahway, NJ, USA) together with Codexis, 
Inc. (CA, USA) where the combination of substrate walking, modelling and mutation was 
used to obtain marginal activity toward the ketone required in a transamination for the 
synthesis of the pharmaceutical Sitagliptin. This formed the basis for further 
development of the enzyme via directed evolution to enable operation at adequate 
concentration (200 g/L), ee (99.95%) and yield (92%), representing a major 
achievement [86].  However, this technology also has its limitations. Firstly the cost, the 
time and the human resources that are required in order to change numerous amino acids 
in a protein and/or screen among thousands of generated mutants for different 
enhancements is a major drawback, especially if more than one trait is sought, thus 
requiring various cycles of mutations [48]. Furthermore, the substrate scope that the 
enzyme can operate with and the process flexibility might be compromised by developing 
the enzyme in favour of one substrate as in the example carried out by Merck. And finally, 
some of the limitations inherent with some biocatalytic processes cannot be solved by 
improving the enzyme. This is the case with unfavourable equilibrium, which is known 
to affect the ω-TAm in the synthetic direction of interest [55].  
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2.1.3. Process engineering 
In such cases, one solution is to make use of process engineering tools to complement 
protein engineering and help to overcome this limitation (see Table 2.2). These tools 
include, for instance, the use of a feeding strategy such as  in situ substrate supply (ISSS) 
or fed-batch and in situ product removal (ISPR) to respectively overcome substrate and 
product inhibition [30, 87-89] and the use of substrate excess and in situ co-product 
removal to shift the equilibrium in favour of product formation [30, 38].  The use of these 
technologies in biocatalysis to address unfavourable thermodynamic equilibrium as well 
as product and substrate inhibition is very well described in scientific literature [90, 91].  
They can be divided into two groups: (i) those that both alleviate the product inhibition 
and shift the equilibrium, such as using an auxiliary phase (solid, liquid or gas) to remove 
the inhibitory product and (ii) those that only shift the equilibrium such as the removal 
of co-product or its conversion through enzymatic cascades into a less toxic compound, 
and/or the use of one substrate in excess. These will further described in Chapter 5. 
2.1.4. Methodologies to implement biocatalytic processes 
Until this point, there were two main routes for designing biocatalytic processes and 
dealing with wild type enzyme limitations: (i) design the process around the limitations 
of the enzyme (sacrificing process yields and productivity), and (ii) to engineer the 
enzyme to fit the process specifications (sacrificing the enzyme scope and process 
flexibility) as depicted in Figure 2.3 A and B. This has been reviewed and properly 
discussed by Burton and co-workers [49] and more recently by Bornscheuer and co-
workers  [48] and by Woodley [55].  
In the present work, a third option is introduced for designing biocatalytic processes, an 
option where protein and process engineering are considered in parallel during process 
development (Figure 2.3 C). This option capitalizes upon the protein engineering tools 
which can be used to broaden the operating window, e.g. decrease substrate and/or 
product inhibition, while process engineering tools can be used to enhance stability 
(through immobilization), shift equilibrium (through substrate excess and/or product 
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and co-product removal) and further alleviate inhibition (controlled release of substrate 
and in situ product removal). 
Fu lfils 
pro cess 
go als?
Implementation
Characteri st ics:
pH, Tem p, [S], 
[P], ee, Vmax 
Protein 
engineering
No
Yes
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pro cess 
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Figure 2.3: Routes for implementation of a biocatalytic process. (Filled arrows) process flow; (dotted arrow) information flow. 
A) Process to fit biocatalyst: the process goals are defined in the beginning, followed by a search for the most suitable 
biocatalyst (based on the process goals). After the characterization of the selected biocatalyst, the process goals are re-defined 
again in order to fit the enzyme optimum conditions. As a result, the process goals might be decreased, sacrificing the yields. 
B) Biocatalyst to fit process: Process goals are defined followed by a search for the most suitable biocatalyst. If the biocatalyst 
does not allow the fulfilling of the process objectives, it goes into a loop of improvements (through protein engineering 
technology) and screening until a catalyst with the desired property (ies) is found. This might take several cycles, since often 
various new properties are needed to achieve the process goals. Furthermore it might result in a very process-specific 
biocatalyst. C) Combined approach: process goals are defined and the most suitable biocatalyst is selected. Based on the 
biocatalyst characteristics, process engineering tools are used to improve process. If the process objectives are not achieved, 
the biocatalyst is marginally improved so that in combination with process engineering tools the process goals can be achieved. 
This is expected to reduce the number of rounds needed for the enzyme development and to eventually reduce the costs as 
well as allowing obtaining a more flexible biocatalyst. 
 
In the context of ω-TAm, there are some successful examples in which engineered 
enzymes have showed improved performance when combined with process engineering 
tools (Figure 2.4). In summary, the process can be improved vertically (towards higher 
biocatalytic yield – gproduct/gbiocatalyst) through improved expression, enzyme purification 
and through immobilization and re-use, and horizontally (towards higher yield and 
product concentration) by alleviating the inhibition and increasing the stability which can 
be initially achieved with protein engineering but should be further enhanced using 
process engineering tools. 
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Figure 2.4 – Examples of combined approach (protein and process engineering) applied to ω-transaminase catalysed 
reactions (U Martin et al. 2007 [45];  { Truppo et al. 2010 [30];  Savile et al. 2010 [31];  Truppo et al. 2012 [92]). ADXs 
= Amine donor excess; ISPR = In situ product removal and IScPR = In situ co-product removal. 
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A biocatalyst can be used in several different formulations. Choosing the right one is an 
important part of the development of a biocatalytic processes [93]. To some extent this is 
determined by the type of industry in which the biocatalyst will be used (whether it is for 
pharmaceutical, fine chemicals or bulk chemical production). For example, if cascade 
reactions and/or co-factor regeneration are required, it would justify the use of whole-
cells (WC) or cell-free extract (CFE). On the other hand, if the formation of side products 
and mass transfer are issues, it would justify the use of purified enzymes (PE) [94]. 
Ultimately, any of these formulations can be presented as a liquid solution, lyophilized 
powder or immobilized preparation. In Chapter 4 the use of immobilized enzyme 
preparations will be discussed, while the Chapter 3 will focus on the use of WC and CFE.
The formulation and the level of purity required for the enzyme greatly influences the 
production cost [95]. According to an analysis performed by Straathof and co-workers in 
2002, it was suggested that about 60% of the reported industrial biocatalytic reactions 
use WC (in either free or immobilized form) as catalysts, with the remaining 40 %  using 
either soluble or immobilized enzymes [96]. This difference can be related to the cost 
associated to prepare enzymes as depicted in Figure 2.5. The more units of operations 
that are necessary to produce and formulate the biocatalyst the higher the production 
cost becomes. This accounts for example for the cost associated with labour, chemical, 
carriers and energy.  
Often the biocatalyst production cost (excluding development costs) for a developed 
production system on an industrial scale is reported to vary from 35-100 €/kg for WC 
and 250-1000 €/kg for PE [97]. Using WC translates into a cheaper solution, as it 
eliminates the need to disrupt the cells, separate the debris and concentrate the enzyme 
solution. However it has increased mass transfer limitation and higher chances of side 
products formation. Indeed this assumes that is not exported outside the cell. For 
enzymes exported outside the cell, the whole scenario changes and the costs are reduced 
since the need for cell disruption and debris separation is eliminated and less purification 
steps are required since most of the undesired  enzymes will be retained inside the cells. 
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The implementation of new biocatalytic processes can be a challenging procedure which 
can require several stages of characterization and evaluation prior to scale up. One of the 
main challenges is to find a suitable enzyme to perform a specific reaction step. When this 
is done, the selected enzymes often demonstrate poor performance under process 
conditions, where high substrate and product concentrations and aggressive media 
composition contrasts with the enzyme’s natural environment. Protein engineering tools 
(e.g. directed evolution) are able to tackle these limitations and develop enzymes with 
improved activity, stability, and enantioselectivity under process conditions. Often, a 
screening procedure needs to take place in order to select the most capable mutants 
among a library. Ideally this procedure should be as fast and robust as possible. 
This chapter focuses on the step of process development which includes the selection and 
characterization of a suitable biocatalyst. This was done by identifying the main issues 
affecting ω-transaminase (e.g. inhibition, stability and activity under process conditions) 
and characterizing a mutant library according to these issues. The library included 
initially 5 ω-transaminase enzymes developed by c-LEcta GmbH (Leipzig, Germany) 
which were compared with respect to inhibition caused by substrates and products, pH 
and temperature stability and with respect to their performance at high substrate 
concentration. Furthermore, aspects such as the biocatalyst formulation and choice of 
amine donor were investigated with respect to their effect on inhibition. This was done 
by employing in total 4 reaction systems featuring two amine donors (isopropylamine - 
IPA and alanine - ALA) and two amine acceptors (acetophenone – APH and benzylacetone 
- BA) and two biocatalyst formulations (lyophilized whole cells and cell-free extract).
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The screening of a large library of enzymes can be extremely time consuming if a logical 
and simplified screening methodology is not followed. Biocatalysts can be compared in 
regard to several criteria (Box 3.1). An efficient way (i.e. fast with reliable output) is to 
select a small number of properties that correspond to the process conditions sought and 
use them as screening criteria. For example, if the process is desired to run at pH 8 
(because the product is unstable at acidic pH, for example) then it would make sense to 
screen the biocatalyst that has good activity at pH 8.  
The screening criteria can be applied in several 
steps or combined in a few steps. They can also 
be applied with increasing complexity. For 
example, a large window (e.g. activity at a very 
low substrate concentration) can be defined as 
the first criterion in order to reduce the library 
size and then a second criterion can be applied. 
The same parameter can be used but with a 
narrower window to further tune the library 
(e.g. by increasing the substrate concentration 
desired). When the library is reduced to a small 
number of biocatalysts then the characterization 
procedure can be started. In this step all the 
required information for the process should be 
collected. This can include kinetics parameters, 
performance in special conditions or any other criteria which were not used in the 
screening phase. This is represented in Figure 3.1 where the methodological approach 
used for mutant screening is depicted.  
  
 Activity 
 Stability  
- to pH 
- to temperature 
- in organic solvents 
- buffers strength 
 Inhibition 
- by substrates 
- by products 
- by other reaction 
component 
 Selectivity (ee) 
 Half life time 
 Substrate range 
Box 3.1 Example of criteria for enzyme screening 
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Figure 3.1 Diagram for a rapid mutant screening and characterization. (Filled arrows – screening flow; dotted 
arrows – information flow) 
In this chapter, activity (at high substrate concentration), inhibition by products and 
substrates and stability to pH and high temperatures were used as screening criteria. The 
screening was divided in two parts: in the first part (which is not shown in this thesis), a 
library of 5 ω-TAm mutants was screened with regard to substrate inhibition/activity at 
30 mM of substrates (APH). This concentration was chosen for being close to the water 
solubility limit for this substrate (this corresponds to Step 1 in the screening diagram 
depicted in Figure 3.1). From this step, three most capable enzymes (showing higher 
activity) were selected for the second part of the screening (Step 2 in Figure 3.1). Finally 
one enzyme was selected and further characterized (Step 3). 
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3.2.1. General 
E. coli BL21 cells over expressing (ATA 40, ATA 44 and ATA 47) and corresponding semi-
purified CFE preparations were obtained from c-LEcta GmbH, Leipzig, Germany. The cells 
were grown and lyophilized in house. All the chemicals were obtained from Sigma-Aldrich 
(Buchs, Switzerland). 
3.2.2. Production of ω-TA (ATA 40, ATA 44 and ATA 47) 
The culture medium (ZYM505) was composed by ZY with 1x M, 1x 505 and 2 mM MgSO4, 
where ZY was composed by 5 g/L of Yeast extract and 10 g/L of Tryptone; M was 
composed by 0.5 M of Na2HPO4, 0.5 M KH2PO4, 1 M NH4Cl and 0.1 M Na2SO4; and 505 was 
composed by 250 g/L of Glycerol and 25 g/L of Glucose. 
Pre-cultures: One colony from LB-agar plates was cultivated in complex media ZYM505 
supplemented with 50 μg/ml kanamycin and incubated overnight at 37 °C (150 rpm). The 
pre-cultures were used to inoculate fermentations with an initial OD600 of 0.1.  
Fermentations: Fermentation was performed at 30°C, pH 7 in fermenters with 1L working 
volume with complex media supplemented with 50 μg/ml kanamycin. The cultures were 
induced with 1mM IPTG at early exponential phase and harvested by centrifugation, 4000 
rpm 20min, 20h after inoculation. The cell pellet was washed with 50 mM potassium 
phosphate buffer (k-PBS) pH 7.4 and stored at -80°C and freeze-dried.  
3.2.3. Freeze drying  
The frozen cells (at -80 ˚C) were lyophilised at -54 ˚C for 6 hours under vacuum (10-2 
mBar) using a Heto LyoLab 3000 from Thermo Scientific (Massachusetts, USA). The 
resulting lyophilized powder was stored at -5 ˚C before use. 
  
61
Chapter 3 – Screening and characterization of biocatalyst   
 
46 
3.2.4. Protein expression level  
Cell samples were sonicated for 10 min at an amplitude of 50 % and a cycle of 0.5. 
Afterwards, the extraction mixture was cooled in an ice bath. The cell debris was removed 
by centrifugation at 14000 rpm for 5 min. 5 μL of loading buffer (4x) and 2 μL of 500 mM 
DTT were added to 13 μL of supernatant. After mixing, the sample was incubated on a 
thermoblock at 95°C for 5 min. A 10x dilution was prepared. 
The samples and 5 μL of Precision Plus Protein™ Standard were loaded onto a 
polyacrylamide gel. A SDS-PAGE running buffer 1x was used. A constant voltage was 
applied for 1 hour. 
The gel was stained with coomassie blue. The gel was analysed using the software 
GelAnalyzer 2010. The molecular weight of TAm was determined using a log linear 
calibration curve to be 48 kDa, which is in accordance with previously published reports 
[98, 99] (Appendix 3A). 
3.2.5. Activity assay 
Activity assays were performed in a thermoshaker (HLC Biotech Model 11, Pforzheim - 
Germany) at 30 ˚ C with orbital shaking of approximately 400 rpm. Samples of 100 μL were 
taken at minute 1, 5 and 10 and added to 400 μL of 1 N HCl to stop the reaction. The 
samples were then centrifuged for 5 minutes at 14100 rpm (MiniSpin plus, Eppendorf AG, 
Hamburg, Germany) and analysed by HPLC. 
3.2.6. Analysis: 
All samples were analysed using HPLC by measuring the concentration of MBA and/or 
APB using an Ultimate 3000 HPLC (Dionex, Sunnyvale, CA, USA). The compounds were 
separated on a Luna 3 Pm C18(2) 100 Å (50 x 4.6 mm) column (Phenomenex, Torrance, 
CA, USA) at a flow rate of 2 mL/min using a multi-step gradient flow of aqueous 0.1% v/v 
trifluoroacetic acid and acetonitrile, with the following percentage of acetonitrile: 0 min 
(0%), 1 min (10%), 2.5 min (10%), 5.9 min (60%), 6 min (0%), 7 min (0%). Compounds 
were detected at 210 nm (3.9 min for MBA and 5.9 for APB). The quantitative analysis was 
performed from peak areas by external standards (Appendix 3B).  
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3.2.7. Step I – Initial screening of library of 5 mutants 
In the first step of the screening (following the diagram in Figure 3.1), 5 ω-TAm mutants 
(all produced by c-LEcta GmbH, Leipzig, Germany) were characterized for their activity at 
30 mM APH (and 1 M IPA as mine donor). From this step 3 mutants were selected for 
further characterization (Steps II and III of the screening diagram Figure 3.1). 
3.2.8. Step II – Further screening of library of 3 mutants 
 Substrate and product Inhibition  
Five reaction mixtures containing increasing concentrations of APH of 0-30 mM (for 
substrate inhibition experiments) and five with increasing concentrations of (S)-MBA of 
0-10 mM (for product inhibition experiments) were prepared with 2 mM PLP, 1 M IPA 
and 100 mM k-PBS pH 7. Prior to its addition, IPA was neutralized using 6 M HCl. The vials 
containing 2.5 mL reaction mixture were tightly closed and pre-incubated for 5 minutes 
at 30 ˚C with continuous agitation of approximately 500 rpm (HLC Biotech, Model 11, 
Pforzheim, Germany) prior to addition of lyophilized CFE (2.1 g/L of ATA 40, 1.18 g/L of 
ATA 44 and 0.85 g/L of ATA 47, dried weight) which were diluted in 0.5 mL 100 mM k-
PBS (pH 7) was added and the activity assay initialized. 
  pH stability  
2.94 g/L  of whole cells  (ATA 40, ATA 44 and ATA 47)  were  incubated at pH 6-10 (using 
a wide range buffer prepared from boric acid, citric acid and trisodium phosphate –
Appendix 3C) and samples were taken at times 0, 0.5, 5 and 24 hours to run the activity 
assay. Prior to addition of the biocatalyst, the reaction mixture was pre incubated at assay 
conditions for 5 minutes. 
  Temperature stability  
2.94 g/L of WC (ATA 40, ATA 44 and ATA 47) were incubated at 30-60 ˚C in a buffer 
solution (0.1 M k-PBS, pH 7) and samples were taken at times 0, 0.5, 5 and 24 hours to run 
the activity assay. Prior to addition of the biocatalyst, the reaction mixture was pre-
incubated at assay conditions for 5 minutes. 
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 Effect of DMSO on inhibition 
For the experiments carried out with DMSO, the same procedure as described in the 
previous section was followed with an additional amount of DMSO being added to the 
reaction mixtures (25 v/v% in total)  
 Performance at high substrate concentration: 
Lyophilized WC (4.06, 3.44 and 4.42 g/L for ATA40, ATA44 and ATA47 respectively – dry 
weight) were run in reaction for 30 h. The reaction mixture consisted of 1 M of IPA, 300 
mM APH, 2 mM PLP, 100 mM k-PBS pH 7. The temperature was fixed at 30 ˚C and agitation 
was 400 rpm. Samples were centrifuged for 5 minutes at 14100 rpm (MiniSpin plus, Hamburg, 
Eppendorf AG, Germany) and analysed by HPLC. 
 Enantiomeric excess determinations 
The enantiomeric excess was analysed using a Chiralpak IB (Daicel Group, Cedex, 
France) column and a mobile phase of 98% n-hexane, 2% isopropanol and 0.1% 
ethylenediamine with a flow rate of 1 ml/min and oven temperature of 35°C. Compounds 
were detected at 254 nm. The samples analysed resulted from a 30 hours reaction of 1 M 
IPA and 300 mM. Samples had also 2 mM PLP and 100 mM k-PBS pH 7.2. 
3.2.9. Step III - Effect of amine donor and catalyst formulation on 
inhibition 
 Substrate inhibition  
Using fixed amounts of either 1 M of IPA or 1 M of ALA, the concentration of amine 
acceptor was varied from 2 mM to 30 or 60 mM for APH while for BA it was varied from 
2 mM to 10 mM or 30 mM and the activity assay proceeded as described for Step I. This 
was done using both WC (5 g/L) and CFE (0.85 g/L) 
 Product inhibition  
30 and 10 mM of APH and BA respectively (approximately corresponding to their 
solubility limit) was used for reaction featuring IPA (1 M) and 10 and 5 mM of APH and 
BA respectively were used for reactions featuring ALA (1 M). The product (MBA and APB) 
concentrations were varied from 0 to 10 mM and the activity assay proceeded as 
described for Part I using both whole cells (5 g/L) and cell-free extract (3 g/L). 
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The results are divided in the 3 Steps (as depicted by the screening diagram in Figure 3.1). 
In Step I, a library of 5 ω-TAm mutants (c-LEcta GmbH, Leipzig, Germany) was screened 
based on the enzymes’ activity at 30 mM (data not shown). From this step, 3 ω-TAm 
mutants were selected for further screening (Step II). In Step II, the mutants were 
compared with respect to degree of inhibition caused both by substrate and products, to 
their performance at high pH and temperatures values, their performance in a water 
miscible organic solvent (DMSO) and finally to their performance at high substrate 
concentrations (300 mM APH).  
In Step III, the best mutant was selected for further characterization where the influence 
of biocatalyst formulation and the amine donor on substrate and product inhibition were 
investigated. 
3.3.1. Step I – Initial screening of library of 5 enzymes 
From the first screening step, three mutants (ATA 40, ATA 44 and ATA 47) were selected 
and carried to Step II. These mutants showed relatively better performance in the 
presence of 30 mM of substrate (APH). 
3.3.2. Step II – Further screening of library of 3 enzymes 
 Substrate inhibition  
Figure 3.2 shows results for substrate inhibition for all the three enzymes (ATA 40, ATA 
44 and ATA 47). It was observed that the inhibition caused by APH was significant for ATA 
40 and ATA 44, with the latter having its activity decreased by more than 50% at the 
substrate concentration of 30 mM, in comparison with the 25% loss observed for ATA 40 
(Figure 3.2).  However, despite this significant loss in relative activity (%), in terms of 
specific activity (μmol MBA.min-1.gCFE-1), ATA 44 showed at 30 mM of substrate about 12 
μmol MBA.min-1.gCFE-1, compared to 8 μmol MBA.min-1.gCFE-1 observed for ATA 40. This 
difference could be related to a better protein expression for ATA 44. In order to confirm 
this the quantification of protein content between the mutants could have been carried 
out, however this was not pursued. 
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On the other hand, no substrate inhibition was observed for ATA 47 at concentrations of 
APH up to the solubility limit (approximately 30 mM at 25 ◦C). The reaction rate increased 
with the increase of substrate concentration. Also the specific activity was found to be 
more than 10 fold higher than ATA 40 and approximately 5 fold higher than ATA 44. 
   
Figure 3.2: Substrate inhibition for ATA 40, ATA 44 and ATA 47. Reactions were ran with concentrations of APH ranging 
from 0 to 30 mM, and with 1 M of IPA, 2 mM of PLP, 0.1 M of k-PBS pH 7 and CFE concentrations (dry weight) were 2.1 g/L 
ATA 40, 1.18 g/L ATA 44 and 0.85 g/L ATA 47. 
The improvements in substrate inhibition could be related to improvements in the 
catalytic centre that may have reduced the affinity towards the substrate. This could be 
observed by the dissociation constant (Km) which was calculated for the 3 enzymes using 
the graphical method (details in Appendix 3D). The Km was found to be 0.34, 0.39 and 7.99 
mM for ATA 40, ATA 44 and ATA 47 respectively. These were calculated using the data 
point for the non-inhibitory regions only, hence being subject to some errors [67] but 
allowing a qualitative comparison. With this, the conclusion can be drawn that ATA 40 
and ATA 44 have higher affinity to the substrate than ATA 47, which could be related to 
an increased pocket size.  
 Product inhibition  
With respect to product inhibition, it was observed that the relative activity loss when 
operating with initial product concentration of 10 mM is roughly similar for the three 
enzymes (more than 80%). However, ATA 47 being a more active mutant, presented 
higher activity at a given product concentration than the other two mutants 
(approximately 10 fold higher), Figure 3.3. Similar to the results for substrate inhibition, 
these experiments were also made using initial rate measurements in order to avoid the 
effect of equilibrium on these results. However, the increasing concentration of product 
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added to the reaction, affected the equilibrium position which became more unfavourable 
with the addition of more product. This had a strong influence on this results.  
   
Figure 3.3: Product inhibition for ATA 40, ATA 44 and ATA 47. Reactions were run with APH fixed at 10 mM and with initial 
concentrations of MBA ranging from 0 to 10 mM. IPA was fixed at 1 M, PLP at 2 mM and pH at 7 using 0.1 M k-PBS. The CFE 
concentration was (dry weight) 2.1 g/L ATA 40, 1.18 g/L ATA 44 and 0.85 g/L ATA 47.  
 pH stability   
The three enzymes were compared in terms of pH stability. A slightly better stability could 
be observed for ATA 44 which at pH 9 and 10 showed superior performance than ATA 40 
and ATA 47 (Figure 3.4). In summary, the pH stability of ATA 44>ATA 47>ATA 40. 
   
Figure 3.4: pH stability: 2.94 g/L of whole cells (ATA 40, ATA 44 and ATA 47) were incubated at pH 6, 7, 8, 9 and 10 (0.05 M 
wide range buffer) and samples were taken at times 0, 0.5, 5 and 24 hours to run the activity test at 30 ˚C (1 M of IPA, 5 mM 
APH, 2 mM of PLP, 0.1 M of k-PBS pH 7).  
 Temperature stability 
Similarly to what was observed for pH stability, also in terms of temperatures stability 
ATA 44 showed a slightly superior performance, while ATA 40 and ATA 47 were strongly 
affected by temperatures superior than 30 °C, especially for incubation periods longer 
than 6 hours (Figure 3.5). In summary the temperature stability of ATA 44>ATA 47>ATA 
40. 
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Figure 3.5: Temperature stability: 2.94 g/L of whole cells (ATA 40, ATA 44 and ATA 47) were incubated at 30, 40, 50 and 60 ˚C 
in a buffer solution (0.1 M potassium phosphate buffer pH 7) and samples were taken at times 0, 0.5, 5 and 24 hours to run 
the activity test at 30 ˚C (1 M of IPA, 5 mM APH, 2 mM of PLP, 0.1 M of k-PBS pH 7) 
 Effect of Solvent on inhibition 
Supported by previous results where Km was observed to be superior for the mutant 
affected the least by substrate inhibition (ATA 47 – section 3.3.2.1), it was hypothesised 
that having a reaction media more favourable to the substrate would allow decreasing the 
concentration of substrate at the enzyme’s catalytic centre, hence decreasing the 
substrate inhibition. This effect can be simulated by adding a water miscible solvent such 
as Dimethyl sulfoxide (DMSO) to the media, making it more favourable for the 
hydrophobic substrate.   
In order to test this theory, the three mutants were characterized for substrate inhibition 
in the presence of 25% DMSO and the results were compared to those obtained in the 
absence of DMSO (section 3.3.2.1) and are shown in Figure 3.6.  For both ATA 40 and ATA 
44, the presence of DMSO had a strong negative effect on the activity. The rates lowered 
when DMSO was added. Between these two enzymes, ATA 44 seemed to have better 
tolerance for DMSO since the difference between the reaction rate in the organic solvent 
and in the buffer were lower than those obtained for ATA 40. The ATA 47 on the other 
hand showed only a minor decrease in activity in the presence of DMSO suggesting higher 
tolerance. In respect to the effect of DMSO on the substrate inhibition, the results obtained 
for ATA 40 and ATA 44 suggested that inhibition by the substrate APH was decreased 
when DMSO was present in the media. In both cases the reaction’s rate increased 
asymptotically with the increase in the substrate concentration until Vmax was achieved 
and from that point it remained constant, compared to the results obtained in the buffer 
media, where the reaction rate decreased after Vmax was achieved. 
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Figure 3.6: Effect of DMSO on substrate inhibition for ATA 40, ATA 44 and ATA 47. Reactions were ran with concentrations of 
acetophenone ranging from 0 to 30 mM, and with 1 M of isopropylamine, 2 mM of PLP, 0.1 M of potassium phosphate buffer 
pH 7 and crude cell extract (2.1 g/L ATA 40, 1.18 g/L ATA 44 and 0.85 g/L ATA 47; c-LEcta GmbH).  
This was not observed for ATA 47 as this enzyme was not affected by substrate inhibition. 
In order to fully study this on ATA 47 it would have been necessary to use substrate 
concentration above the solubility limit in the presence of DMSO. However this 
experiment was not performed. 
Similarly to what was performed in section 3.3.2.1, the Km and Vmax were calculated for 
the 3 enzymes also in the presence of 25% DMSO and the results are compared in Table 
3.1. The apparent decrease in Vmax observed for all three mutants confirms the negative 
effect of DMSO on the enzyme activity while the increase of Km for all the enzymes (with 
the exception of ATA 47) confirms the decrease of substrate affinity, hence decrease in 
inhibition. The parameters calculated for ATA 47 are to be assumed underestimated since 
the maximum rate obtained is not a result of Vmax being achieved but due to the solubility 
limit. Substrate concentrations above this limit did not further increase the reaction rate, 
as will be shown further.  
Table 3.1 – Km and Vmax in presence of 0% and 25% of DMSO for ATA 40, ATA 44 and ATA 47. The arrows reflects the 
comparison between the reaction in the presence of 0% and 25% of DMSO 
 0% DMSO 25 % DMSO 
Enzyme Km (mM) 
Vmax 
(μmolMBA.min-1gCFE-1) 
Km 
(mM) 
Vmax 
(μmolMBA.min-1gCFE-1) 
ATA 40 0.34 10.70 2.58 Ç   5.58 È 
ATA 44 0.39 26.11 5.46 Ç 20.75 È 
ATA 47 7.99 133.34 4.43 È 95.24 È 
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 Performance at high substrate concentration 
The three enzymes were used in a 30 hour reaction with 300 mM of APH and 1 M of amine 
donor IPA. They were compared with respect to the final product concentration as well 
as the biocatalytic yield and the result is presented in Figure 3.7, where it can be seen that 
ATA 47 showed approximately 24-fold higher product concentration (4.7 g MBA/L) in 
comparison with the ATA 40 and about 4 fold higher than ATA 44.  The ee was found to 
be 99.9% for all the three enzymes. 
With these results, ATA 47 was selected for further characterization. Although this 
enzyme showed superior performance, it should be noted that the final product 
concentration obtained is still below the equilibrium yields of 9.5 g MBA/ L. This suggests 
that product inhibition is a major issue, as shown in section 3.3.2.2.  
In Chapter 5, the way in which process engineering tools could play an important role in 
solving this, will be discussed.  
 
Figure 3.7: Performance at higher substrate concentration. Lyophilized WC (2.94 g/L ATA 40, 3,44 g/L ATA 44 and 4.42 g/L 
ATA 47) were run for 30 hours with 1 M of IPA, 300  mM APH, 2 mM of PLP, 0.1 M of k-PBS pH 7. The temperature was fixed 
at 30 ˚C and agitation was approximately 500 rpm.  
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3.3.3. Step III – Biocatalyst characterization 
 Influence of catalyst formulation on inhibition 
In this section, whole cells (WC) and cell-free extract (CFE) formulations of the enzyme 
selected from the previous step (ATA 47), were compared in respect to substrate and 
product inhibition in order to understand whether the presence of the cellular membrane 
(in a WC) would have any effect on inhibition since the enzymes are not directly exposed 
to the media in this type of formulation. These were made using two prochiral ketones/ 
amine acceptor (APH and BA) and IPA as amine donor.  
3.3.3.1.1. Substrate inhibition 
The inhibition profile for WC and CFE presented in Figure 3.8 show very similar trends 
for the two formulations, suggesting no major differences in substrate inhibition. The 
rates initially increase with increasing substrate concentrations until the solubility limit 
is reached. At higher concentrations, the enzyme experiences only the concentration of 
substrate in the aqueous phase and therefore the rate does not increase further. This is 
observed for both substrates.  
   
Figure 3.8: Substrate inhibition profile as function of biocatalyst formulation; A) varying concentration of APH (2-60 mM) and 
B) varying concentration of BA (2-30 mM) run with 1 M of IPA and 2 mM of PLP at 30 ˚C and pH 7. (Squares): WC 5 g.L-1 (dry 
weight) and (circles): CFE 0.85 g L-1 (dry weight); (dashed line): experimental solubility limit at room temperature.  
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3.3.3.1.2. Product inhibition 
Similar to what was observed for substrate inhibition, also inhibition by product seems to 
equally affect both catalyst formulations in both reaction systems. These results, together 
with those obtained for substrate inhibition (section 3.3.2.1) suggest that inhibition 
affects equally both biocatalyst formulations, and that the presence of cellular membrane 
(in WC) does not help in alleviating the inhibition caused by substrate and product. This 
could be related to the fact that both formulations were used as lyophilized powder. It is 
reasonable to assume that the cellular membrane (or at least the proteins responsible for 
transportation across the membrane) are destroyed during the lyophilisation process, 
allowing free circulation of compounds in and outside the cell. 
  
Figure 3.9: Product inhibition profile as function of biocatalyst formulation; A) varying concentration of MBA and B) varying 
concentration of APB (0 – 10 mM for both) were run with 1 M IPA, 2 mM PLP and 30 mM APH (for A) or 10 mM BA (for B). 
Reaction were run at 30 ˚C and pH 7; (squares): WC 5 g.L-1 (dry weight) and (circles): CFE 3 g L-1 (dry weight); (dashed line): 
experimental solubility limit at room temperature.  
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 Influence of amine donor on inhibition 
In this section, the effect of amine donor on the inhibition was investigated. This was done 
by comparing substrate and product inhibition profiles using 1 M of ALA and 1 M of IPA. 
3.3.3.2.1. Substrate inhibition 
The results depicted in Figure 3.10 suggest that substrate inhibition is not influenced by 
the use of ALA or IPA as the amine donor, at least in the evaluated concentration range of 
substrates. The main difference observed was regarding the solubility limits of APH and 
BA which seemed to be lowered when ALA was used as the amine donor. The solubility of 
both APH and BA decreased from 30 and 10 mM to approximately 20 and 6 mM, 
respectively (visually observed – data not shown).  
  
Figure 3.10: Substrate inhibition profile as function of amine donor; A) varying concentration of APH (0-30 mM) and B) varying 
concentration of BA (0-10 mM) were run with 1 M of ALA as amine donor (squares) or 1 M of IPA as amine donor (circles) 
and 2 mM of PLP. Reactions were at 30 ˚C and pH 7 using 5 g L-1 WC (dry weight) as catalyst. 
3.3.3.2.2. Product inhibition 
On the other hand, substantial differences in the degree of product inhibition were 
observed between the two amine donors. Product inhibition was more prominent when 
ALA was used as amine donor with the reaction rate dropping to zero already at 3 mM of 
MBA and 10 mM of APB, as can be observed in Figure 3.11.  
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Figure 3.11 Product inhibition profile as function of amine donor; A) varying concentration of MBA (0-20 mM) and B) varying 
concentration of APB (0-20 mM) were run with 1 M of ALA as amine donor (squares) or 1 M of IPA as amine donor (circles). 
Reactions were at 30 ˚C and pH 7 using 2 mM of PLP and 5 g L-1 WC (dry weight) as catalyst. 
 
A possible explanation for this could rely on the interaction of the amine donor with the 
enzyme. As described before (section 2.1.1.2), product inhibition can be caused by the 
interaction of the product with the wrong form of the enzyme in the reverse reaction (i.e. 
Q interacting with F in Figure 2.1) which would cause the formation of an abortive 
complex stopping the reaction. However, it is also reasonable to assume that the products 
(MBA and APB) have higher affinity (lower Km) to the enzyme’s catalytic centre than then 
amine donors (ALA and IPA). This would make it difficult for the amine donors to bind to 
the enzyme afterwards if the product is still occupying the catalytic centre (since both the 
amine donor and the product bind to the same form of the enzyme, E). So it can be 
hypothesised that IPA is able to cause detachment of the products from the catalytic 
centre and bind to the enzyme better than ALA does. This could have been confirm by 
measuring the Km for both the amine donors (IPA and ALA) and the products (MBA and 
APB). However this was not investigated.  
In addition, as mentioned before, this experiment is also influenced by the equilibrium 
position. Increasing concentration of the product will inevitably change the equilibrium 
position, and therefore the reaction rate decreases. This is more expressive for reactions 
where ALA is used as amine donor which are more affected by the equilibrium. This could 
have been avoided if a constant substrate/product rate were maintained at the different 
initial product concentration. Nevertheless, these findings emphasize the need for process 
engineering tools to deal with the decreased activity in the presence of product. 
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The screening of biocatalysts can be simplified if a methodology is followed. This process 
needs to be efficient, fast and reproducible. Here, a methodological approach has been 
suggested consisting of the following steps: i) create a list of screening constraints or 
criteria that represent challenges to the process to be developed; ii) use one or a few of 
these criteria to reduce the library, which can be done in more than one step; and iii) after 
reducing the library use the remaining constraints to further characterize the remaining 
biocatalysts. 
In the present study, enzyme activity at 30 mM was used as first criterion to evaluate the 
initial library consisting of 5 enzymes and this allowed the reduction of the library to 3 
enzymes. Inhibition by substrates and products was used as a second criterion, which 
allowed selection of one suitable biocatalyst, the ATA 47.  This enzyme showed an 
improved performance at high substrate concentrations without being inhibited at 
substrate concentrations up to the solubility limit. It also showed a slightly improved 
stability at high pH, and improved enantioselectivity. However, product inhibition 
continues to be a major issue. This will be dealt with in Chapter 5 by employing the ISPR 
technology. Nevertheless, the enzyme was selected for further characterization. 
Considering that ATA 47 had an increased stability in presence of high substrate 
concentrations it was expected that it also had a slightly improved stability in presence of 
organic solvents. This was investigated and confirmed by adding DMSO (25%) to the 
reaction mixture. ATA 47 showed similar performance in the presence of DMSO as in the 
presence of buffer. This opened the possibility of using water miscible solvents to increase 
substrate and products solubility. However, in order to obtain high concentrations of 
product (e.g. 30-50 g/L), higher concentrations of substrate are required in the aqueous 
phase and consequently much more DMSO would be needed in order to solubilize it. It 
was measured that circa 50% DMSO would be needed to solubilize about 200 mM (~25 
g/L) of APH (Appendix 3F) and this would require an even more stable enzyme. 
Nevertheless, the use of DMSO was confirmed to decrease substrate inhibition to a certain 
degree as was demonstrated here for ATA 40 and ATA 44. 
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Selection of the right biocatalyst formulation is crucial, as it has a strong impact on the 
process cost, as discussed earlier in Chapter 2. The more the number of steps or unit 
operations required to produce the catalyst, the higher the cost. Indeed these steps bring 
benefits to the process, such as more selective catalysts and less side products (as in using 
purified enzyme), or increased storage stability and easier handling (lyophilized 
biocatalyst), easy separation and ability to re-use the biocatalyst (in case of 
immobilization of biocatalyst) or in situ co-factor regeneration (WC). Besides the obvious 
advantages of the different formulations, very little is known regarding the performance 
of the different formulations with respect to inhibition for example. Often, questions arise 
on whether the presence of a cell wall would have a beneficial effect on the inhibition due 
to selective mass transport across the membrane. This question was addressed in this 
chapter by comparing the substrate and product inhibition profiles when using both WC 
and CFE (both lyophilized) and no major difference was observed between the two 
(section 3.3.3.1). It would have been interesting to include non-lyophilised WC in this 
study in order to fully study the role of the cellular membrane on inhibition. This was 
however not performed.   
Another important question often raised in ω-TAm catalysed reactions lies on the choice 
of amine donor. This has great influence not only on the DSP but also on the process 
options that can be used to alleviate limitations such as the thermodynamic equilibrium. 
IPA is often used since it is a relatively inexpensive substrate [32]. When used, it forms 
the co-product acetone, which can theoretically be removed by vacuum or nitrogen 
sweeping [52] in order to shift the equilibrium. These strategies are not selective though 
and could potentially cause also the removal of the the ketone substrate, as will be 
discussed in Chapter 5. Alternatively cascade reactions can be used to selectively remove 
acetone [32].  ALA is another commonly used amine donor [30]. The major advantage of 
using it relies on the fact that it forms pyruvate as co-product, which can be easily 
removed by the lactate dehydrogenase (LDH)/glucose dehydrogenase (GDH) cascade 
system [30]. These two amine donors were tested for their effect on substrate and product 
inhibition. While no major difference in substrate inhibition was found, the opposite was 
observed regarding product inhibition. The use of ALA worsened the inhibitory effect of 
both products to a critical point, with reactions rates dropping to zero at very small 
product concentration (3.3.3.2).  However, has discussed earlier, it is possible that the 
equilibrium position is negatively influencing these results.
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Inhibition is heavily present in the transaminase catalysed reactions. The chiral product 
competes with the ketone substrate (amine acceptor) for the catalytic centre, and the 
opposite happens in the reverse reaction. This, alongside with the unfavourable 
thermodynamic equilibrium, represents the major drawbacks to these reactions as it was 
here demonstrated. Protein engineering has the potential to alleviate the inhibition by 
substrates and/or products and broaden the operating space. With continuous 
improvements and with a rational screening methodology, improved mutants can be 
identified. The use of a screening methodology can help simplifying this process while 
allowing an efficient stepwise screening. In this study, a methodology was development 
and successfully demonstrated. 
Despite the improvements that can be achieved by engineering the biocatalyst, this will 
never affect directly the thermodynamic equilibrium since it is a function of the substrates 
only. In such case, process engineering tools such as ISPR can help overcoming this, as it 
will be further discussed in Chapter 5. 
The choice of the amine donor is of extreme importance, as it was role demonstrated. It 
affects not only the thermodynamic equilibrium, but also the inhibition profile. This was 
very clear with especially emphasis for the inhibition caused by the products (MBA and 
APB). When ALA was used as amine donor, the product inhibition was found to be more 
prominent, with the reaction rates reaching zero at very low product concentrations. This 
difference in product inhibition profile as function of the choice of amine donor has never 
been observed or discussed before in scientific literature.  
The thermo stability of the selected mutant was however found to be slightly inferior in 
comparison to other mutants present in the initial library. Immobilisation of the 
biocatalyst can help to increase the stability but also allow the re-use of the biocatalyst as 
well as facilitate the DSP. This will be pursued in Chapter 4. 
 
77
  
62 
 
 
In this chapter, the results regarding the experimental work carried out to screen and 
select suitable supports to immobilize ω-TAm enzymes are presented and discussed. A 
screening methodology was developed and applied to 20 synthetic macroporous carriers, 
representing 3 types of interactions with the enzymes: i) hydrophobic interactions, using 
octadecyl functional groups; ii) covalent bonding, using epoxy functional groups and iii) 
ionic interaction, using amine functional groups present on the surface of the resin. The 
influence of the following parameters on the immobilization efficiency were studied: 
particle and pore size, length of functional group and the immobilization mechanism.  
Two types of ω-TAm enzymes were immobilized: a (S)-selective, developed and supplied 
by c-LEcta GmbH, Leipzig , Germany (hereafter designated as “S-TAm”) and a (R)-
selective, developed and supplied by DSM Innovative Synthesis BV, Geleen, Netherlands 
(hereafter designated as “R-TAm”). The immobilized biocatalysts were tested for their 
activity throughout many cycles of 24 hours under process conditions, as well as for their 
activity in non-conventional conditions such as: i) high temperature, which could 
potentially allow increasing the reaction rate and also the evaporation of volatile co-
products such as acetone (to shift equilibrium); ii) reaction in organic solvents, which 
could allow reactions in pure solvents to increase the substrate and product solubility or 
to carry out 2 liquid-liquid phase systems as an ISPR/ISSS strategy.  Suitable carriers 
were found following the screening methodology developed here. The selected carrier 
allowed retention of the enzyme activity over a long period of operation under process 
conditions, it allowed re-use of the enzyme for several cycles, and it increased the 
biocatalyst storage period at ambient temperature. The outcome of these results will 
assist during the process considerations chapter (Chapter 5).
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Documented attempts to immobilize enzymes date back as far as 1916, when Nelsonand 
Griffin reported that an invertase immobilized on charcoal was still active after the 
immobilization process [100]. Since then, several immobilization techniques have been 
described in the scientific literature for different enzymes. However, only a few of these 
immobilized preparations have made their way towards industrial implementation 
[101].  Most of the immobilized enzymes used at industrial scale are glucose isomerase 
(immobilized on inorganic carriers) for production of fructose corn syrup, penicillin 
acylase (covalently attached to polyacrylate carriers) for production of semi-synthetic 
penicillins, lactase (immobilized on an ion exchange resin) for production of low-lactose 
milk, lipase from Thermomyces lanuginosus (immobilized on silica) for fat modiﬁcation 
and lipase B from Candida Antarctica (immobilized on polyacrylate) for use in resolutions 
in the manufacture of pharmaceutical intermediates [23]. 
Considering the long list of advantages that the use of 
an immobilized biocatalyst offer compared to its free 
formulation (see Box 4.1), it would be expected that a 
large number of processes would be running using 
immobilized biocatalysts as well as a large number of 
commercially available immobilized enzymes. 
However, this is not the reality.  Lipase is probably the 
most successful case of a commercially available 
immobilized enzyme which is supplied by several 
companies such as Novozymes A/S, Denmark 
(Novozym®435 and Lipozyme® TL IM), Roche 
Molecular Biochemicals, Germany (Chirazyme L-2), as 
well as similar preparations from SPRIN Technologies S.p.A (Italy), c-LEcta GmbH 
(Germany) and CLEA Technologies B.V (The Netherlands) [102].  
 
Main advantages of immobilization 
 
x easy recovery and reuse 
x improved activity 
x improved operational stability  
x improved storage stability  
x possibility for continuous 
operation in packed bed reactors,  
x minimization of protein 
contamination in the product 
Box 4.1: Example of advantages offered by 
immobilization. 
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A possible reason for this trend can be the lack of a general, and simple to use, method 
for immobilization that can be applied to any enzyme. Hence, a trial and error approach 
often is required whenever one wishes to utilize immobilized enzymes.  
Furthermore, the loss in activity due to introduction of mass transfer limitation and loss 
of active enzymes by leaching or irreversible denaturation, which are commonly 
observed in immobilization of enzymes, can be a limiting factor. Another disadvantage 
which could limit the use of immobilized enzymes is the increase of the biocatalyst cost 
contribution in the production cost. However, the cost contribution of the immobilized 
enzyme for an implemented full scale process can potentially be lower than for a free 
enzyme, since the immobilized enzyme can be reused for many reaction cycles [32]. 
4.1.1. Immobilization of ω-TAm 
For challenging processes, such as the synthesis of chiral amines using ω-TAm, where 
several process strategies need to be applied in order to achieve higher biocatalytic yield 
(gproduct/gbiocatalyst), higher product concentration (gproduct/L) and reaction yield (%), 
immobilizing the catalyst can be decisive for the process feasibility. As will be discussed 
in Chapter 5, some of the strategies necessary to shift equilibrium and overcome product 
inhibition makes use of external agents such as organic solvents, or polymeric resins 
which, in theory, can decrease the biocatalyst stability and activity or interfere with its 
availability in the reactor (by binding onto column resin for example). In both cases, 
immobilizing the biocatalyst can be advantageous, especially when operating with cell-
free extract (CFE) or purified enzymes (PE) which are more exposed to media condition 
than when formulated as whole cells (WC). Moreover, the use of a immobilized 
biocatalyst can drastically reduce the costs associated with the biocatalyst and 
downstream processing, as immobilization would ease the separation of the biocatalyst 
from the products, and would also allow its re utilization for several cycles, increasing the 
biocatalytic yield (as discussed in Chapter 2).  
There is a limited amount of scientific literature reporting the use of immobilized ω-TAm 
with focus on both CFE and WC.  For instance, immobilized WC of ω-TAm by entrapment 
in calcium alginate beads has been applied by Shin and co-workers in the kinetic 
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resolution of chiral amines in a packed bed reactor [103]. The authors reported 
diffusional limitations and changes in substrate and product inhibition. In another study 
it was also reported that both Vmax and Km changed when WC were immobilized in 
calcium alginate beads, indicating diffusional limitations [104]. This has been overcome 
in another unrelated work where WC and permeabilized cells have been immobilized by 
entrapment in PVA-gel (Lentikats®) with no diffusional limitations and with an 
immobilization efficiency of 100% (observed activity/activity immobilized) [105].  
Attempts to immobilize E. coli WC by crosslinking with glutaraldehyde, or by entrapment 
with carrageenan and polyacrylamide were reported unsuccessful, with more than 50% 
of activity being lost in the case of crosslinking and entrapment with polyacrylamide, 
while the entrapment using  carrageenan resulted  in a mechanically unstable 
preparation [106]. In the same work, the authors reported immobilization of WC using 
hydrous titanium oxide (surface adsorption), calcium alginate (entrapment) and chitosan 
(by cell flocculation). The former was reported to show very poor loading capacity (less 
than 0.1 gWC/gcarrier, dry weight) and consequently decreased immobilization yield, while 
the preparation made with calcium alginate had decreased activity due to mass transfer 
limitations already at small loading as 0.2 gWC/gcarrier. This contrasted with the 
preparation made using chitosan which allowed loadings up to 3.2 g WC/g carrier (dry 
weight) and more than 60% residual activity.  
Immobilization of CFE of ω-TAm has been achieved both by covalent linkage to different 
solid support materials  and by entrapment in sol–gel matrices [107, 108] with reported 
immobilization yields of 20–50% protein (immobilized protein/total protein) and less 
than 20% of remaining activity [109]. Others works have reported low immobilization 
yields as well as poor residual activity (<50%) after immobilization by covalent 
attachment to carriers [110-112]. On the other hand, the same studies reported increased 
storage stability, often explained by the immobilization of the native proteases from the 
CFE which then become unable to degrade the ω-TAm.  
Enzyme recycle studies have also been reported with immobilized transaminase 
enzymes. Preparation of ω-TAm immobilized on chitosan beads was reported to retain 
77% activity after five reaction cycles of 8 hours each under the process conditions (25 
mM MBA, 25 mM PYR, 0.1 M k-PBS and 1 mM PLP)  however it was also susceptible to 
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severe substrate and product inhibition [109]. Cárdenas-Fernández and co-workers also 
reported 5 times re-use (in cycles of 3 hours) of ω-TAm WC with retention of 80% of 
initial activity [105]. Another study reports an improvement in the operational stability 
of the enzyme as result of the immobilization [108]. The enzyme was immobilized in sol–
gel matrices and was reported to have a slightly improved activity at higher temperatures 
compared to free enzyme, although the activity at higher pH (9-11) was significantly 
inferior. Moreover, it was possible to re-use the preparation in 8 cycles of 24 hours each 
with a decrease of about 20% in the maximum conversion achievable. 
In a recent work, Truppo and co-workers reported the development of an immobilized 
ω-TAm capable of operating in organic solvents (namely isopropyl acetate, isopropanol 
and toluene) [113]. However, it is not clear how much this is a result of the immobilization 
itself or a result of the prior improvements to the enzyme achieved through protein 
engineering techniques [31], as previously mentioned in Chapter 2. Nevertheless, the 
immobilized preparation allowed 10 times recycling in optimized reaction conditions, 
corresponding to ca. 200 hours of operation. While the stability can be associated with 
the protein engineering, the ability to filter, recover and re-use the biocatalyst is a feature 
that only immobilization makes possible. 
4.1.2. Motivation for this work: 
In some of the mentioned work, immobilization techniques using supports such as 
calcium alginate, hydrogels, hydrous titanium oxide and others, which require prior 
preparation are reported. Moreover, some of these compounds, or the preparation steps 
they are involved in, require special handling for being toxic or exothermic. This is the 
case of preparation of hydrous titanium oxide for instance, which is carried out by 
employing the exothermic reaction between hydrochloric acid (HCl) and titanium 
tetrachloride (TCl4) [114]. This can be a disadvantage for large scale production of 
immobilized enzymes where the procedures should be quick, robust, scalable and 
reproducible, while preserving the enzyme activity [115]. Moreover, working 
environment issues such as the handling of chemicals and dust-producing materials 
should be considered at such scale [115]. In addition, the mechanical stability of the 
immobilized preparation needs to be considered when scaling up a reaction using 
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immobilized biocatalyst. The carrier should be resistant to mechanical forces, as this can 
limit their applicability [116]. These concerns suggest the need for a different 
immobilization solution which is easier to use while allowing reproducibility, retention 
of the enzyme activity and ultimately providing mechanical rigidity to the enzyme.  
Furthermore, a structured screening approach procedure for immobilization carriers 
featuring ω-TAm is lacking. This work addresses these issues and gives an economic 
evaluation of the immobilization using the selected carriers.  
4.1.3. Overview of immobilization methods   
Over the last century, several methods have been developed to immobilize both free 
enzymes and whole cells. Immobilization of enzymes (CFE) will be the focus of this study. 
The immobilization methods for enzymes can be basically organized in three main groups 
(as depicted in Figure 4.1): i) immobilization by binding to a solid support (carrier); ii) 
immobilization by cross-linking and; iii) immobilization by entrapment (encapsulation) 
[117].  
 
Figure 4.1 Classification of immobilization methods. Adapted from [117]. 
 
Immobilized 
Enzymes
Binding to carriers
Covalent binding
Ionic binding
Adsorptive binding
Crosslinking
Direct crosslinking
Crystalization + 
crosslinking
Co-crosslinking
Co-polymerization
Encapsulation/ 
inclusion
Membrane devices
Microcapsules
Liposomes/ 
reversed micelles
Organic solvents
83
Chapter 4 – Immobilization of ω-transaminase 
 
68 
 Binding to carriers:  
Enzymes can be physically attached to supports through hydrophobic or van der Waals 
interactions, or chemically attached through ionic or covalent interactions. Physical 
interactions are however, generally too weak to keep the enzyme fixed to the carrier 
under industrial conditions (vigorous mixing, high reactant and product concentrations 
and high ionic strength), leading to enzyme leaching and consequently to a decrease in 
the activity. On the other hand, chemical interactions are stronger, being covalent 
interactions stronger than the ionic interactions, and thus significantly reduce or 
eliminate the risk of enzyme leaching from the support. One of the main drawbacks often 
associated with this type of immobilization is the high cost for the carriers, especially the 
ones of synthetic origin [118]. Nevertheless, the immobilization of enzymes using porous 
support such as polymeric resins, are free of intensive labour for carrier preparations, as 
these carriers are commercially available and ready to use. They are very versatile as it 
is possible to have different functional groups which can interact with enzymes in 
different manners as well as different particle and pore sizes which provide a wide range 
of possible immobilization mechanism for different enzymes at different operating 
conditions. Furthermore resins are mechanically stable supports, which allow the 
immobilized enzyme to be loaded in packed bed columns, for example [60, 117-119].   
 Cross-linking  
When cross-linked, the enzymes are covalently bond using a di-functional agent such as 
glutaraldehyde. In this method the enzyme acts as its own carrier, without requiring a 
support, which can bring several economic benefits. The immobilization is achieved 
through generation of enzyme aggregates or crystals of enzymes add mix those with 
precipitants such as acetone, ammonium sulphate, ethanol or 1,2-dimethoxyethane, 
followed by addition of a crosslinker, commonly glutaraldehyde [60, 117-119]. This type 
of immobilization brings some disadvantages such as the time consuming and labour 
intensive procedure to achieve the immobilization, the often reported loss of activity due 
to chemical changes caused to the enzymes when crosslinking them, the impossibility of 
loading the biocatalyst in columns and finally the often reported activity loss upon 
recycling [120].  
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 Entrapment (Encapsulation) 
Enzymes (and whole cells) can also be immobilized by entrapment using a polymer 
network such as an organic polymer, a silica sol-gel, or a membrane device such as a 
hollow fibre or a microcapsule. Encapsulation is one of the best means of avoiding any 
negative influence on the enzyme structure. However, mass transfer limitations for the 
substrates diffusion are often observed in this type of immobilization [60, 117-119].  
4.1.4. Selection of suitable supports for immobilization 
Considering the multiple options for enzyme immobilization, as depicted in Figure 4.1, it 
can be difficult to select the most suitable method for an enzyme of interest. Trial and 
error approaches can be very labour intensive and time consuming, hence, guidelines and 
constraints are required to simplify the carrier selection procedure.  
As discussed earlier, at full scale immobilization procedures should be quick and robust. 
It is also crucial to avoid the handling of dangerous chemicals and dust-producing 
materials which are often used in immobilization by entrapment and crosslinking. 
Finally, the immobilization is desired to provide an increase of mechanical stability to the 
catalyst. For this reason this work focuses on the immobilization of enzymes through 
binding to solid carriers.  
Some guidelines for selection of solid carriers can be found in scientific literature focusing 
on the ideal carrier properties which appear to be suitable to most of the enzymes [60, 
117]. These include the following list of guidelines: 
 the driving force for enzyme-carrier binding interaction should be as mild as 
possible. A harsh condition (e.g: extreme pH or temperature) can lead to loss of 
activity due to change in the enzyme conformation or complete denaturation; 
 the support should be highly porous so the enzymes and substrates can easily 
diffuse. Pore sizes of 10-100 nm appear to make the internal surface accessible for 
immobilization of most enzymes; 
 the surface area should be large (>100 m2g–1) as it increases the number of 
functional groups per unit of space and possibly allowing higher enzyme loading; 
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 the carrier itself should be mechanically stable and insoluble under the reaction 
conditions in order to prevent both enzyme loss or/and contamination of product, 
especially if stirred tank reactors are used as the shear forces can destroy the 
carrier. Carriers stable in the temperatures ranges of 10-60 ˚C and pH of 5-10 
should be suitable for most biocatalytic processes; 
 the shape of the support is preferred to be spherical particles with very low 
swelling properties;  
 the particle size should not be too small. This influences the type of filtration sieves 
required for biocatalyst separation when working on repeated batch mode in 
stirred tank reactors or using column reactors in batch and continuous modes, 
since small particles can result in high back pressures. Particles with diameter 
between 0.1 to 0.8 mm appear to be suitable for most enzymes;  
These guidelines give already an excellent overview on the desired carrier properties 
which satisfy most of the enzymes. There are several commercially available supports 
which successfully fulfil these characteristics. They can be divided into those of inorganic 
and organic origin. Examples of inorganic origin supports are: Silica gel (commercially 
available under the names Spherosil®, Pall, USA or Aerosil®, Evonik Industries AG, 
Germany) and Organopolysiloxanes (commercially available as Deloxan®, Evonik 
Industries AG, Germany).  Organic supports can be of natural occurrence, such as chitosan 
and dextran, or more mechanically stable and more commonly used, of synthetic origin 
such as polymeric resins. These are mainly made of polystyrene, polyacrylate, polyvinyls, 
polyamide and polypropylene. They are commercialized as purely adsorptive supports, 
as ion exchangers or with epoxy functional groups (allowing covalent bonding). These 
supports are commercialized by several companies, under different trade names such as 
Amberlite, Duolite and Dowex (Dow Chemicals. USA), Lewatit (Lanxess, Germany), 
Diaion, Sepabeads and Relyzmes (Resindion, Italy), Purolite ECR® (Purolite, USA), among 
others [60]. 
The work by Truppo and co-workers [92], featured ω-TAm immobilized on a 
macroporous hydrophobic support, Sepabeads EXE 120 (Mitsubishi, Japan). As 
mentioned before the preparation showed remarkable stability in organic solvent and 
good residual activity after 10 batch-cycles. This work opened a new door regarding the 
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immobilization of ω-TAm on rigid synthetic polymers. However, the carrier used is not 
commercially available and is protected by a patent application [121]. Therefore, a step-
wise characterization of various commercially available polymeric supports (hereafter 
simply referred to as “resins”) is required to screen and select a suitable carrier that can 
potentially be applied to ω-TAm.
 
The resin library was built based on the guidelines discussed in section 4.1.3. The library 
comprised 20 commercially available macroporous polymeric resins composed by a rigid 
polymethacrylate polymer matrix (Figure 4.3). The library contained resins establishing 
in total 3 different types of interaction with the enzyme (Figure 4.2): 
i. hydrophobic interactions using otcadecyl functional groups present on the 
surface of the resin;  
ii. covalent bonding using epoxy functional groups present on the surface of the 
resin, and; 
iii. ionic interaction using the amine functional groups present on the surface of the 
resin. 
i) 
 
ii) 
 
iii) 
 
Figure 4.2: Immobilization mechanism. i) hydrophobic interactions using octadecyl functional groups; ii) covalent bonding 
using epoxy functional groups; iii) ionic interaction using the amine functional groups; 
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Besides the multiple options for immobilization mechanisms, the library was also 
comprised of resins with different functional group lengths as well as different bead and 
pore size grades in order to understand the effect of these properties on the 
immobilization of transaminase (Table 4.1).  
The library was characterized with regard to loading capacity, activity retention, enzyme 
leaching, re-usability, solvent, temperature stability and storage stability. Based on these, 
a screening methodology was developed which is discussed in the following section.  
 
     
     
Figure 4.3 SEM pictures of macroporous polymeric resin (Relizyme OD403/m). (A = 100x magnification, B = 500x, C = 5000x 
and D = 20.000x) 
 
 
A B
C D
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Table 4.1: List of resins for enzyme immobilization and their properties. “s” grades correspond to bead sizes in the range of 
0.1-0.3 mm and “m” grade to bead size in the range of 0.2-0.5. All the Relizymes have pore diameters between 40-60 nm 
and Sepabeads 10-20 nm. Carriers B and C are resins establishing hydrophobic interaction with the enzyme; D to G are resins 
establishing covalent bonding with the enzymes and H to K establish ionic interaction. Specfications according to the 
manufacturer (Resindion Srl, Italy) 
 
 Structure and functional group Resin ID Resin name 
Pore : 
(nm) 
Beads : 
(mm) 
Hy
dr
op
ho
bi
c 
 
B-s Relizyme OD403/s 
40-60 
0.1-0.3 
B-m Relizyme OD403/m 0.2-0.5 
C-s Sepabeads EC-OD/s 
10-20 
0.1-0.3 
C-m Sepabeads EC-OD/m 0.2-0.5 
Co
va
le
nt
 in
te
ra
ct
io
n 
 
D-s Relizyme EP403/s 
40-60 
0.1-0.3 
D-m Relizyme EP403 /m 0.2-0.5 
E-s Sepabeads EC-EP /s 
10-20 
0.1-0.3 
E-m Sepabeads EC-EP/m 0.2-0.5 
 
F-s Relizyme HFA403 /s 
40-60 
0.1-0.3 
F-m Relizyme HFA403/m 0.2-0.5 
G-s Sepabeads EC-HFA/s 
10-20 
0.1-0.3 
G-m Sepabeads EC-HFA/m 0.2-0.5 
Io
ni
c i
nt
er
ac
tio
n  
H-s Relizyme EA403/s 
40-60 
0.1-0.3 
H-m Relizyme EA403/m 0.2-0.5 
I-s Sepabeads EC-EA/s 
10-20 
0.1-0.3 
I-m Sepabeads EC-EA/m 0.2-0.5 
 
J-s Relizyme HA403/s 
40-60 
0.1-0.3 
J-m Relizyme HA403/m 0.2-0.5 
K-s Sepabeads EC-HA/s 
10-20 
0.1-0.3 
K-m Sepabeads EC-HA/s 0.2-0.5 
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Suitable supports for immobilization can be selected based on different factors, 
depending on the features desired. Often, the immobilization of enzymes is carried out to 
increase the enzyme stability, especially in non-conventional media (e.g. organic solvent, 
high pH or temperature), while in other cases the possibility of re-using the biocatalyst is 
more emphasized. 
In a challenging process such as the synthesis of chiral amines using ω-TAm, where the 
biocatalyst contribution cost is presumably  high, the main advantage that immobilization 
can bring is the possibility to re-use the biocatalyst [32]. Furthermore, in order to 
implement the process engineering strategies mentioned in Chapter 2, it would be an 
advantage if immobilization could also bring operational stability. With this in mind, a 
screening methodology was elaborated in order to select suitable supports to immobilize 
both (S)- and (R)-selective ω-TAm.  The methodology is divided in 4 steps of 
characterization as described below and illustrated in Figure 4.4: 
 Step I: Prior to any experimental work, the library should be screened according 
to the carrier stability (pH and temperature). These properties (carrier 
operational pH and temperature) should match the reaction conditions. Resins 
showing these properties lower than the reaction conditions are discarded; 
 Step II: The resins are tested for: a) capacity to immobilize the enzyme, this can be 
evaluated through the loading capacity (gImm-CFE/gresin) and/or immobilization 
yield (gImm-CFE/gCFE x 100 or activityImm-CFE/activityCFE); and b) capacity to retain 
enzyme’s activity (activityImm-CFE/activityCFE). A threshold of 0.9 (activityImm-
CFE/activityCFE) was defined in this study in order to select only the most suitable 
resins. Preparations showing residual activity or immobilization yields <0.9 were 
discarded. The pre-selected resins are expected to have properties favourable to 
the enzyme, thus, other type (e.g. S or R-ω-TAm), or ω-TAm from other 
microorganism sources (with similar Mw) can be introduced in the screening at 
this stage; 
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 Step III: The pre-selected preparations are tested for their activity throughout 
several cycles in reaction conditions. In the current study, a total of 8 cycles were 
made and preparations showing residual activities (activityImm-CFE/activityCFE) 
lower than 0.5 were discarded. 
 Step IV: The suitable selected resins are tested for activity at high temperatures, 
activity in organic solvent and activity after a long storage period at room 
temperature.  
STEP II: IMMOBILIZATION EFFICIENCY
Loading
capacity
Residual 
activity
(n3) carriers
(n2) carriers
Yes
STEP III: OPERATIONAL STABILITY
Re-use of the 
biocatalyst Resin stability
STEP IV: ACTIVITY UNDER ALTERNATIVE CONDITIONS
Activity under 
high temperature
Activity under 
organic solvent 
Activity after long 
storage period
(n1) carriers
(n) carriers
Yield and 
activity ≥ 90%?No
Carrier
discarded
Residual 
activity ≥ 50%?
Yes
Carrier
discarded No
1st enzyme
2nd enzyme
STEP I: CARRIER COMPATIBILY
pH range Temperature range
(n4) carriers
Properties 
match reaction 
cnditions?
No
Carrier
discarded
Yes
 
Figure 4.4: Screening diagram (n4>n3>n2>n1) 
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All the resins were purchased from Resindion S.R.L (Milan, Italy). The chemicals were all 
obtained from Sigma-Aldrich (Buchs, Switzerland). The S-TAm, formulated as lyophilized 
cell-free extract, was purchased from c-LEcta GmbH (Leipzig, Germany) and the R-TAm 
(WC) was kindly supplied by DSM Innovative Synthesis (Geleen, The Netherlands). With 
exception for assays regarding temperature stability, all the experiments were run in 
duplicate. 
4.4.1. Pre-treatment of S-TAm enzymes:  
The enzymes were obtained already formulated as a lyophilized CFE powder. An enzyme 
solution of 5 gCFE/L (dry weight) was diluted in 100 mM k-PBS pH 7 containing 8 mM of 
PLP and 1 mL of this solution was added to the resins.  
4.4.2. Pre-treatment of R-TAm enzymes:  
The R-TAm was obtained as frozen centrifuged fermentation broth. The cells were re-
suspended in 100 mM k-PBS pH 7 containing 8 mM of PLP solution (with a buffer/WC cell 
mass ratio of 2:1).   The OD at 620 nm was measured to be approximately 0.3 (after 30 
times dilution). The suspension was sonicated using a Sonics vibra-cell TM, sonicator 
Model”CV.18 9836A (USA), set for 10 minutes with 75% of amplitude and a pulse of 10. 
The OD was once again measured to be approximately 0.03 (after 30 times dilution). The 
sonicated was then centrifuged (Eppendorf Model 5415 R, Hamburg - Germany) for 10 
minutes at 1300 rpm and the pellet was discarded. The supernatant was diluted with 100 
mM k-PBS pH 7 containing 8 mM of PLP with a ratio 1:9. The final solution corresponded 
to approximately 7.9 gCFE/L (dry weight) when lyophilized. 
Lyophilisation:  The sample were frozen -80 ˚C overnight and lyophilised at -54 ˚C for 6 
hours under vacuum (10E-2 mBar) using a Heto LyoLab 3000 from Thermo Scientific 
(Massachusetts, USA). 
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4.4.3. Immobilization procedure: 
The resins (50 mg for S-TAm and 100 mg for R-TAm) were washed with 1 mL 100 mM k-
PBS pH 7 at room temperature.  After 1 minute the washing buffer was discarded by 
means of a syringe with needle. Afterwards, 1 mL of the enzyme solution was added to 
the resins. The preparations were placed on an orbital shaking incubator (IKA ® KS, 
Model 130 Basic - Germany) at room temperature (25-27 ˚C) for 48 h at 400 rpm.  
4.4.4. Activity assay: 
The activity assay was carried out in 4 mL vials at 30 ˚C at approximately 400 rpm (IKA 
® KS, Model 130 Basic - Germany). The reaction mixture (1 mL final volume) for S-TA 
was composed of 1 M IPA, 30 mM APH, 2 mM PLP and 100 mM k-PBS pH 7. For R-TA, the 
reaction mixture (2 mL) was composed of 50 mM DL-(-)-MBA, 10 mM BA, 2 mM PLP and 
100 mM k-PBS pH 7. Samples (100 μL) were taken at hours 1.5, 3, 6 and 24, diluted into 
400 μL of 1 M HCl and centrifuged for 10 minutes (Eppendorf Model 5415 R - Germany) 
at 1300 rpm prior to analysis. 
4.4.5. Analytical: 
All the samples were analysed by measuring the concentration of (S)-MBA (for reactions 
catalysed by S-TAm) and (R)-APB (for reactions catalysed by R-TAm) using HPLC (Agilent 
1100 Series). The compounds were separated on a Prevail C18 250x4.6 mm, 5 μm column 
(Alltech Associates Inc., Illinois, USA) at a flow rate of 2 mL/min using a multi-step 
gradient flow of aqueous 100 mM Perchloric acid and pure acetonitrile, with the following 
percentage of acetonitrile: 0 min (0%), 1 min (10%), 2.5 min (10%), 5.9 min (60%), 6 min 
(0%), 7 min (0%).  Compounds were detected at 210 nm. The quantitative analysis was 
performed based on peak areas from external standards. 
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4.4.6. Step I of screening – Carrier compatibility 
The MSDS (material safety data sheet) obtained from the manufacturer was used to find 
the carrier proprieties.  For all the resins establishing a covalent interactions with the 
enzymes (resins D, E, F and G from Table 4.1), the temperature and pH operational 
stability was found to be in the range of 0-10 ˚C and 5-8, respectively. For all the other 
carriers, the operational stability reported for temperature and pH is 2-60 ˚C and 1-14, 
respectively. Considering that most of ω-TAm catalysed reactions reported are run in 
temperatures between 25 ˚C and 60 ˚C and pH from 6 to 8, the covalent resins were 
considered not compatible with the process. Therefore they were discarded. 
4.4.7. Step II of screening: Immobilization efficiency 
After the immobilization, samples were taken from the supernatant and assayed for 
residual activity in order to estimate the amount of enzymes that did not bind to the 
carrier. The remaining supernatant was discarded and the resins were washed twice (for 
2 minutes and 1h30 respectively) with 100 mM k-PBS pH 7.0 under mild agitation at 
room temperature (25-27 ˚C). Samples were taken from the supernatant after the second 
washing and analysed for activity in order to quantify the amount of enzyme that might 
have leaked out of the carrier (leakage quantification). The remaining washing buffer was 
discarded and reaction mixture was added to the resin and activity assay was carried out 
to estimate the residual activity in the immobilized. Free enzymes treated in the same 
conditions were used as reference. 
4.4.8. Step III of screening: Operational stability 
Both (S)- and (R)-selective ω-TAm immobilized, as previously described, were re-used 
for 8 cycles of 24 hours each (with exception for cycle number 5 which lasted 72 hours). 
Samples were taken at hours 1.5, 3, 6, and 24 or 72. After each cycle, the remaining 
reaction mixture was discarded and the resins were washed once with 1 mL of 100 mM 
k-PBS pH 7. The washing buffer was removed (by means of a syringe with a needle) and 
fresh reaction mixture was added to start the new cycle. 
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4.4.9. Step IV of screening: Activity under alternative conditions  
 Activity under high temperature 
Free enzymes were incubated for 12 hours at 50 °C in 100 mM k-PBS pH7 solution 
containing 2 mM PLP. After the incubation, reaction mixture was added to the enzymes 
and the activity assay was initiated at 50 °C. The immobilized enzymes were incubated in 
the reaction mix used for the activity assay (as described in 4.4.4). After the incubation, 
the liquid was discarded and the immobilized enzymes were rinsed with 100 mM k-PBS 
pH7 solution before fresh reaction mixture was added to start the activity assay.  
 Activity under organic solvents 
Lyophilized enzymes (5 mg for S-TAm and 7.9 mg fo R-TAm - dry weight) and 
immobilized enzymes (prepared as previously described and followed by a drying step 
with Nitrogen sweeping) were tested for activity in water saturated toluene, isopropyl 
acetate, cyclohexane and 50 % isopropanol. The solvents were saturated with equal 
volume of aqueous solution (100 mM k-PBS pH 7, containing 2 mM of PLP) for 72 hours 
under vigorous mixing to ensure proper saturation of both phases. The aqueous phase 
was discarded and IPA and APH (final concentrations of 1 M and 30 mM, respectively) 
were added to the saturated organic phase for the reaction using S-TAm, while DL-MBA 
and BA (final concentration of 50 mM and 10 mM respectively) were added to reactions 
using R-TAm. The activity assay was carried out in 4 mL vials at 30 ˚C at approximately 
400 rpm (IKA ® KS, Model 130 Basic - Germany). Samples of 100 μL were taken at 1.5, 3, 
6 and 24 hours, diluted in 400 μL acetonitrile, centrifuged and analysed by HPLC. 
 Activity after storage: 
Free and immobilized enzymes (prepared as described in 4.4.1) were left in the fume 
hood for 20 days at room temperature (which oscillate between 25-27 °C). The free 
enzymes were prepared in 100 mM k-PBS pH 7.0, 8 mM PLP solution, while the 
immobilized enzymes were left in a semi wet state (the excess of immobilization buffer 
was removed by means of a syringe). 
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In addition, the immobilized enzymes previously used in Step III of characterization 
(section 4.4.8) were washed with 100 mM k-PBS pH 7.0, 8 mM PLP solution after the 8th 
cycle, the excess washing buffer was then removed by means of a syringe and the 
immobilized preparations were left in the fume hood (25-27 °C ) for 60 days. After the 
resting period, the biocatalysts were added to the reaction mixtures and the activity assay 
was initiated. 
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4.5.1. Step I of screening – Carrier stability 
Based on the MSDS files obtained from the manufacturer, it was observed that for all the 
resins establishing covalent interaction with enzyme (resins D, E, F and G), the 
temperature and pH operational stability was in the range of 0-10 ˚C and 5-8, 
respectively. For all the other carriers, the operational stability was in the range of 2-60 
˚C and 1-14, for temperature and pH respectively. Considering that most of ω-TAm 
catalysed reactions reported are run in temperatures between 25 and 60 ˚C and pH from 
6 to 8, it was concluded that these resins were not compatible with the process 
conditions. This was experimentally confirmed in an assay where these resins dissolved 
in the reaction solution after 24 h of operation (data not shown).  Resins B, C, H, I, J and K 
were selected for the next step of the screening.  
4.5.2. Step II of screening – Immobilization efficiency 
The immobilization yield (activityImm-CFE/activityCFE), together with the loading capacity 
(gImm-CFE/gResin) of the carrier is of high importance, since low immobilization yield and 
low loading capacity is often translated into an economically infeasible immobilization 
process. Often, a reference loading capacity of 0.1 gImm-CFE/gResin is used in scientific 
literature as ideal [60, 102].  
In this step, these parameters were used to evaluate the performance of the different 
preparations and the results are summarized in Figure 4.5, and are discussed in the 
following sections.  
 Leakage quantification 
For all the resins the results suggested no significant enzyme leakage after 1h30min 
washing with 100 mM k-PBS pH 7, since no activity was detected in the washing buffer 
(data not shown).  
97
Chapter 4 – Immobilization of ω-transaminase 
 
82 
 Diffusional limitations 
No mass transfer limitations or diffusional effects were observed. For all the resins, the 
activity missing in the carrier (characterized by the low activity in the immobilized) was 
traced back in the supernatant (corresponded activity in the aqueous phase) as it can be 
observed in Figure 4.5. For some of the preparations, the biocatalytic activity appeared 
to be enhanced as result of the immobilization. This was observed, for instance, with 
carriers H, I, J and K where the sum of the activity in the supernatant and the activity in 
the immobilized exceed 100%. 
 
Figure 4.5 – Relative activity in the immobilized and in the supernatant. Blue bars - relative activity in the supernatant (not 
immobilized enzyme); Red bars - relative activity in the immobilized, dashed line – threshold for screening. Results based 
on initial rate measurements for supernatants and immobilized, in comparison with initial rate measurements for free 
enzyme. 
 Effect of functional group and its length on the immobilization yield: 
The results obtained suggested better loading capacity for resins establishing ionic 
interactions with the enzyme in comparison with those establishing hydrophobic 
interactions. Within this group, the resins having long length functional groups appeared 
to have better loading capacity for the enzyme. This can be observed for the resins Jm, Js, 
Ks and Km which showed the highest activity in the immobilized (and also the least 
activity in the supernatant), while the resins showing short length functional groups 
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showed a slightly inferior loading activity in the immobilized and in average more activity 
in the supernatant (resins Hs, Hm, Is and Im). In theory this could be related to the 
obstruction of the enzyme’s catalytic centre upon immobilization in case of short length 
functional group due to proximity of the enzyme to the carrier surface. This is often 
overcome by the use of spacers [60, 117, 120]. However, if this would have been the case, 
it would have resulted in low activity both in the supernatant and in the immobilized, 
since enzymes would be still loaded onto the carrier  but not active due to a inaccessible 
catalytic centre or wrong conformation, and this was not observed. Hence, it can be 
hypothesized that there is an easier interaction of long length functional groups of the 
resin with groups on the enzyme as observed for the carriers J and K in comparison with 
H and I. Fs, Jm, Js, Fm and Gs (Figure 4.5).  This was also observed for the covalent resins 
(data not shown), where the resins F and G (long chain functional group) showed better 
residual activity and loading capacity in comparison with resins D and E (short chain 
function group). 
 Effect of particle size on the immobilization yield: 
The particle size also appear to have an effect on the immobilization yield as well, with 
the “m” grade carriers (0.2-0.5 nm mean particle size) showing in general higher residual 
activity hence loading capacity than the “s” grade (0.1-0.3 nm). This can be observed for 
all the resins (Figure 4.5). This is potentially due to the higher surface area, which also 
corresponds to higher functional group density.  
 Effect of pore size on the immobilization yield: 
Finally, the results also indicate an effect of pore size on the immobilization yield. Resins 
showing larger pore size (40-60 nm) showed in general better immobilization yield than 
those having a smaller pore size (10-20 nm). For instance, immobilizations with carrier 
B (hydrophobic resins) showed higher immobilization yield than immobilization with C. 
The same is observed for H and I, and finally for J and K, respectively (Figure 4.5)  
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 Summary of the results obtained in Step II 
Considering these results, the influence of the different properties on the immobilization 
of ɘǦTAm can be organized as follow (based on immobilization yield): 
 length of functional group: long > short;   
 immobilization mechanism: covalent1 > ionic > hydrophobic; 
 particle size: 0.2-0.5 mm > 0.1-0.3 mm; 
 pore diameter: 40-60 nm > 10-20 nm. 
This suggests the ideal carrier for immobilization of ɘǦTAm should be particles with 
mean diameter in the range of 0.2-0.5 mm, with long functional group chain and a pore 
diameter in the range of 40-60 nm. The larger particle size is convenient since it will 
influence the type of filters required to separate the biocatalyst in the downstream 
processing phase, as previously discussed. 
Together with these criteria, a threshold of 90% for residual activity and immobilization 
yield was set and all the preparations showing lower residual activity were discarded. In 
summary, the following resins were selected for Step III: Bm, Hm, Im, Jm and Km. All these 
resins had a loading capacity comparable to the reference of 0.1 gImm-CFE/gResin used in 
literature  [60, 102], as can be observed in Table 4.2. 
Table 4.2 Summary of residual activity (activityImm-CFE/activityCFE.100) and loading capacity (gImm-CFE/gResin) for the pre-selected 
resins. The “activityImm-CFE” was obtained from the difference between the activity of free CFE and the activity in the 
supernatant (after immobilization).  
Resin # Residual activity 
(%) 
Loading capacity 
(gImm-CFE/gResin) 
Bm 92.2 0.09 
Hm 99.0 0.10 
Im 82.5 0.08 
Jm 96.9 0.10 
Km 94.4 0.09 
 
                                                        
1 Although not shown here, immobilization was also carried out using covalent resins. Excellent 
immobilization yields were observed. However, after 24 hours under the reaction condition the 
preparation dissolved in the reaction mixture. 
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4.5.3. Step III of screening – Operational stability 
Equally important as the loading capacity, the ability to re-use the biocatalyst is in most 
cases the key advantage pursued by industry with regard to immobilization. The five pre-
selected resins from Step II were re-used for 8 cycles of 24 hours each under the reaction 
condition (with exception for cycle number 5 which lasted 72 hours instead of 24). In 
total the five resins were subjected to approximately 250 hours of operation (pH 7, and 
temperature of 30 ˚C).  
A second ω-TAm (R-TAm, from DSM) was introduced at this stage of the screening. 
Although this enzyme was from a different organism, it was assumed that the five 
selected resins would have similar affinity to this new enzyme. Both initial rate and 
production over time were used to evaluate the biocatalysts performance. The results are 
presented in Figure 4.6 and Figure 4.7, for production over time and initial rate 
measurements experiments, respectively. 
 Immobilization yields: 
The immobilization yield for S-TAm was similar or superior to the ones obtained in Step 
II (approximately 100% for all the selected 5 resins) while for R-TAm the immobilization 
yield were around 50% (Appendix 4B), despite the fact double amount of resins was used. 
On the other hand, the amount of R-TAm (CFE) use was superior to the one used for S-
TAm (7.9 g/L in comparison with 5 g/L - dry weight), hence the protein content in the R-
TAm solution immobilized can be expected to be superior. It is also possible that the 
expression level and the purification level in both cases are different since both enzymes 
were prepared by different laboratories, being the S-TAm supplied in a semi-purified 
formulation, which could explain the difference in immobilization yield. 
 Operational stability (biocatalyst re-cycle) 
The results obtained for biocatalyst re-use for both S-TAm and R-TAm were evaluated by 
following the conversion over time for both enzymes throughout 8 cycles (Figure 4.6 A 
and Figure 4.6 B) and also by following the initial rate measurements for each cycle 
(Figure 4.7 A and Figure 4.7 B for S-TAm and R-TAm, respectively).  
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Based on the maximum possible conversions achieved at the end of each cycle, the 
preparations using the resins Bm, Jm and Km showed better performance among the 5 
for S-TAm. For these 3 preparations, the maximum possible conversions (comparing to 
the free enzymes) were achieved at the end of all the cycles (Figure 4.6 A). For R-TAm, all 
the 5 preparations showed maximum possible conversion after 24 hours in all the cycles 
(Figure 4.6 B), suggesting an excellent activity retention despite the lower immobilization 
yield.  
 
Figure 4.6: Conversion over time for the different cycles (A: using immobilized S-TAm; B: using immobilized R-TAm). Dashed 
line marks the maximum conversion after 24 hours achieved for free enzyme (used as reference) under similar conditions.  
However, these results do not say much about the enzyme activity at each cycle and how 
much of the activity is lost. A different picture would be obtained if higher substrates 
concentration were used and if thermodynamic equilibrium and product inhibition were 
not limiting these reactions. In order to better evaluate the performance throughout the 
different cycles, initial rate measurements were plotted for both enzymes and are 
presented in Figure 4.7. As expected, due to the high immobilization yield achieved, all 
the preparations for S-TAm presented in the first cycle an activity which is comparable 
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to the free enzyme activity (illustrated by the dashed line in Figure 4.7 A). However, in 
the second cycle the activity decreases almost in 50% for all of the preparations and from 
this point the loss of activity for the following 7 cycles is not so accentuated, especially 
for the preparations using Bm, Jm and Km which kept 50-60% of the initial activity after 
the 8 cycles (about 250 hours of operation).  
 
Figure 4.7: Initial rate measurements for different cycles. A: using immobilized S-TAm; B: using immobilized R-TAm). Dashed 
line marks the maximum conversion after 24 hours achieved for free enzyme (used as reference) under similar conditions.  
Since protein quantification studies were not performed between the cycles, it is not clear 
whether the accentuated loss of activity from the first to the second cycle is due to enzyme 
leaching or deactivation. Enzyme leaching would not be expected to occur with carriers 
establishing ionic interactions, as previously discussed.  
The results for initial rate measurements for R-TAm showed a better conservation of 
activity throughout the 8 cycles for all the preparations, with special emphasis to 
preparations featuring the resins Bm and Im which retained more than 90% of the 
activity (Figure 4.7 B). 
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Based on these results, the resin library was reduced to 3 carriers: Bm, which showed 
good activity retention for both enzymes; Jm and Im, which showed good performance 
for S-TAm and R-TAm, respectively.  
4.5.4. Step IV of screening –Activity under alternative conditions 
Stability is one of the improvements often used to justify the need for immobilization. 
Many authors reported enhancement of the biocatalyst stability as result of 
immobilization using many different enzymes reported [122, 123]. 
Temperature stability is one of the improvements which can be achieved through 
immobilizing the enzyme. A more thermo stable biocatalyst may open the possibility of 
carrying out reactions at higher temperatures, which can be translated into higher 
reaction rates and the possibility of new process options such as the evaporation of 
volatile co-products such as acetone in order to shift reaction equilibrium [32].  
Furthermore, the activity in non-conventional conditions (or alternative conditions), 
such as in organic solvents, is often discussed and reported in several scientific literature 
[92, 122, 124]. As previously discussed, having biocatalyst which can operate in organic 
solvents can make possible the use of ISPR using liquid-liquid separation or reaction in 
pure organic phase which could bring advantages such as an increased substrate and 
product solubility [32]. 
Finally, the possibility to keep the immobilized preparation for long period of time can 
also be advantageous and it is equally widely discussed and pursued [117, 119, 122, 125, 
126]. It can save time and allow immobilization of large amount of enzyme in advance for 
future utilization as well as it opening the possibility for commercialization of the 
immobilized enzyme. 
 In order to fully explore the improvements in the biocatalyst resulting from the 
immobilization, temperature, solvent and storage stability experiments were carried out 
to the preparations of S-TAm and R-TAm immobilized in the 3 pre-selected resins. The 
results are presented and discussed in the following sections. 
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 Activity under high temperature  
The immobilized enzymes were incubated for 24 hours at 50 °C and compared to free 
enzymes incubated at the same temperature but for 12 hours. Both were finally 
compared to the free enzymes incubated at 30 °C for 24 hours. The results illustrated in 
Figure 4.8 A and Figure 4.8 B for S-TAm and R-TAm respectively, show that free enzymes 
incubated at 50 °C lose about 80% and 100% of its activity (respectively). None of the 
immobilized preparations of S-TAm showed substantial improvements under the assay 
conditions (50 °C), when compared with the free enzyme treated under the same 
conditions. The best result for the S-TAm was obtained with the preparations of the resin 
Jm (long chain ionic exchange resin) which showed slightly higher residual activity in 
comparison to the free enzymes (Figure 4.8 A).  
On the other hand, the results were more prominent for the R-TAm, which was found to 
retain 80% of its activity in the immobilization preparation of resin Bm (hydrophobic) 
and about 30% with the Im (short chain ionic exchange), in comparison with the 0% of 
residual activity measured in free enzymes (Figure 4.8 B). These encouraging results 
illustrate an enhanced stability at 50 °C, achieved as result of immobilization. 
   
Figure 4.8: Temperature stability for S-TAm (A) and R-TAm preparations (B). 
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 Activity under organic solvent  
Free and immobilized enzymes were used to run reactions in water saturated organic 
solvents, both water-miscible and water-immiscible. Similar experiment have been 
previously reported with excellent results [92]. However, the results obtained here 
suggest that the biocatalyst activity in organic phase was not enhanced as result of 
immobilization. None of the immobilized preparations performed better than free 
enzymes in any of the solvents with exception for the assay performed under 50% 
isopropanol, where almost 5% of residual activity was found in the preparation of S-TAm 
immobilized with resin Jm (Figure 4.9). As previously mentioned, a good performance in 
organic solvent is related to the activity of the enzyme itself under the organic solvent. 
On the other hand, these results could also be related to a poor mass transfer of the 
substrate from the organic phase to the biocatalyst itself, or the lack of the cofactor (PLP) 
in the reaction mixture, since PLP is not soluble in organic phase. However, this 
possibility was not further experimentally explored. 
 
Figure 4.9: Activity of S-TAm under organic solvent. IPAc (isopropylacetate), iPrOH (isopropyl alcohol). ND – No activity 
detected. 
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 Activity after storage period  
The results for the storage stability presented in Figure 4.10 show an improved stability 
at room temperature for all the immobilized preparations, since these retained more 
activity than the free enzyme formulations of both S-TAm and R-TAm. 
  
Figure 4.10: Relative activity after storage at room temperature for S-TAm (A) and R-TAm (B). NM - Not measured.  
Similarly to what was observed for the operational stability experiment (section 4.5.3), 
the storage stability of the immobilized preparation also appears to slightly lose activity 
in the first cycles/days, stabilising from that point. Both immobilized enzymes (using 
both hydrophobic and ionic exchange resins) retained more activity after 20 and 60 days 
in comparison with their free formulations. In general, the ion exchange resins (Im and 
Jm) allow more activity retention than the hydrophobic resins (Bm) after 60 days. More 
than 50 % and 40% of residual activity was observed for S-TAm and R-TAm immobilized 
on the ionic exchange support, after 60 days. These results are more encouraging than 
those previously reported where losses of 30 % and 92% of activity of ω-TAm 
immobilized on chitosan and Eupergit® C, respectively, after 3.5 weeks (c.a. 24 days) 
under 4 °C were obtained [109]. The same study reports a possible benefit effect of the 
co-factor PLP on the enzyme stability over time. This was not investigated in this thesis. 
The outcome of this experiment allows a better understanding of the period the 
immobilized preparations can be stored. A better activity retention is expected if the 
preparations were stored at 4-5 °C.  
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4.5.5. Immobilization costs:  
The cost associated with the introduction of the immobilization step in the catalyst 
formulation (Figure 4.11) can be decisive for the success of the whole immobilization 
process, especially when using a synthetic carrier, where the costs are often reported as 
the highest for an immobilization carriers [20]. Factors such as the immobilization yield, 
the loading capacity of the carrier and the number of times that it is possible to re-use the 
preparation have a significant impact in the biocatalyst cost contribution to the process. 
In some biocatalytic processes the cost associated with the biocatalyst (in house 
production and formulation) can be about 35%, as described by Tuvfesson and co-
workers [97] for lipase catalysed reactions. It can be expected that for ω-TAm catalysed 
reactions, this fraction could be even higher if one considers that the biocatalyst 
production costs for ω-TAm are expectedly higher than for lipase-catalysed reactions 
(since processes featuring ω-TAm are relatively new).  
1) Fermenation 2) Biocatalyst formulation 4) Downstream processing3) Reaction  
Figure 4.11: Overall Biocatalysis process scheme 
 
In the next sections, the immobilization costs associated with the use of resins to 
immobilize ω-TAm will be discussed. The calculations were made with exclusive focus on 
the cost associated with the enzyme and carrier. Costs associated with capital expenses 
(e.g. equipment) and utilities (e.g. electricity), other raw materials or labour required to 
implement the process depicted in Figure 4.12 have not been considered.  
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Unless stated otherwise, all the calculations were based on the following process 
characteristics: 
 Number of cycles/batches= 10 
 Reaction volume: 10 L (pilot scale) 
 Enzyme concentration in the process: 10 gCFE/L (dry weight) 
 Resin loading capacity = 0.1 gCFE/gResin (assumed 100% immobilization yield)  
 Enzyme cost: 100-1000 €/Kg 
Mixing/immobilization
Cell free extract/
Purified enzyme
Buffer solution
Carrier
Filtration
Waste
Immobilized
enzymes
Drying
Immobilized
enzymes
Reaction
Reactants
Filtration
Enzyme recycle
Product stream
(to Dowstream
processing)
BIOCATALYST FORMULATION REACTION
Figure 4.12: Overall immobilization process scheme. 
 Carrier cost: 
The cost associated with the porous synthetic polymers to immobilize enzymes is 
reported to vary from 20 to 200 €/Kg [23]. As mentioned before, several manufacturers 
supply suitable similar carriers as the ones used here, and the prices vary from 
manufacturer to manufacturer. Since a rigorous investigation was not performed 
regarding to the price difference between them, it is difficult to fairly discuss about which 
supplier has the best offer. For this work, all the carriers were obtained from Resindion 
Slr. (Milan, Italy). The price of resins used in this work vary from 180 to approximately 
720 €/Kg (full price presented in Appendix 4C). These prices were however calculated 
based on the manufacturer’s price for 5 and 10 Kg packages, which, in theory, is enough 
to immobilize up to 1 Kg of enzyme (assuming a loading of 0.1 gCFE/gResin considered in 
this study).  It is reasonable to assume that purchase of larger amounts would 
significantly reduce the price per kilogram. 
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The type of immobilization mechanism established by the carrier has a significant impact 
on the price. According to the data collected (Appendix 4C), the covalent resins seem to 
be the most expensive, followed by the hydrophobic ones. Or another way of looking at 
this is to look at the length of the functional group: carriers with longer functional group 
chains are in general more costly than carriers having shorter ones. This can be observed 
among the covalent resins, for instance where F and G (long length functional groups) are 
in average 3 times more expensive than the resins D and E (short length functional 
groups). Also the particle size and pore size seems to have an influence on the price. The 
smaller the particles and/or pore size, the more expensive the resin becomes. 
Nevertheless, the resin costs can be disregarded if a high loading capacity or various 
number of cycles are possible, as will be discussed in the following sections. The 3 
selected carriers (Bm, Im and Jm) will be used to perform the economic evaluation. The 
purchasing cost for these resins can be found in Table 4.3 
Table 4.3: Resins prices. Calculated from 5 and 10 Kg packages obtained from the supplier homepage 
(http://www.resindion.com) 
Resin Resin name Cost (€/kg) 
B-m Relizyme OD403/m 576 
I-m Sepabeads EC-EA/m 183 
J-m Relizyme HA403/m 221 
 
 Influence of enzyme production or purchase cost: 
As mentioned in previous sections, immobilization can be a great advantage especially in 
processes where the cost of the biocatalyst represents a large part of the operating costs. 
This is illustrated in Figure 4.13 where the cost associated with the biocatalyst 
production/purchase required to run a 10 cycles in a 10 L scale was compared between 
free and immobilized enzymes. The real cost associated with production or purchase of 
large amount of biocatalyst is not clear as there is no consensus in the scientific literature. 
Different authors suggest different price ranges, nevertheless this often goes from 
100€/kg up to 1000 €/Kg for CFE [32, 97, 102]. For this reason, this range has been 
chosen in this work to illustrate the effect of enzyme cost on the process operating costs. 
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The biocatalyst production or purchase costs is known to be scale depended (i.e. the 
larger is the production scale of the biocatalyst, the less is the production/purchase cost)  
From the Figure 4.13, it clear that for a biocatalyst where production or purchase cost is 
about 100 €/Kg or less, the costs associated with the immobilization (using any of the 
three carriers) surpass the cost of using free enzymes (600 € and 200 € for preparations 
using the hydrophobic and ionic resins, respectively, in comparison with 100 € for the 
use of free enzymes). On the other hand, as the cost associated with the production or 
purchase of biocatalyst increases the more advantageous it becomes to immobilize it. 
 
Figure 4.13 Biocatalyst cost contribution to the process operating costs (€).Calculations based on a 10 L scale reactor, an 
enzyme concentration of 10 gCFE/L, carrier loading of 0.1 gImm-CFE/gResin (assumed 100% immobilization yield) and 10 recycles.  
This is mainly due to the high cost associated with the carrier which is more significant 
for the hydrophobic carrier (Bm). In cases where the enzyme production or purchase 
costs are low, the carrier has the greater cost contribution to the cost associated with 
preparing the immobilized biocatalyst. However, when the enzyme cost increases, it 
becomes more advantageous to immobilize the enzyme, since this will allow using the 
same preparation for 10 cycles and avoid using large amount of enzyme (which would 
multiply the costs by a factor of 10).  This reinforces the advantage of using immobilized 
biocatalyst when operating with potentially expensive biocatalyst. 
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 Influence of number or cycles achievable: 
On the other hand, another way to justify the use of immobilized enzymes is to increase 
the number of cycles achieved with its immobilized formulation. This is demonstrated in 
Figure 4.14 where the enzyme purchase or production cost was varied from 100 to 1000 
€/kg (x-axis) and the number of cycles it was possible to achieve was varied from 10 to 
50. For a scenario where the enzyme cost is 100€/kg (the lowest here considered), at 
least 20 cycles are required in order to make immobilization economically attractive 
when using the ionic exchange resins (Im and Jm), and more than 50 recycles when 
considering the use of hydrophobic carrier (Bm) 
As the enzyme cost increases, fewer number of cycles are required to justify the 
immobilization, as discusses in previous section. 
 
Figure 4.14: Cost associated with the biocatalyst in the process (y-axis) as function of the production or purchase cost of 
biocatalyst (x-axis) and the number of cycles. Calculations based on a 10 L scale reactor, an enzyme concentration of 10 g 
(DW)/L, carrier loading of 10 g resin/ g protein (assumed 100% immobilization yield) and 10 to 50 recycles.  
 
  
0
1000
2000
3000
4000
5000
0 100 200 300 400 500 600 700 800 900 1000
Bi
oc
at
al
ys
t c
on
tr
ib
ut
io
n 
co
st
 
on
 th
e 
pr
oc
es
s o
pe
ra
tin
g 
co
st
s (
€)
Enzyme purchase or production cost (€/Kg)
Free enzyme (10 cycles)
Free enzyme (20 cycles)
Free enzyme (50 cycles)
Bm (10, 20 and 50 cycles)
Im (10, 20 and 50 cycles)
Im (10, 20 and 50 cycles)
Bm (10, 20 and 50 cycles)
112
  4.5-Results and discussion 
 
97 
4.5.6. Volume occupied by the preparation in the reactor:  
Another important parameter that needs to be kept in mind when considering the use of 
immobilized biocatalysts, is the volume the immobilized preparation occupies in the 
reactor. An overloaded reactor can limit the stirring and consequently the mass transfer.  
In order to illustrate the impact of the resin loading capacity on the reactor volume, a 
calculation was made and presented in the Figure 4.15, considering a 10 L reactor with 
an CFE concentration ranged from 10 to 60 g/L and a resin loading capacity of 0.1 gImm-
CFE/gResin and 0.2 gImm-CFE/gResin (with 100% of theoretical immobilization yield) and a 
resin density of 1.1 g/mL (data obtained from the manufacturer MSDS files).  
 
Figure 4.15: Influence of enzyme concentration and loading capacity of the resin in the volume occupied by the preparation 
in the reactor. 
From Figure 4.15 it can be observed that higher enzyme concentrations in the reactor 
will require a higher amount of carrier, which will consequently occupy more space in 
the reactor. Higher enzyme concentrations can be an option for accelerating slow 
reaction rates. Furthermore, the need for a second or third enzyme such as in the case of 
enzymatic cascades reactions, used for instance to shift equilibrium [30, 32], can increase 
the amount of enzymes required in the vessel. In such case it would be desirable to use a 
carrier with a high loading capacity, which can potentially allow co-immobilization of 
enzymes. Another strategy that can help decrease the amount of carrier required is to 
immobilize purified enzymes instead of CFE. In addition, packed bed reactors (PBS) can 
be employed to solve the issues related with the volume occupied by the biocatalyst in 
the stirred tank reactor (STR).
0
20
40
60
80
100
0
2
4
6
8
10
0 10 20 30 40 50 60 70
Re
ac
to
r v
ol
um
e 
oc
cu
pi
ed
 (%
)
Vo
lu
m
e 
oc
cu
pi
ed
 (L
)
Enzyme concetration (g/L)
0.1 gImm-CFE/gResin
0.2 gImm-CFE/gResin
113
Chapter 4 – Immobilization of ω-transaminase   
 
98 
 
The immobilization of ω-TAm on macroporous polymeric resins was achieved with 
excellent activity retention (Figure 4.5). Physical properties of the carries were found to 
have a strong influence on the immobilization yield with carriers having longer functional 
groups showing better affinity to the enzyme than the ones having shorter functional 
groups. This is often related to obstruction of the catalytic centre of the enzyme when 
immobilization occurs too close to the resin surface or related to potential utilization of 
critical residues of amino acids in the enzyme (necessary for the catalytic activity). Often, 
spacers are introduced in order to increase the space between the enzyme and the carrier 
surface [60, 117, 120]. Regarding the particle size, it was observed that larger particle 
size resulted in higher immobilization yields.. Larger pore size (40-60 nm rather then 10-
20 nm) seems to be preferred by the transaminase which is in the range of what has been 
established as the common pore size for most of enzymes (30-60 nm) [60, 117]. This gives 
a clear indication of properties required to immobilize ω-TAm from other sources with a 
similar molecular weight.  
The screening methodology developed allowed selection of 3 suitable resins for 
immobilization of both (R)- and (S)-selective ω-TAm and enhancing their performance. 
The methodology is composed by 4 steps. In Step I, the carrier properties are evaluated 
and compared with the reaction conditions. Carriers showing operational stability lower 
than those required by the process (i.e. lower pH and temperature stability) were 
discarded. In this step, all the covalent carriers were rejected due to very poor mechanical 
and operational stability. These carriers were stable only at temperatures below 10 °C 
and dissolved in the reaction after 24 hours under process conditions (data not shown). 
As an alternative, carriers from another supplier showing better operational stability, 
such as the Purolite® ECR series (Purolite, UK), which are reportedly stable under 
stronger shear forces and able to sustain pH values up to 9 and temperatures up to 50 °C 
(according to the MSDS data file supplied by the manufacturer) could have been 
considered. Another possibility, would be to pre-activate the ionic exchange resins using 
glutaraldehyde, turning them into a covalent carrier, as demonstrated in several studies 
[120, 122, 126-128]. However, due to time restrictions neither approaches were tried. 
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Based on the constraints set for carrier selection from Step II to Step III (>90% 
immobilization yield), 5 resins were selected: Bm, Jm, Im Hm and Km. The resins were 
successfully re-used for 8 cycles of 24 hours in Step III. The results suggested that more 
cycles could have been achieved if the experiment had been allowed to proceed further 
(Figure 4.6 and Figure 4.7). This was more evident for the preparation of R-TAm which, 
despite the lower immobilization yield obtained, retained more than 90% of the initial 
activity after 250 hours in continuous operation. It is possible that these results could 
have been improved if a longer immobilization time would have been considered. Higher 
operational stability as result of a longer immobilization time has previously been 
reported [117]. This was however not tried in this work. From this Step, 3 resins were 
selected considering that they had more than 50% of residual activity after 8 cycles in 
operation (Bm, Im, and Jm). 
In Step IV, the activity under alternative conditions and storage stability of both enzymes 
immobilized on the three pre-selected carriers were tested. Preparations were evaluated 
for activity after exposure to high temperature (50 ˚C), to organic solvents and to long 
resting periods at ambient temperature. The results for temperature stability revealed an 
excellent performance for preparations of R-TAm immobilized on the hydrophobic 
carrier (Bm), which had more than 80% of residual activity after 24 hours incubated at 
50 ◦C, while no activity was found for free enzyme incubated for 12 at the same 
temperature. However, the same carrier did not show similar enhancement for S-TAm 
which retained only approximately 16% of its initial activity. It should be noted that this 
experiment was not a conventional temperature stability experiment, where the 
biocatalyst is incubated at the desired temperature and the activity assay is run at the 
optimum temperature. In this case both the incubation and the activity assay were 
performed at 50 °C. This has over challenged the biocatalysts and the carrier. 
Nevertheless, the results obtained suggested an improvement in stability achieved 
through immobilization. This trend was not observed for solvent stability experiments, 
where the results suggest a rather poor performance with all the preparations showing 
lower than 10% of residual activity, contrasting with previous work [92].  This could be 
explained by the fact that the enzymes used were not developed to operate in organic 
solvents, while in the cited work the biocatalyst used is known to be engineered to 
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operate under high substrate concentrations and organic solvents [31]. Furthermore, the 
mass transfer of the substrates from the organic phase to the biocatalyst could be reduced 
as the presence of water is crucial. Some authors have achieved good results with ω-TAm 
(of another origin) by adjusting the water activity  in the reactor to 0.6 [129]. This 
guaranteed that only the minimum amount of water required was present in the reactor.  
Another possible reason for the low performance in the solvent phase could be related to 
the lack of the co-factor PLP in the reaction mixture. Although the solvents were saturated 
in a buffer solution containing PLP, one should expect that a very small amount of it was 
present in the organic phase, since the water content in this phase was also very small, as 
shown in Appendix 4A, and considering that PLP is not soluble in the organic phase. This 
issue has not been discussed in any of the published works featuring reaction in organic 
solvents. 
The results obtained for the activity after storage at room temperature show that the 
immobilized enzymes were able to be stored at room temperature (25-27 °C) for period 
of 20 days with 40-90% of its initial activity retained and 30-50% after 60 days (Figure 
4.10). These results are among the highest reported for immobilized transaminase [103, 
106, 111]. Results obtained with another enzyme (penicillin G amidase) showed an 
enhancement in the storage stability when enzymes were allowed to interact with the 
carrier for longer period of time[130]. This could be an option to improve the storage 
stability for ω-TAm. Furthermore, the cofactor seems to have a great influence on the 
enzyme stability [109]. An optimization of the co-factor concentration could have 
possibly improved these results.  
It is important to consider the costs associated with the immobilization as this will be the 
decisive factor for the immobilization. The cost contribution from the immobilization is 
related to the number of cycles that is possible to achieve with the preparation (the more 
cycles achieved the less the impact of the carrier cost on the immobilization), as well as 
the cost associated with the production or purchase of the enzyme.
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Immobilization of ω-TAm by adsorption onto rigid supports was achieved in this chapter. It 
was demonstrated that immobilization granted an improved performance of both S-TAm and 
R-TAm. The immobilized preparation showed great performance at high temperature, as well 
as an increased storage stability and good retention of activity after 8 cycles of 24 hours in 
reaction conditions, corresponding to about 250 hours of operation. 
A screening methodology was developed and successfully demonstrated for the 
screening and selection of suitable carriers to immobilize ω-TAm. With this methodology 
three carries were successfully selected and used in reaction conditions. This work 
demonstrates the first documented step-wise screening of commercially available 
enzyme carriers for ω-TAm following a screening methodology, and the first documented 
attempt to immobilize (R)-selective ω-TAm. 
In summary, with respect to the immobilization of ω-TAm CFE using macroporous 
polymeric resins, it can be concluded that: 
 the ideal resin for immobilization of ω-TAm should be particles with diameter in 
the range of 0.2-06 mm or more, with a pore diameter in the range of 40-60 nm 
and preferably with long chain functional groups; 
 the selected resins allowed a loading capacity of approximately 0.1 gCFE/gResin; 
 the selected resins allowed the re-use of the enzyme for 8 cycles of 24 hours each, 
corresponding to c.a. 250 hours of continuous operation, with more than 90% of 
the initial activity being retained at the end (for the best case, R-TAm);  
 the immobilization of enzymes using the selected resins allowed the retention of 
c.a. 90% of the initial activity after a 24 hours incubation at 50 °C (R-TAm 
immobilized on hydrophobic carrier), while the free formulation treated under 
similar conditions showed no activity; 
 the immobilization did not enhance the performance of the enzymes in organic 
solvents; 
 the immobilization improved the storage stability of the biocatalyst.
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ω-Transaminases are strongly affected by product inhibition and unfavourable 
thermodynamic equilibrium, as demonstrated in Chapter 3. This, combined with the low 
water solubility of the substrate often reported, makes the process development for this 
enzyme a real challenge. As discussed in Chapter 2 and 3, protein engineering has the 
potential to solve some of these issues, however, in some cases process engineering tools 
also need to be implemented. Many strategies to overcome these issues can be found in 
the scientific literature. In this chapter these strategies are reviewed. Their potentials and 
limitations are discussed. These tools include, for instance, the use of in situ substrate 
supply (ISSS) and product removal (ISPR) to respectively control substrate and product 
toxicity and the use of substrate excess and in situ co-product removal (IScPR) to shift the 
equilibrium in favour of product formation and also biocatalyst immobilization to 
improve stability. 
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Over the last few decades, several strategies have been suggested and implemented in 
biocatalysis with the objective of increasing the stability, activity and productivity. 
Contrasting with the enzyme development strategies (such as recombinant DNA 
technology, directed evolution or random mutagenesis, which were discussed in Chapter 
2), process engineering tools do not seek alter the structure of the biocatalyst. Instead, 
these strategies manipulate the media conditions or reactor configuration, for example, 
in order to attain higher process or biocatalytic performance.  As discussed in Chapter 1, 
these strategies are divided as follows: 
 
i. reaction engineering strategies: which, in the 
context of ω-TAm, it would consider the change 
of amine donors or the use of amine donor 
excess to make the process more 
thermodynamically favoured;  
ii. process engineering strategies: which would 
include strategies such the use of an auxiliary 
phase (solid, liquid or gas) to deal with 
equilibrium issues and/or product inhibition), 
and also immobilization of the biocatalyst to 
improve stability and allow its re-use, and; 
iii. reactor engineering strategies: which 
considers, for instance, the use of fed-batch 
reactors to alleviate substrate inhibition or low-
water solubility issues, the use of membrane 
reactors to decrease product contamination, or 
new reactor designs to accommodate process 
engineering strategies. 
  
 
Biocatalyst stability: 
x Immobilization 
x Reaction design  
 
Product inhibition: 
x In situ product removal 
 
Substrate inhibition 
x Fed-batch 
x In situ substrate supply 
 
Unfavourable equilibrium 
x Excess of one substrate  
x In situ product removal 
x In situ co-product removal 
 
Low substrate solubility 
x Water miscible solvents 
x In situ substrate supply 
x Fed-batch 
 
Enzyme separation/re-use 
x Membrane reactor 
x Immobilization 
Box 5.1 Process engineering strategies 
used in biocatalysis 
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For simplicity, these three strategies will be treated as one in this thesis and designated 
as “process engineering” strategies. Some of these strategies have already been 
introduced in the previous chapters. These include the immobilization of the biocatalyst 
to improve stability and allow re-use of catalyst, the use of in situ substrate supply (ISSS) 
and product removal (ISPR) strategies to respectively control substrate and product 
toxicity  and the use of substrate excess and in situ co-product removal (IScPR) to shift 
the equilibrium in favour of products formation. ISSS strategies have the advantage of 
both alleviating substrate inhibition as well as solving the problem of low substrate 
solubility, as will be discussed in the coming sections, as well as ISPR which besides 
alleviating product inhibition also allows shifting the equilibrium. A list including the 
most common strategies used for different limitations can be found in Box 5.1.   
In this chapter, these strategies will be tested and discussed with the main focus on 
product inhibition and equilibrium shifting strategies. These can be divided into two 
groups: (i) those that both alleviate the product inhibition and shift the equilibrium, such 
as using water-immiscible organic solvents or polymeric resins to remove the inhibitory 
product as soon as it is formed (ISPR) and (ii) those that only shift the equilibrium such 
as the evaporation of co-product or its selective conversion through enzymatic cascades 
to a non-inhibitory compound (IScPR) (Table 5.1).  
Table 5.1: List of common methods for in situ product and co-product removal in transamination. 
  
 Product removal 
(adsorption onto   
polymeric resins) 
Product removal  
(extraction with  
organic solvent) 
Co-product removal 
(evaporation) 
Co-product removal 
(enzymatic cascades 
reactions)  
Alleviate product 
inhibition 9 9 8 8 
Shift equilibrium 9 9 9 9 
Property used Ionic or hydrophobic 
interactions 
Hydrophobicity Volatility, vapour 
pressure 
Functional groups 
Methods Adsorption onto a 
water-insoluble 
polymeric carrier 
Extraction with water-
immiscible solvent 
Distillation, vacuum, 
gas stripping, or 
evaporation 
Selective chemical or 
biocatalytic reactions 
Advantages/ 
Limitations 
Low selectivity, 
(hydrophobic resins), 
may require 
immobilized 
biocatalyst 
Low selectivity, hard to 
find suitable non-toxic 
solvent, may require 
immobilized 
biocatalyst 
Not selective, 
applicable to limited 
number of 
compounds, 
 can harm biocatalyst 
Very selective,  
Applicable to limited 
number of compounds 
Improvements/ 
Reference 
Conv. improved  
Truppo et al. 
(2010)[30] 
Reaction rate 
improved Shin and Kim 
(1997)[50] 
Yield and e.e improved  
Yun et al. (2004)[131]  
Yield improved  
Shin and Kim 
(1999)[33] 
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5.1.1. Thermodynamic equilibrium 
The transamination reaction is reversible and the maximum achievable conversion is 
thus determined by the initial concentrations and the thermodynamic equilibrium 
constant (Keq) of the reaction. Keq in turn is determined by the change in Gibbs free 
energy for the reaction, which is given by the difference in ΔG between the products and 
the reactants. For the amine transfer from an amino acid to an alpha keto acid to form 
another amino acid, the change in Gibbs free energy is small and thus the equilibrium 
constant is around one [132]. However, for the transfer of an amine group from an amino 
acid to acetophenone (APH) for instance, the equilibrium is strongly in the favour of the 
amine donor. For instance, a Keq of about 10-3 has been reported for the synthesis of 
methylbenzylamine (MBA) using IPA as the amine donor,  based on experimental 
determination and parameter estimation from kinetics results [53, 76]. This becomes 
even more critical when ALA, for example, is used as the amine donor (as discussed in 
Chapter 2). Truppo and co-workers have reported that the transamination of APH with 
10 equivalents of L-ALA was completed at 3% conversion, as opposed to the theoretical 
equilibrium conversion of 9% [34]. In a recent publication, experimental values of Keq 
for several ω-TAm catalysed reactions have been reported [53]. By knowing the reaction 
Gibbs free energy (ΔG), one can determine the process strategy needed to meet the 
requirements in terms of yield and product concentration. Different strategies inherently 
bring about different cost structures and therefore one can identify the reactions that are 
likely to be able to be scaled-up and applied in industry. Therefore knowledge of the 
reaction equilibrium constant (Gibbs free energy) allows a more intelligent process 
design.  
 Determination of equilibrium constant of reaction (Keq) 
There are several methods to estimate or experimentally calculate the equilibrium 
constants in a reaction. A small overview is given in the following sections. 
5.1.1.1.1. Kinetic parameters estimation: 
The equilibrium constant can be calculated through estimation of the kinetic parameters 
of a reaction (Chapter 2). By knowing the various reaction parameters (Km, Vmax and 
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Ki), one can calculate the equilibrium constant using the Haldane relationship (equation 
4.1) [43, 76]: 
2f P Q f Q P f P Q P Q
cat M M cat M i cat M i i i
EQ r A B r B A r A B A B
cat M M cat M i cat M i i i
K K K K K K K K K K KK  = = = =
K K K K K K K K K K K
§ · § · § ·  ¨ ¸ ¨ ¸ ¨ ¸© ¹ © ¹ © ¹  
(4.1)  
whereୡୟ୲୤ ୡୟ୲୰  are catalytic turnover of the reaction; ୑୅ ǡ ୑୆ ǡ ୑
୕ ୑୔  are the 
Michaelis parameters for amine donor, amine acceptor, amine product and the ketone co-
product, respectively; and ୧୅୧
୕ are the inhibition parameters for the amine donor 
and amine product respectively. The determination of Keq constant is however affected 
by errors in the parameter estimation. If the parameters are miscalculated, the 
accumulated error will eventually be represented in the estimated equilibrium constant. 
5.1.1.1.2. Group contribution: 
Jankowski et al. (2008) have developed a group contribution method for estimating Gibbs 
free energies for biochemical reactions in aqueous solutions at pH 7 and 25 qC, having a 
standard error of ±2 kcal/mol (c.a. 8.37 kj/mol) [133]. The method consist of estimating 
the ΔrG (Gibbs energy of reaction) based on the molecular structures of the compounds 
involved in the reaction. Hence, the molecular structure of a single compound is 
decomposed into a set of smaller molecular substructures based on the hypothesis that 
ΔrG and ΔfG (Gibbs energy of formation) can be estimated using a linear model where 
each model parameter is associated with one of the constituent molecular substructures 
(or groups) that combine to form the compound. This methodology was recently applied 
by Seo et al. (2011) in the comparison of the transamination potential of different amine 
donors, where 1-aminoindan was estimated to be thermodynamically favourable for the 
transamination of APH [134].  
5.1.1.1.3. Experimental determination: 
A more conventional method for the estimation of equilibrium constants is to allow 
reactants to reach equilibrium from both directions of the reaction [135, 136]. However 
this approach was argued by Tufvesson et al (2012) to be difficult to reproduce due to 
slow reaction rates and the occurrence of phenomena, such as degradation or 
evaporation of the reactants [53].  
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The authors suggest an alternative approach which is a modification of the former, 
consisting of observing the reaction rate using varying compositions of the reactants and 
products to ﬁnd the point where the forward and reverse reactions converge to give a 
zero net reaction. This was done by calculating the reaction quotient Q (Equation 4.2) 
over a time period long enough to allow the reaction to occur (normally between 1 and 4 
h), for mixtures of reactants and products at different concentrations. 
ܳ ൌ ሾொሿൈሾ௉ሿሾ஺ሿൈሾ஻ሿ       (4.2) 
where [A], [B], [Q], and [P] correspond to the concentration of the reactants. Then, ܳ௧Ȁܳ଴ 
is plotted against ܳ଴ and the equilibrium constant is obtained from a power curve fitting 
by calculating the value of ܳ଴ corresponding to ܳ௧Ȁܳ଴ ൌ ͳ [53].  
5.1.2. Strategies to shift the thermodynamic equilibrium 
In order to overcome the thermodynamic limitations in transaminase catalysed reactions 
there are several solutions that have been shown to (at least) partly overcome these: i) 
addition of excess of amine donor, ii) application of ISPR using an auxiliary phase such as 
organic solvents or polymeric resins, ii) auto-degradation of the product and use of 
enzymatic cascades or whole-cell catalysis. These will be further explained in the coming 
sections. 
 Addition of excess of amine donor 
The easiest option for shifting the equilibrium towards a high yield of the product would, 
in principle, be to use an excess of the amine donor. This strategy was applied by Savile 
et al. (2010) for the production of Sitagliptin at high substrate concentrations using 
approximately 10-fold excess of IPA [31]. However, the use of this strategy is limited to 
those cases when the equilibrium is only slightly unfavourable. In fact, from the Savile 
article it can be extrapolated that the Keq in this case is close to unity. 
The reason for the limitation to this strategy is that if the substrate concentration is to be 
kept at a high level (>50 gproduct/L), there will be an upper limitation to how large an 
excess of amine donor can be used, with stoichiometric equivalents in the range of 1–50 
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times, approaching the limits of amine donor solubility. In Figure 5.1 the necessary excess 
of amine donor required to achieve a yield of 90% at varying Keq values is plotted. As can 
be seen, to achieve a yield of 90% an excess of 100-fold is required if the Keq value is 10-
1. Similarly, if the Keq value is 10-3 (which is the case of production of MBA using IPA as 
amine donor), an excess of 10,000-fold would be required, which for obvious reasons is 
unrealistic. As a consequence, for transaminations where Keq is lower than 10-2 adding 
an excess of amine donor will not be sufficient to reach the process metrics and thus 
additional strategies are required.  
 
Figure 5.1 The equilibrium constant (Keq) determines the excess of amine donor required to reach a thermodynamic 
equilibrium of 90% (solid line). The broken lines are visual support for an excess of 1 and 50, which can be considered process 
boundaries. Adapted from [32] 
 
Equlibrium constant (Keq) 
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 Removal of (co-) product (ISPR and IScPR) to an auxiliary phase 
A second method to shift the equilibrium position in favour of the desired product is to 
remove the product or co-product from the media during the reaction itself, that is, in situ 
product removal (ISPR) and co-product removal (IScPR). Again, the equilibrium constant 
of the reaction determines how low a concentration of product or co-product is required 
to achieve the target yield. Figure 5.2 shows the relationship between Keq and co-product 
concentration to achieve 90% yield when using an initial concentration of 1 M ketone and 
a 10-fold excess of amine donor for the synthesis of a chiral amine. As it can be seen, at 
Keq values <10-3 the required co-product concentration will need to be <1 mM. 
 
Figure 5.2: Concentration of co-product required to reach 90% yield when using an initial concentration of 1 mol/L ketone 
and a tenfold excess of amine donor for the synthesis of chiral amine. 
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This is important to keep in mind when considering which methods can be used to shift 
the equilibrium. The best strategy for ISPR will depend on the properties of the product 
amine as well as the other components in the reaction mixture. In general, a strategy will 
be favourable when it produces a big driving force for separating the product from the 
other components. The physico-chemical properties that are most commonly exploited 
for ISPR are volatility, solubility, charge, hydrophobicity, and molecular size [137]. ISPR 
strategies are particularly relevant when considering transamination reactions, as they 
enable a shift of the reaction equilibrium position as well as reducing product inhibition, 
as mentioned before. There are many examples to illustrate the use of ISPR strategies in 
connection with transaminase catalysed reactions. A summary of the different 
approaches for ISPR, including the improvements achieved and main drawbacks, can be 
found in Table 5.2.  
Table 5.2: In situ recovery techniques applied for biocatalytic transamination. 
Reaction 
system 
Comparison ISPR 
vs. without ISPR 
ISPR method 
applied 
Major drawback References 
D-MBA ֖ APH 
(B. thuringiensis JS64) 
nine fold higher 
reaction rate 
Extraction with 
organic solvent 
Decreased enzyme 
stability 
Shin and Kim,  
1997 [50] 
D-MBA ֖ APH 
(B. thuringiensis JS64) 99% vs. 54,7% (ee) 
Membrane extraction 
(perstraction) 
Demand for highly 
purified enzyme a 
Shin et al,  
2001 [103] 
sec-But.A ֖ 2-butanone 
(E.coli BL21) 98% vs. 32% (ee) 
Evaporation of the volatile 
inhibitory product 
Evaporation of the 
reaction media (e.g 
water) 
Yun et al,  
2004 [131] 
sec-ButA ֖ (R )sec-ButA 
(B. megaterium SC6394) 
Enzymatic 
resolution with 
99% (ee) 
Distillation of the volatile 
amine product 
Limit number of amines 
can be recovered using 
distillation. 
Hanson et al. 
2008 [138] 
BA ֖ (R)-APB 
(ATA-117) 
92% conversion 
obtained (99% ee). 
Extraction with organic 
solvent combined pH 
setting b 
Organic solvents used: 
potential decrease of 
enzyme stability 
Koszelewski et 
al. 2008 [139] 
APH ֖ D-MBA 
(ATA-113 and ATA-117) 
99% vs. 10% 
(max conv.) 
Extraction with ion 
exchange resins 
Dimension and cost of 
resins (fine particles) 
Truppo et al, 
2010 [30] 
D-MBA: D-methylbenzylamine; APH: acetophenone; sec-But.A: sec-butylamine; BA: Benzylacetone; APB: 3-amino-1-
phenylbutane. a) To reduce the residence time and consequently minimize product inhibition. b) Followed by evaporation 
under reduced pressure of the organic solvent in order to obtain the product. 
For instance, integration of extractive recovery with the reaction step allows the shifting 
of the equilibrium by extracting the product into the second phase. The second phase can 
be a liquid (liquid-liquid extraction) as employed by Shin and Kim 1997 and Koszelewski 
et al. 2008 [50, 139], or a solid resin (solid-liquid extraction) as suggested by Woodley 
and co-workers 2008 [91], and employed by Truppo et al. (2010) [30]. The latter was 
shown to be an efficient method to also overcome product inhibition and shifting 
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equilibrium in the production of both (R)- and (S)-MBA. A substrate concentration of 50 
g/L (0.4 M) and about 200 g of ion-exchange for product adsorption resulted in an 
improved reaction rate and 100% theoretical yield. This strategy further allowed the 
product to be easily recovered by filtration and washing of the resin. However, the added 
cost of using large amounts of resin needs to be considered, especially considering that 
the resin cost varies as function of several parameters such as particle size, functional 
groups and pore size. Multiple re-uses of the resin will be necessary for a reasonable cost 
contribution. Another common limiting factor regarding this technology, is related to the 
selectivity of the separation and the relative concentration of the reaction components, 
including the solvent. For instance, an observed problem when using either solvent or 
resin extraction is that the ketones and the amines have similar distribution behaviour 
and therefore will co-extract into the solvent or resin unless another driving force is put 
in place. This is well illustrated in the report by Truppo et al. (2010) employing the use 
of resins to extract the product. The amine donor IPA was seen to compete with the 
product (MBA) for binding to the resin. The similarity between the pKa value of the 
product and the amine donor (9.54 and 10.73, respectively) also excludes using 
ionization for separation, since at pH 7 more than 99% of both compounds are 
protonated. This problem was, however, alleviated in the report by changing the amine 
donor to alanine and implementing a cascade enzymatic system to degrade the pyruvate 
(as will be described later). 
Evaporation of a volatile product (or co-product) may also be an option for shifting the 
equilibrium towards the product. This has been suggested as an option if IPA or 2-
butanamine are used as the amine donor yielding ACE or butanone, respectively, as co-
substrates [131]. For volatile amines, distillation could also be a possible route for 
product recovery in transamination. For example (R)-sec-butylamine (boiling point of 
63qC) was recovered by distillation of the product mixture under basic conditions [138]. 
Also Savile et al. 2010 reported a slight improvement in yield by sweeping the reactor 
with nitrogen gas to remove the formed ACE [31]. The selectivity is, however, also very 
problematic when using the evaporation strategy. Assuming ideal conditions, an estimate 
of the vapour composition can quickly be estimated based on Raoult’s law (Eq. 4.3),  
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where,  ݔ௜
௩௔௣ is molar fraction of compound i in vapour phase; ݌௜כ is the vapour pressure 
of pure compound (Table 5.3) and ݔ௜௟  is the molar fraction of compound i in liquid phase. 
As an example, if 10 mM of ACE is being removed from a water solution the relative 
amount of water (Cwater=55 M) evaporated will be over 500 times that of acetone. Hence, 
in a thermodynamically unfavourable system, the concentration of acetone will need to 
be reduced significantly beyond this point as shown previously, making the problem 
more difficult. Similarly, the volatility of any co-solvent and the donor amine need to be 
considered when using this approach. 
Table 5.3: Vapour pressure values of pure compounds at 25 qC. Adapted from [32]. 
Compound Pvap (mbar) 
Acetophenone 0.53 
α-methylbenzylamine 0.72 
Alanine Non volatile 
Pyruvic acid 1.7 
Acetone 309 
2-propyl amine 773a 
Acetaldehyde 1202 
2-butyl amine 237a 
2-butanone 121 
Water 30.7 
a: at reaction conditions (pH 7) the vapour pressure of amines are negligible due to protonation of the amine. 
 Auto degradation of Co-Product  
A very convenient, but not widely applicable approach is the use of a self-degrading co-
product or products. It was demonstrated that when using ornithine or lysine as amine 
donor, the formed amino-keto acid is cyclized spontaneously, thus favouring the reaction 
in the direction of the amine [140-142]. Also Truppo et al. (2010) used a similar approach 
where the product cyclized, thereby shifting the equilibrium of the reaction [30]. This 
strategy is of course limited to use of these compounds as amine donor. 
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 Enzymatic Cascades Reactions  
A much explored approach to obtain a high yield of the desired product is to couple the 
transamination reaction to other enzymatic steps that convert the co-product (e.g. 
pyruvate or acetone) into a non-reactive species or back to the original substrate (Figure 
5.3). One early strategy, employed by Chao et al. (1999), was the combined use of 
phosphoenolpyruvate carboxykinase (PcK, EC 4.1.1.32) and pyruvate kinase (EC 
2.7.1.40) to convert the formed oxaloacetate to pyruvate in a two-step reaction [143]. A 
simpler strategy was reported by Fotheringham and co-workers (1999) in a process for 
making amino acids, where the transamination was coupled to acetolactate synthase (EC 
2.2.1.6), which converted the formed pyruvate co-product to the non-reactive acetoin 
[144]. Significant yield and purity advantages over the process using the transaminase 
alone were reported, with an eight to ten fold increase in the ratio of product to the major 
impurity. 
Another common strategy to eliminate the pyruvate is through the addition of lactate 
dehydrogenase (LDH, EC 1.1.1.27), converting pyruvate to lactic acid while 
simultaneously oxidizing NADH to NAD+ [33, 34, 145, 146]. Although the system has been 
shown to work effectively, the main drawback is the requirement of the co-factor NADH, 
which needs to be re-generated. When using cell-free transaminase, this can be achieved 
by adding glucose dehydrogenase (GDH, EC 1.1.99.10) or formate dehydrogenase (FDH, 
EC 1.2.1.2) together with glucose or formate (Figure 5.3). The same effect could also be 
achieved by using a whole-cell system as most organisms already have a system for 
pyruvate metabolism and NADH regeneration.  
In a report by Hohne et al. (2008) it was shown that the equilibrium can instead be shifted 
by the use of pyruvate decarboxylase (PDC, EC 4.1.1.1). The major argument for using this 
(in contrast to LDH) is that cofactor recycling is eliminated, and the reaction is practically 
irreversible as the products are very volatile (acetaldehyde and CO2), and would be 
evaporated for the desired shift of equilibrium [145]. 
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Figure 5.3: Example of enzymatic cascade reactions used in transamination (Tam: Transaminase, (Y)ADH: Yeast alcohol 
dehydrogenase; LDH: Lactose dehydrogenase; GDH: Glucose dehydrogenase. 
Truppo et al. (2009) developed a novel system for the resolution of racemic amines using 
a transaminase coupled with an amino acid oxidase (AAO, EC 1.4.3.2). In contrast to 
previously reported approaches that use a stoichiometric amount of amine acceptor, the 
system described here employs a catalytic amount of amine acceptor (pyruvate) that is 
continuously recycled in situ by an AAO and molecular oxygen [147]. 
Pyruvate can also be reconverted into L-alanine with L-alanine dehydrogenase (EC 
1.4.1.5) coupled with FDH for NADH regeneration, which therefore in principle only 
consumes stoichiometric amounts of ammonium formate [139].  
These strategies are summarized in Table 5.4. Regardless of the cascade system 
employed, the interactions and compatibility of each of the enzymes and their associated 
reagents need to be considered. For instance, the introduction of high concentrations of 
formate (for use with FDH) is likely to affect the activity and stability of the other enzymes 
as well as the formation of high concentrations of isopropanol (formed when YADH is 
used to convert acetone) [38]. So it is crucial to weigh the pros and cons of introducing a 
cascade strategy. Also the costs associated with introduction of more enzymes and 
cofactors and the respective downstream processing costs need to be considered. 
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Table 5.4 Enzymatic cascades for shifting the equilibrium 
 Enzymes Co-reactants a Co-products Refs. 
Oxaloacetate 
degradation PcK, PK α-KG, ATP Pyruvate, CO2 [143] 
Pyruvate 
 degradation ALS Alanine CO2, acetoin [144] 
 PDC Alanine CO2, acetaldehyde [145] 
 PDC, ADH, FDH Alanine, NADH, Formate CO2, ethanol N/R 
 LDH, GDH Alanine, Glucose, NADH Lactic acid, gluconic acid [33] 
 LDH, FDH Alanine, Formate, NH4
+, 
NADH Lactic acid, CO2 [139] 
Co-product 
degradation (Y)ADH, GDH IPA/ButA, glucose, NADH 2-propyl/butyl alcohol, gluconic acid N/R 
 (Y)ADH, FDH IPA/ButA, formate, NADH 2-propyl/butyl alcohol, CO2 [38] 
Alanine 
recycling AADH, GDH Alanine, NH4
+, NADPH Pyruvate (low), H2O [147] 
a Reactants that are required for the reaction additionally to the amine acceptor (ketone) ALS - Acetolactate synthase; PDC-
Pyruvate decarboxylase; ADH-Alcohol dehydrogenase; FDH-Formate dehydrogenase; GDH-Glucose dehydrogenase; 
IPA/ButA: isopropylamine or 2-butyl amine; PcK- Phosphophenol pyruvate carboxykinase; PK-pyruvate kinase. α-KG - Alpha-
Ketoglutaric acid; ATP - Adenosine triphosphate 
 Whole Cell catalysis  
Despite the fact that the multi-enzyme cascade approach has the potential to be very 
successful, the economic burden of using multiple enzymes is significant [23]. In 
particular the combination with the addition of co-factor (NAD(P)H) will increase the 
process cost, even when using low concentrations [148]. Co-immobilizing the enzymes 
and/or the co-factors [149] could help to lower the costs associated with the biocatalysts, 
as previously discussed in Chapter 4. 
Also, using a WC as the biocatalyst could be a suitable strategy to overcome the 
limitations associated with co-factor recycling and multiple enzyme usage. Whole cell 
strategies have become a very promising field especially for biocatalytic reactions which 
usually require co-factor addition and/or regeneration [150]. The wild-type 
microorganism containing the desired ω-TA may be used, but the more common 
approach is to clone the desired ω-TAm into a host vector. For example the use of 
recombinant E. coli [36, 40] or Pichia pastoris [151] expressing ω-TAm, optionally 
following a similar approach as seen for cascades, creating so called cassettes over-
expressing the production of the enzymes involved in the degradation or recycling of the 
co-product. Nevertheless, the number of available ω-TAm with a known gene sequence 
is still rather limited [37, 152]. 
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Several authors have shown that chromosomal integration of genes under a suitable 
regulatory system to an E. coli or P. pastoris mutant is a very useful route for constructing 
a whole-cell biocatalyst that is able to synthesize chiral amines to high specific activities 
and that can maintain activity for extended periods under reaction conditions in the 
presence of an organic phase [37-39, 144, 153]. However, the adequate expression level 
of each protein still remains a challenge [154]. Other typical drawbacks found in whole-
cell biocatalysis, such as uncontrolled side reactions (and consequently unwanted side 
products) and slower reaction rates (due to trans-membrane diffusion problems and 
higher metabolic burden), are also encountered in the ω-TAm reaction using whole cell. 
Consequently the lower cost of using whole cells has to be weighed against these 
drawbacks to find the most suitable catalyst form [93]. 
5.1.3. Substrate inhibition and low water solubility 
For the success of most biocatalytic routes, it is also critical to be able to supply substrates 
at concentration above 50–100 g/L [155]. A common characteristic inherent to aqueous 
biocatalytic processes is the low solubility of many substrates in water. Operating the 
process at too low substrate concentration would lead to a low volumetric productivity 
and thereby high costs for equipment and downstream processing for product recovery. 
A list of solubility of some of the compounds used for transamination reactions is shown 
in Table 5.5 from where it is evident that for compounds such as APH and BA, which are 
used as case studies in this thesis, a feeding strategy has to be employed to supply the 
substrate at a high concentration [89], if the biocatalyst is not developed to tolerate high 
concentrations of these compounds. When a biocatalytic route is limited by substrate 
availability, whether due to low aqueous solubility, slow dissolution rate, or 
inhibition/toxicity, the controlled addition (feeding) of the substrate into the reaction 
medium is a common solution [156-158]. This strategy can also help to minimize imine 
dimer formation [31] and increase the enantiomer excess obtained [159].  
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Table 5.5 Data for solubility of some compounds used in transamination. 
    Aqueous solubilitya 
(Saq) 
Critical conc. for cellb 
(Ccrit) 
Compound Log P (g/L) (mol/L) (g/L) (mol/L) 
Acetophenone 1.58 4.48 0.04 1.63 0.01 
Benzylacetone 1.96 1.63 0.01 0.76 0.005 
α-methylbenzylamine 1.49 42 0.35 9.55 0.08 
Alanine -2.96 165 1.85 26.38 0.30 
Pyruvic acid -1.24 1000 11.36 109.25 1.24 
Acetone -0.24 1000 17.22 100.10 1.72 
Isopropylamine 0.26 1000 16.92 100.47 1.70 
Butanone 0.29 223 3.09 32.01 0.44 
sec-Butylamine 0.74 112 1.53 18.64 0.25 
a: estimated based on Log P using EPI Suite (http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm) 
b: estimated based on aqueous solubility using the correlation: ܔܗ܏൫࡯܋ܚܑܜǡ൯ ൌ ૙Ǥ ૠૢ ൈ ܔܗ܏൫ࡿࢇࢗǤ൯ െ ૙Ǥ ૠ૝. [88] 
The substrate itself can be added beyond its solubility, thereby forming a second phase. 
However, this can cause toxicity and stability problems depending on the properties of 
the compound. The molecular toxicity, or the critical concentration (Ccrit), is defined as 
the concentration at which the catalytic activity is lost [160] or reduced by half [161]. 
Compounds with an aqueous solubility between 0.0003 and 1 M usually require an 
auxiliary phase for the purpose of in situ substrate supply [88]. As seen in Table 5.5, this 
range includes for instance APH and BA which are known to have low water solubility 
and have an inhibitory effect on the catalytic activity [51, 142] as was shown in Chapter 
2.  
To increase productivity, despite the use of an improved biocatalyst able to tolerate 
higher substrate concentrations (as discussed and demonstrated in Chapter 2 and 3), 
three other main strategies can be applied, as illustrated in Figure 5.4: 
i. the substrate can be fed at an optimized rate to the media using a precision pump 
(Fed-batch mode);  
ii. a water miscible co-solvent (e.g., THF, iso-propanol, DMSO) that increases the 
solubility of the substrate in the aqueous phase or aqueous media saturated with 
a water immiscible solvent (e.g., toluene, heptane, ethylacetate) can be used; 
iii. an auxiliary phase saturated with the substrate can be used to act as a reservoir 
for the substrate. The auxiliary phase can be a liquid (water immiscible solvent 
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such as toluene, heptane or ethylacetate) or a solid (such as polymeric resins).  If 
the auxiliary phase has equal affinity to the product, a substrate feeding-product 
removing strategy using the same support can be employed, as described by 
Hilker and co-workers 2004 [162]. 
The effect of different water miscible solvents on the amination of BA was investigated 
by Koszelewski et al. 2008 [139]. It was seen that the addition of 15% DMSO resulted in 
a better enzymatic activity. This result, together with the ones obtained in Chapter 3, 
highlight the potential of this strategy. However, as also demonstrated, there are issues 
related to the amount of the solvent that are required to solubilize the desired 
concentration of substrate and also concerns related with the biocatalyst stability that 
need to be considered. The addition of solvents can decrease the stability of the 
biocatalyst and might also cause downstream processing problems, since the solvent 
needs to be separated from the product and preferably recycled.  
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Figure 5.4: Representation of substrate supply strategies. 
An example of a 2-phase system was reported by Shin and Kim 1997, who used 
cyclohexanone in the resolution of MBA, which increased the reaction rate nine fold and 
allowed the resolution of 500 mM MBA with an ee of >95% and 51% conversion [50]. A 
reported drawback was decreased stability of the enzyme due to the aqueous/organic 
interface. This problem was alleviated in another report by Shin and co-workers, using a 
reactor with the two liquid phases separated by a membrane [62]. Membrane extraction 
was also used in connection with a packed-bed reactor where whole cells were 
immobilized in calcium alginate beads [103]. 
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Many different solvents can be used for this purpose, although for industrial applications 
it is important that the solvents are generally regarded as safe (GRAS), which limits the 
number of available solvents. Also, the environmental impact of using solvents should be 
considered as VOC (volatile organic compound) emissions are one of the main 
contributors to the environmental impact of pharmaceutical processes [163]. Further, 
the costs and efforts associated with wastewater treatment of side streams containing 
organic solvents are often complex and closely related with the solubility and toxicity of 
the solvents used [150]. 
Another alternative would be use polymeric resins as reservoir for substrates. This would 
minimize the concern and the costs associated with downstream processing and waste 
water treatment as resins are insoluble and therefore easily separated from the media by 
means of a filter. A major limitation for this strategy is the limited capacity of the resins 
towards the substrate and the enormous space they may occupy in the reactor. This can 
be however solved by using an external column packed with the resins. 
 
5.1.4. Product Inhibition and in situ product removal 
As mentioned in the previous section, 
strategies to alleviate product inhibition also 
have the potential to shift the equilibrium in 
favour of products. The advantages 
introduced by including an in situ product 
removal step go beyond the decrease in 
product inhibition and equilibrium shift. The 
whole downstream process is facilitated 
with ISPR. If the right configuration is used, 
the product-biocatalyst separation is 
immediately guaranteed, reducing the total number of steps required. Furthermore, also 
the reactor volume required can be reduced since larger amounts of product can be 
obtained and stored in the ISPR support. This decreases the reaction time (equilibrium 
Benefit Impact 
Increased product 
concentration (gP/L) 
Reduced reactor volume, 
easier DSP 
Increased biocatalytic 
yield (gP/gB) Reduced catalyst costs 
Increased yield on 
substrate (gP/gS)  Reduced substrate costs 
Increased volumetric 
productivity (gP/l.h)
  
Reduced reactor volume 
and/or processing time, 
easier DSP 
Abbreviations: DSP, downstream processing; gB, grams 
biocatalyst; gP, grams product; gS, grams substrate. 
Box 5.2: The potential benefits of in situ product removal 
adapted from [15] 
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shift), allows higher product concentration to be obtained with less biocatalyst and 
improves the conversion (Box 5.2). 
ISPR strategies can be applied in several configurations. They have been reviewed by 
Woodley et. al 2008 and divided in a simplified fashion in:  
i. those where the removal support (liquid or solid) is in direct contact with the 
biocatalyst, and  
ii. those where the support does not contact directly with the biocatalyst (indirect 
contact), often achieved by immobilizing the biocatalyst or physically separating 
them using a membrane reactor or similar. 
Inside each of these configurations, the removal support can be located inside the reactor 
or externally, the latter requiring the use of an external column or second tank and solid 
removal supports [91]. The process itself can be carried out in batch mode, semi-batch or 
even in continuous mode with substrate being continuously added and the product (plus 
ISPR support) being continuously removed and fresh supports being added (Figure 5.5). 
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Figure 5.5: Schematic flow-sheet showing internal and external modes of ISPR operation with direct and indirect cell 
contact. Adapted from [91]. 
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Independently of the configuration chosen, the main challenge associated with ISPR is the 
selection of a separation method. This is chosen based on key properties (either physical 
or chemical) that the compound to be separated needs to have distinct from any other 
compound involved in the reaction in order to allow implementation of ISPR. Some 
examples of ISPR applied to transamination making use of hydrophobicity (extraction 
with solvent) and charge difference (extraction using ion exchange resins) have already 
been mentioned. Evaporation also has been reported, although this is not applicable to 
the product since it would be lost (Table 5.2). Alternatively, distillation could be used in 
theory, however this hasn’t been reported in the context of ω-TAm catalysed reactions. 
Methods for ISPR should be easy to implement and reproducible with great product 
recovery capacity. Selecting a method for ISPR follows the same principle as selecting the 
method for downstream processing with the difference that the unit operation for 
separation is integrated in the reaction step, so the presence of the biocatalysts should be 
considered as it is desired that they remain active during the ISPR process. This concern 
as regards biocatalyst viability is what makes ISPR more challenging than the 
downstream processing (DSP) itself, but both are intrinsically related.
 
In a reaction such as the transamination, where products and substrates are so similar in 
properties, DSP can be a great challenge. Substrates and products are similar in their 
hydrophobicity (ketone substrate and amine product), net charge (amine donor and 
amine product) and volatilities (amine donor – at pi and ketone co-product). The 
molecular weights between the species are also very similar since only an amine group is 
transferred from one compound to another. This creates a major challenge to purify the 
product, hence even more of a challenge to integrate this into the reactor (for means of 
ISPR). The first step is to separate the biocatalyst from the media, or to first disrupt the 
cells before separation, if whole cells are used and the product is intracellular. In case of 
ω-TAm catalysed reactions employing the use of E. coli WC or CFE, the products are 
extracellular, avoiding the need for cell disruption, and the media can be easily separated 
from the biocatalyst by means of centrifugation or filtration which, in case of immobilized 
biocatalyst, should be sufficient to remove most of the proteins. In case of an ISPR 
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strategy being implemented, the biocatalyst is in theory retained in the reactor, 
facilitating the separation process as discussed before. After this, the real challenge 
begins: the separation of products from the substrates and from the rest of media 
components. In order to do this, it is important to study the chemical and physical 
properties of all the compounds involved in the reaction, since different properties will 
allow different types of separation strategy (Table 5.6). 
Table 5.6 . Classification of key substrate and product separation technique. Adapted from [137] 
Driving force Example techniques 
Physical properties 
Volatility Distillation, Gas stripping 
Molecular weight or size Membranes (MF, UF etc.), 
Centrifugation, Size exclusion 
Solubility Pervaporation or Perstraction 
Extraction (solvents, SCCO2) 
Precipitation,Crystallization 
Chemical properties 
Charge Ion-exchange, Electrodialysis 
Hydrophobicity HIC, Adsorption 
Table 5.7 summarizes the chemical and physical properties of the compounds involved 
in the four model reactions systems used in this thesis (Chapter 1). It can be observed 
that the substrates and products present several similar properties, as already 
mentioned: the amine donors (ALA and IPA) and the ketone co-product (PYR and ACE), 
respectively, share similarities in molecular weights (Mw), boiling points (although the 
amine donors charge can be manipulated by pH adjustments), similarities in the 
hydrophobicity (logP) and solubility in water (Saq). In the same way, the ketone 
substrates (BA and APH) and the amine products (APB and MBA), respectively, present 
similar molecular weight, boiling points, solubility and hydrophobicity. This suggest that 
more than one strategy is required to fully distinguish products from substrates. 
The choice of amine donor has a very important weight on this. As mentioned before, the 
choice of IPA brings the advantage of making possible the use of an excess of a relatively 
inexpensive substrate to help shift equilibrium, despite the discussed limitations. 
However, it also increases the difficulty of the product separation.  
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Table 5.7: Chemical and physical properties for compounds separation 
 Mw 
(g/mol) 
Tb 
(˚C) 
Tm 
(˚C) pKa LogP 
P vap 
(mmHG) 
S aq 
(g/L) 
Alanine 89.09 380.28 292.0 2.33, 9.71 -2.96 2.68E-8 165 
Isopropylamine 59.11 31.7 -95.1 10.73 0.26 5.80E+2 1000 
Benzylacetone 148.21 233.5 -13.0 N/A 1.96 6.51E-2 3.26 
Acetophenone 120.15 202.0 -9.86 N/A 1.58 3.97E-1 6.13 
α-Methylbenzylamine 121.18 185 -65.0 9.75 1.49 5.00E-1 43.0 
3-amino-1-phenyl butane 149.24 223 22.46 10.63 2.12 6.72E-3 12.0 
Acetone 58.08 55.5 -98.3 N/A -0.24 2.32E+2 1000 
Pyruvic acid 88.06 186.79 13.8 2.30 -1.24 1.29E+0 1000 
This is illustrated in Figure 5.6 where two properties (hydrophobicity and molecular 
charge) are used to evaluate the separation of the components involved in two reactions 
systems: (i) ALA and BA reacting to form PYR and the APB, and; (ii) IPA and BA reacting 
to form ACE and APB.  This considers separation in situ, where pH values cannot be 
manipulated to extreme values in order to preserve the biocatalyst activity. From the 
figure, it becomes obvious that the product (APB) can easily be separated from all the 
other components using hydrophobicity in both reaction systems, except for the ketone 
substrate (BA) which is as hydrophobic as the product (APB) (Figure 5.6 A and B). This 
suggests that: i) for ISPR using hydrophobicity, the separation might not be efficient and 
also result in the removal of the ketone substrate; and ii) if hydrophobicity is used as a 
first step of the DSP, another technique (e.g. separation by charge) needs to be applied 
afterwards to distinguish between substrate and product.  
 
Figure 5.6: Interaction matrix for species separation under reaction conditions (pH ~7). Red – impossible to separate; green 
– separation is possible; black – not applicable. ALA=Alanine, IPA= Isopropylamine, BA=Benzylacetone, APB= 3-amino-1-
phenylbutane; PYR = Pyruvic acid, ACE= Acetone. Based on logP and pka values. 
  
ALA BA APB PYR IPA BA APB ACE ALA BA APB PYR IPA BA APB ACE
ALA IPA ALA IPA
BA BA BA BA
APB APB APB APB
PYR ACE PYR ACE
C D
Net charge
A B
Hydrophobicity
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On the other hand, if the separation by charge is considered in first place, the product 
(APB) can be easily separated from all the other components (with no exception) in cases 
when ALA is used as the amine donor (Figure 5.6 C). This contrasts with the scenario in 
which IPA is used as the amine donor, where the separation between the amine product 
(APB) and the amine donor (IPA) is compromised (Figure 5.6 D). This difference lies in 
the amphoteric properties of ALA (and all amino acids in general). ALA has 2 levels of 
protonation associated with pKa values of 2.33 (for protonation of the carboxylic group) 
and 9.71 (for protonation of amino group). This means that ALA has an isoelectric point 
(Pi) of c.a. 6.02 and at pH values around the Pi, the net charge of the compound is zero, 
contrasting with IPA which has a pKa = Pi of 10.63 and is fully protonated at reactions pH 
(c.a. 7), as depicted in Figure 5.7. 
 
Figure 5.7 Percentage of species with neutral net charge. Created based on pKa values. 
Liquid–liquid extraction is a common strategy for the downstream recovery in 
transamination that allows recovery of a large range of different amines. Extraction under 
either acidic or basic conditions allows control of the amine product if protonated, and 
thus provides an efficient tool for separating the amine from other components in the 
product stream (in particular the remaining substrate ketone). For example, such an 
approach was applied in the post-reaction recovery of (R)-APB by Koszelewski and co-
workers [37, 139]. The reaction involved the use of ALA as the amine donor and BA as 
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substrate. After the reaction the authors implemented a pH adjustment by adding 5 M of 
HCL, which lowered the pH to 1, causing the protonation of the amine donor and the 
product (becoming positively charged). Afterwards dichloromethane (DCM) was added 
to remove the ketone substrate (by means of hydrophobicity) while both the amine donor 
and the product remained in aqueous phase due to their charged properties. Afterwards 
a new pH adjustment was applied to the remaining aqueous phase, increasing the pH to 
12 (10 M NaOH), which caused the deprotonation of the amine product (net charge 
become null) while the remaining amine donor became negatively charged due to 
deprotonation of the carboxylic group. This allowed exclusive removal of the amine 
product to the organic phase (DCM) which is later separated from the product by means 
of distillation (Figure 5.8). Such an approach would not be successful if IPA was used as 
the amine donor since this would not be completely removed in step 2 due to its low 
hydrophobicity. Only in the last step (distillation) it would have been completely 
separated from the amine product (due to its low boiling point) as depicted in Figure 5.9. 
Reaction
Biocatalyst 
separation
Decrease of pH 
+ extraction
HCL
Increase of pH
+ extraction 
Aqueous 
phase
DCM NaOH
Organic
 phase
APB+
BA
PYR-
ALA
APB+
BA
PYR
ALA+ APBALA- APB
Distilation
APB
DCM
DCM
BA
Buffer, 
ALA-, PYR_
DCM
DCM
PYR_
Step 1 Step 2 Step 3
APB
 
Figure 5.8: Schematic overview for DSP featuring Alanine as amine donor (ALA= Alanine, BA= Benzylacetone, 
APB= 3-amino-1-phenylbutane, PYR= Pyruvic acid, HCl = Hydrochloric acid, DCM= Dichloromethane. The charge 
of different species at different stages is represented by the presence of (+) for positively charged, (-) for 
negatively charged and no sign for neutral net charged species. 
In both cases, the first step could be replaced by an adsorptive process (by means of 
hydrophobic polymeric resins) in order to avoid the use of large amounts of solvents as 
discussed earlier. This step could also be integrated in the reaction (ISPR) as it will be 
demonstrated later. In the second step, on the other hand, the solvent cannot be replaced 
by a solid support, since it is important to have the product in organic phase for the 
distillation. 
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Also ion exchange resins could be used to separate the charged product from the 
remaining reaction components in the first step, in the case where ALA is used as amine 
donor. The 2 last steps of DSP would remain unchanged. 
In conclusion, different amine donors require different DSP options. The costs and time 
can be reduced by evaluating the impact of different amine donors upfront, designing the 
reaction based on the DSP options in what could be called reverse process design. 
Reaction
Biocatalyst 
separation
Decrease of pH
+ extraction
HCL
Increase of pH
+ extraction 
Aqueous 
phase
DCM NaOH
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APB+
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IPA+
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IPA+ APBIPA APB
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APB
IPA 
DCM
DCM
BA
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IPA, ACE
DCM
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APB
 
Figure 5.9 Schematic overview for DSP featuring Isopropylamine as amine donor (IPA= Isopropylamine, BA= 
Benzylacetone, APB= 3-amino-1-phenylbutane, ACE= Acetone, HCl = Hydrochloric acid, DCM= Dichloromethane. 
The charge of different species at different stages is represented by the presence of (+) for positively charged,  
(-) for negatively charged and no sign for neutral net charged species. 
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In this chapter, the strategies overviewed in Chapter 5 are implemented with the 
objective of increasing the productivity in the selected model reactions. This chapter 
focuses on the description and screening of suitable auxiliary phase (resins) for 
implementation of ISPR/ISSS strategies, as well as the laboratory scale demonstration of 
the potential and limitations of the different strategies. 
The following strategies were considered in this chapter:  
i) use of amine donor excess (ADXs) and co-product removal (IScPR) to help 
displacing the thermodynamic equilibrium.  
ii) the selection of amine donor (IPA vs. ALA) to enable the removal of ACE by 
nitrogen sweeping (in case when IPA is used) or the enzymatic removal of PYR 
through enzymatic cascade reaction (in case when ALA is used); 
iii) the removal of product (ISPR) using hydrophobic and ion exchange polymeric 
resins to aid in displacing equilibrium as well as alleviating product inhibition; 
iv) The use of fed-batch or in situ substrate supply (ISSS) to overcome the ketone 
substrate solubility issues. 
Excellent results were obtained by combining the following strategies: 1) Fed-batch + 
ISPR using hydrophobic resins + ACE removal using nitrogen sweeping, when IPA was 
used as the amine donor, and 2) ISPR using ion exchange resins + enzymatic removal of 
pyruvate, when ALA was used as the amine donor. 
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The auxiliary phase used for ISPR, ISSS or IScPR can be a liquid (such as organic solvent), 
a solid (such polymeric resins) or a gas (such as nitrogen used to evaporate volatile 
compounds), as described in Chapter 5. While the use of gas auxiliary phases has only 
been demonstrated to evaporate the co-product and not to recover the product itself, the 
use of both liquid and solid phases can easily be applied to remove the product of interest 
and/or act as reservoir for the substrate, as also discussed and demonstrated in Chapter 
5. The following sections give an overview of these two possible technologies for 
ISPR/ISSS. 
6.1.1. Extraction using organic solvents  
The use of organic solvents in chemical and pharmaceutical industries is well established. 
Organic solvents play a very important role in these industries. As time went by, and due 
to pressure and enormous effort from governments and environmental/health 
institutions, some of the most toxic and dangerous solvents have been eliminated, 
replaced by those regarded as safer or greener and also recycled to minimize the amount 
of solvents used, hence reducing their impact on health and environment [164].   
There are several published guidelines for solvent selection. Most of them focus on the 
health risks, environmental impact and operational safety and these criteria are used to 
classify the different solvents [165]. The most famous and widely used is the 
GlaxoSmithKline’s (GSK) solvent selection guide which gives an overview about the safety 
issues for a range of solvents. However, to be used in ISPR, the solvent also needs to 
present other key features besides the operational safety, which can be controlled by 
using solvents with high flash points and low vapour pressures.  
In addition, the solvent needs to be insoluble in water and have good partition towards 
the product, which is often characterized by logP values higher than 1. At the same time 
the solvent needs to be biocompatible (low toxicity towards the biocatalyst). Solvents 
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with logP > 4 are often considered to be 
biocompatible as will be demonstrated below. 
Lastly, it should be possible to separate the product 
from the solvent itself. This can be easily achieved 
through distillation, however it is important that the 
solvent has a different boiling point than the 
product and that both do not form and azeotropic 
mixture (Box 6.1). 
One can easily elaborate a list of solvents that fulfils 
these criteria, however, it is important to note that 
these all have to be met at the same time, and often 
the list of solvents available is drastically reduced 
due to incompatibility between the criteria. The most obvious example is the 
incompatibility between good partition and biocompatibility. Often the solvents that 
show high capacity towards the products are the one that are more aggressive towards 
the biocatalyst. This can be in theory overcome by immobilization, as it was 
demonstrated by Truppo and co-workers, 2012 [92]. However, as concluded in Chapter 
4, the immobilization not always enhance the stability in presence of solvents. This is 
mainly due to poor solvent stability of the biocatalyst itself which is severely affected, 
especially by solvents with LogP values lower than 4. This can be observed Appendix 6A, 
which is the result of study where toxicity of different solvents towards the biocatalyst 
was tested in respected to product and substrate partition. For this reason, the use of 
organic solvents for ISSS and ISPR were not considered in this thesis. 
A possible solution to overcome this biocompatibility vs. partition issue would be to 
design a reactor that guarantees a good mixture between the aqueous and organic phase 
(ensuring good mass transfer) while preventing the biocatalyst directly contacting with 
the solvent or the interface between the two phases. Inspired by the technology available 
for continuous liquid-liquid extraction (Appendix 6B-1, 2), a design for a reactor system 
integrated with a liquid- liquid extraction apparatus was proposed (Appendix 6B-3), but 
never tested.  
Guidelines for solvent selection: 
 
Product extraction: 
- Insoluble in water (LogP>1), 
 
Operational safety: 
- High flash point;  
- Low Pvap 
- inert (non-reactive) 
 
Biocompatibility: 
- Low toxicity to biocatalyst (LogP >4) 
 
Separation (Distillation): 
- Tb solvent ≠  Tb product 
- Do not form azeotrope with the 
product 
Box 6.1: Criteria for solvent selection for ISPR 
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6.1.2. Adsorption onto a solid support – Polymeric resins  
The use of sorbents date back several centuries, although the term itself was only 
introduced  in 1909 by J. W. McBrain  [166]. By definition, the sorbed solute (which can 
be a gas or a liquid) is denominated as sorbate and the sorbing agent (liquid or solid) is 
referred to as sorbent. This designation applies to Liquid-solid, liquid-liquid, gas-liquid or 
gas-solid interactions. 
 Hydrophobic polymeric resins 
On the other hand, adsorption processes are designated as sorption operations in which 
components of a fluid phase (solutes) are selectively transferred to insoluble, rigid 
particles suspended in a vessel or packed in a column. Thus, adsorption is a designation 
which applies only to liquid-solid or gas-solid interactions [166]. More precisely, in the 
adsorptive process molecules, atoms or ions, in a gas or liquid phase, diffuse to the surface 
of a solid, where they bond with the solid surface or are held by weak intermolecular 
forces (physical interaction). The solid support (the adsorbent) is normally a small-
diameter particle composed by interconnected pores where the solute (or the adsorbate) 
is adsorbed. The presence of pores combined with the small diameter of the particles 
provide a large surface area for adsorption per unit of volume. The solute can be 
externally adsorbed on the particle surface (1), internally adsorbed on the adsorbent (2), 
or in the inter pore space (3). The pores diameter can also be used as a size exclusion 
factor which can prevent bulky molecules (e.g. proteins) of being adsorbed (4), as 
depicted in Figure 6.1. 
 
Figure 6.1 Schematic representation of the adsorption processes. Shaded surface – Adsorbent; (1) solute adsorbed on the 
surface of the particle, (2) bulky solute retained on the surface of the particle (3) solute retained in the inner pore space,. 
 
3
1
2
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Adsorption has been used for centuries to improve the taste of water by using charred 
wood, or for the decolorization of liquids by adsorption with bone char and other 
materials. Adsorption (of gas) was first described in 1773, but it was only in 1960s that 
its industrial utilization escalated with the invention of molecular sieves zeolites [167]. 
The most common solid adsorbents are: activated alumina, silica gel, activated carbon, 
molecular sieves and polymeric resins.  
Polymeric resins are typically spherical particles produced by polymerization of styrene 
and divinylbenzene (Figure 6.2), or by polymerization of acrylic esters for adsorbing 
polar solutes. Nowadays, these particles have several applications such as, 
immobilization of enzymes as shown in Chapter 4; gas purification (e.g. removal of 
organics from vent streams) or liquid purification (e.g. removal of organics from water, 
vice-versa). In this chapter they will be used for ISPR and ISSS.  
 
Figure 6.2: Polymerisation of cross linked polystyrene out of styrene and divinylbenzene 
 Ion exchange polymeric resins  
In an ion-exchange process, ions of positive charge (cations) or negative charge (anions) 
in a liquid solution, replace dissimilar and replaceable ions, called counterions, of the 
same charge present. These counterions are coupled to an immobile, insoluble and 
permanently bound co-ion of the opposite charge [166], as illustrated in Figure 6.3. Ion 
exchangers can be defined as insoluble materials that carry exchangeable ions, either 
cations or anions. By treatment of an ion exchanger with a solution containing ions of the 
same charge, the ions in solution can replace the ones bound to the resin for a 
stoichiometrically equivalent amount. In most cases, this process is reversible and the ion 
exchanger can be regenerated. Ion exchange is a diffusion process and therefore it does 
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not follow usual chemical reaction kinetics. Ion exchangers can be separated into cationic, 
anionic or amphoteric ion exchangers that are capable of exchanging cations as well as 
anions. Additionally, there are several types of materials that can be used as an ion 
exchanger including minerals, coals, resins and synthetic inorganic ion exchangers [166]. 
SO3-
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SO3-
SO3-SO3
-
SO3-
SO3-
SO3-
Na+
H+
Na+
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OH-
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Na+
Na+
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Na+
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SO3-Na+
 
Figure 6.3 Schematic representation of the ion exchange process. Shaded surface correspond to the surface of the particle 
covered by the co-ion or ion exchange (SO3-). 
In this work, polymeric ion exchange resins were compared with hydrophobic resins with 
respect to their capacity to remove the amine products. Ion exchange resins can be 
obtained by the same process as described for hydrophobic ones, by the polymerization 
of styrene and divinylbenzene. The type of functional group present on the resin 
determines which type of ion exchange it belongs to. They can be i) weak-base anionic 
exchange resins, ii) strong-base anionic exchange resins, iii)weak-acid cationic exchange 
resins and iv) strong-acid cationic exchange resins [166]. Due to the strong acidity of the 
functional group, strong-acid cationic exchange resins can operate over a wide pH range. 
The most common functional group in this type of ion exchangers is sulfonic acid (Figure 
6.3). Strong-acid cationic exchange resins are used commercially in many areas, including 
etherification (mainly for the production of methyl tert-butyl ether, MTBE), dehydration, 
alkylation and condensation reactions, as well as for water softening and 
demineralization [166, 168]. They are fairly selective, ranging somewhere between 
electrolytes and highly selective enzymes. Regeneration of the resin is possible by 
reintroduction of the functional groups or by treatment with acids or solvents [166, 169].
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The selection of suitable polymeric resins to be used for ISPR or at DSP follows similar 
principles, with the exception that ISPR requires the resin to be biocompatible, similar to 
what was discussed for organic solvents in the previous section. Furthermore, some of 
the criteria used for the screening of immobilization carriers (Chapter 4) also applies in 
this case.  
The biocompatibility, or non-interaction of the resin 
with the biocatalyst can achieved by either using resins 
with small pore (preventing the biocatalyst from being 
adsorbed), or by physically separating the resin from 
the biocatalyst by means of external column, 
membrane or immobilization of the biocatalyst. Other 
important criteria are presented in Box 6.2. 
In this work, the resins selected had very similar 
properties. They were similar in the matrix 
composition, particle size and average pore diameter. 
This allows the conclusion that the cost per Kg does not 
vary much inside the selected library. For this reason, 
and for a matter of simplicity, the resins were screened based on their capacity to adsorb 
the different compounds in the reaction. This was done by exposing isolated compounds 
under vigorous mixing with the resins and measuring afterwards the amount of 
compound adsorbed. While this allows a rapid selection of the resin with the highest 
capacity towards the products, it does not give a precise quantification of the real 
selectivity of the resins towards the different compounds in the reaction, nor information 
regarding the mass transfer kinetics. However, it gives a fair overview of the resins’ 
affinity towards the different compounds.  This will be further extended in the results 
section. 
  
Guidelines for sorbent selection: 
 
The ideal sorbent should have: 
 
- High selectivity: to enable an 
efficient separation; 
- High capacity: to minimize the 
amount of sorbent needed; 
- Favourable kinetic: for a rapid 
sorption; 
- Chemical and thermal stability 
- Extremely low solubility in the 
media; 
- Mechanical stability: to prevent 
crushing or and erosion; 
- Capability to be regenerated 
Box 6.2: Criteria for resin selection. 
Adapted from [55]. 
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6.2.1. Resins library 
Two ion exchange resins were used for screening (Table 6.1). Both resins were strong 
acid cationic exchangers, stable at temperatures range from -20 to 125 qC and pH of 0 to 
14 (according to the MSDS date obtained from the manufacturer). Both resins are widely 
used for demineralization of water for production of industrial steam (according to the 
manufacturer: LANXESS AG, Germany) and none have been previously used for ISPR in 
ω-TAm catalysed reactions. In the work by Truppo et al, implementing ISPR using an ion 
exchange resin [30], the reported resin (Amberlite XAD1180N) was found to have 
hydrophobic properties rather than the reported ionic exchange properties. Therefore, a 
comparison between the selected resins and the one used in the above cited work was 
not possible. This resin was however included in the library of hydrophobic resins (Table 
6.2). 
Table 6.1: Library of cation exchange resins. SDB: Styrene-Divinyl Benzene 
Resin Ionic 
form 
Functional 
group 
Matrix Avg. pore 
d. (nm) 
Surface area  
[m2/g] 
Avg. particle 
d. (mm) 
LEWATIT MonoPlus SP 112 Na+  ܱܵଷି SDB - - 0.65 
LEWATIT K 2629 H+ ܱܵଷି SDB 33 40 0.5 
The library of neutral, hydrophobic resins were composed of 9 resins, from 3 different 
manufactures (LANXESS – Lewatit; DOW chemicals – Amberchrom, Amberlite and 
Dowex; Mitsubishi Chemical – Diaion and Sepabeads) (Table 6.2). Industrial applications 
for these resins varies from enzyme immobilization, polishing of water streams, 
adsorption of traces of organic compounds. Similarly to the ion exchange, these ones have 
also not previously been used for ISPR in ω-TAm catalysed reactions. 
Table 6.2 Library of neutral hydrophobic resins. SDB: Styrene-Divinyl Benzene 
Resin 
Matrix 
composition 
Avg. pore  
d. (nm) 
Min. surface area  
[m2/g] 
Avg. particle 
d. (mm) 
Amberchrom CG300 SDB 300 700 ~ 0.12 
Dowex Optipore L-493 SDB 46 1100 0.42 - 0.85 
LEWATIT AF 5 Carbon 8 1500 0.4 - 0.8 
LEWATIT VP OC 1600 methacrylate 130 150 0.32 - 0.45 
Amberlite XAD1180N SDB 300 600 0.35 - 0.60 
LEWATIT VP OC 1064 MD PH SDB 50 800 0.44 - 0.54 
Diaion HP-20SS SDB 260 500 ~ 0.5 
Amberlite XAD7HP Acrylic ester 90 450 0.56 - 0.71 
Sepabeads SP850 SDB 38 1000 ~ 0.5 
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The selected resins were tested in various process options with the objective of studying 
their effect on the productivity.  
A set up at 2 mL scale was developed to simultaneously test the different options 
featuring hydrophobic resins (Figure 6.4): (A) control reaction (reaction without 
ISPR/ISSS/IScPR); (B) reaction with ISPR only; (C) reaction with ISPR combined with 
ISSS;  D) reaction with ISPR combined with Fed-batch; (E) reaction with ISPR combined 
with Fed-batch and acetone removal (IScPR); and (F) reaction with ISPR combined with 
Fed-batch and acetone removal (IScPR) using immobilized enzymes and external column 
to accommodate the ISPR resins. These were tested using the (S)-selective ω-TAm (c-
LEcta GmbH, Leipzig, Germany) selected from Chapter 3 and the model reaction system 
featured IPA as the amine donor and BA or APH as substrate. 
The ion exchange resins were tested at 10 mL scale. The model reaction used featured 
ALA as the amine donor and BA as ketone substrate. The reaction was catalysed by a (R)-
selective ω-TAm (DSM Innovative Synthesis, Geleen, The Netherlands). Three scenarios 
were compared: (G) control reaction (without ISPR/ISSS/IScPR); (H) reaction with IScPR 
only (PYR removal through cascade reactions using LDH/GDH system); and (I) reaction 
with ISPR (ion exchange resin) and IScPR (PYR removal through cascade reactions using 
LDH/GDH system). The scenario H was run using isolated enzymes and whole cells for 
comparison. 
These nine experiments allowed a good understanding of the effect of the different 
process strategies on the productivity and on maximum product concentration 
achievable.
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Commercial-grade reagents and solvents were purchased from Sigma-Aldrich (Buchs, 
Switzerland) and used without further purification. The enzyme ω-TAm (ATA 47) which 
came as lyophilized CFE powder was supplied by c-LEcta GmbH (Leipzig, Germany). The 
WC of E. coli over expressing ω-TAm (ATA 47) were grown in-house as described in 
Chapter 2. In all experiments the biocatalyst amount refers to grams of lyophilized CFE 
or WC powder. Resins were kindly provided by Sigma Aldrich (Buchs, Switzerland) and 
LANXESS AG (Germany). 
HPLC 
Samples were measured using an Ultimate 3000 HPLC (Dionex. Sunnyvale, CA, USA). The 
compounds were separated on a Luna 3 Pm C18(2) 100 Å (50 x 4.6 mm) column 
(Phenomenex, Torrance, CA, USA) at a flow rate of 2 mL/min using a multi-step gradient 
flow of aqueous 0.1% v/v trifluoroacetic acid and acetonitrile, with the following 
percentage of acetonitrile: 0 min (0%), 1 min (10%), 2.5 min (10%), 5.9 min (60%), 6 min 
(0%), 7 min (0%). Compounds were detected at 210 nm (3.9 min for MBA, 5.9 for APB, 
7.3 for APH and 7.9 for BA). The quantitative analysis was performed from peak areas by 
external standards 
6.4.1. Screening of polymeric resins for ISPR/ISSS 
The screening of hydrophobic and ion exchange resins was done by quantifying their 
loading capacity towards the products (MBA and APB) and the substrates (APH and BA).  
 Screening of hydrophobic resins 
Approximately 50 mg of each of the nine hydrophobic polymeric resins: Lewatit AF 5, 
Lewatit VP OC 1064 MD PH, Lewatit VP OC 1600 (LANXESS AG, Leverkusen, Germany), 
Amberchrom CG300, Amberlite XAD1180N, Amberlite XAD7HP, Dowex Optipore L-493 
(Dow Chemical, Midland, MI, USA) and Diaion HP-20SS and Sepabeads SP850 (Mitsubishi 
Chemical, Tokyo, Japan) were initially washed with 100 mM k-PBS (pH 7) and kept in 
solution for 30 min at room temperature and with soft agitation (~400 rpm - HLC Biotech, 
Model 11, Pforzheim, Germany) to allow swelling of the resins. After that the buffer 
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solution was removed and to each of the resins was added approximately (in separated 
vessels): 0.3 M MBA, 0.05 M APH, 0.04 M of APB, 0.01 M of BA, 2.1 M ACE and 2 M IPA, all 
prepared in 100 mM k-PBS (pH 7) to a volume of 2 mL. The solutions were mixed for 24 
hours, and after that 500 μL samples from the aqueous phase were taken and analysed.  
The amount adsorbed onto the solid phase was calculated by difference from the starting 
concentrations. The concentration of IPA was measured ex-situ on an UV 1800 
Spectrophotometer (Shimadzu, Kyoto, Japan) quantified at wavelength of 590 nm with 
fixed temperature of 30 qC using protocols developed by Rahman and co-workers [170]. 
The concentration of ACE was measured ex-situ on an UV 1800 Spectrophotometer 
(Shimadzu, Kyoto, Japan) quantified at wavelength of 280 nm with fixed temperature of 
30 qC using an internal standard. The concentrations of BA, APH, MBA and APB were 
measured by HPLC as described above. 
 Optimization of hydrophobic resin loading 
In order to understand how the loading of the selected resin (Lewatit AF 5) affected the 
adsorption of products and substrates, approximately 0.4 M of BA, APH, MBA and APB 
(prepared in 100 mM k-PBS pH 7 to a volume of 2 mL) were incubated with 100 g/L and 
150 g/L of resin for 24 hours at approximately 400 rpm and 30 qC (HLC Biotech, Model 
11, Germany). Samples (500 μL) were taken from the aqueous phase, diluted in 
acetonitrile and analysed by HPLC.  
 Screening of ion exchange resins 
Approximately 50 mg of each of the two ion exchange resins (Lewatit MonoPlus SP 112 
and Lewatit K 2629) were initially rinsed once with 1M HCl and afterwards with 100 mM 
with k-PBS (pH 7) in order to remove the HCl and ensure neutral pH for 30 min at room 
temperature and with mild agitation (~400 rpm - HLC Biotech, Model 11, Pforzheim, 
Germany). After that the buffer solution was removed and to each of the resins was added 
approximately (in separated vessels) 0.3 M MBA, 0.05 M APH, 0.05 M of APB, 0.014 M of 
BA, all prepared in 100 mM k-PBS (pH 7) to a volume of 2 mL. The solutions were mixed 
for 24 hours, and after that 500 μL sample from the aqueous phase were taken and 
analysed by HPLC.  
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 Optimization of ion exchange resins resin  
Increasing loadings (50-800 g/L) of the selected resin (Lewatit MonoPlus SP 112) were 
initially washed with 1 M HCl and afterwards with 100 mM with k-PBS (pH 7) in order to 
remove the HCl and ensure neutral pH.  Afterwards, approximately 0.35 M of BA and 0.24 
M of APB were prepared separately to a volume of 2 mL in 100 mM k-PBS pH 7, was added 
to each of the vials containing different resin loadings. The solution were mixed for 24 
hours at 400 rpm and 30 qC (HLC Biotech, Model 11, Pforzheim, Germany). After that, 
samples of 500 μL were taken from the aqueous phase and analysed by HPLC.  
6.4.2. Rapid characterization of process strategies  
 Process strategies featuring hydrophobic resins and ACE removal 
In all the experiments the resins were washed with 100 mM k-PBS for 1 hour to allow 
swelling prior usage. The excess of liquid was removed using syringes. 
For experiments where nitrogen was used to evaporate the ACE, the reactor was pre-
installed with an open output where the gas could freely flow out the vessel to an exhaust 
installed above the setup.  
The biocatalyst used in this section was a S-TAm (ATA 47 from c-LEcta GmbH, Germany) 
formulated as CFE or WC lyophilized powders. 
6.4.2.1.1. Acetone removal assay 
The effect of nitrogen sweeping to remove the ACE was tested in the production of MBA. 
The nitrogen was supplied at a flow rate of c.a. 1.7×10-6 m3.s-1 and saturated in two 
consecutive vessels containing water vigorously mixed prior to its addition to the reactor 
(Appendix 6C). The reaction mixture was composed by 1 M IPA, 0.5 M APH, 2 mM PLP, 
and 0.1 M k-PBS (pH 7) and 27.4 g/L WC was used. The temperature at the saturation 
vessels and reactor were kept at 30 ˚C. Reaction were ran at 2 mL scale with agitation 
kept at 400 rpm (HLC Biotech, Model 11, Pforzheim, Germany). Samples were taken at 2, 
4, 7 and 24 hours and analysed by HPLC. 
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6.4.2.1.2. Process characterization assay  
A setup was prepared to test the 6 process options simultaneously (Appendix 6C). For all 
the reactions the pH was kept at 7 using 100 mM k-PBS (pH 7), the temperature at 30 ˚C 
and agitation at 400 rpm (HLC Biotech, Model 11, Germany). The co-factor (PLP) 
concentration was 2 mM. In the reactions A-E 5 g/L of CFE was used. For reaction F 5 g/L 
of CFE were immobilized using 50 mg of Relizyme HA403/M (with approximately 100% 
of immobilization yield).  
The reactions conditions for each of the scenario (A-F) are summarized in Table 6.3, 
where the ISPR resins refers to Lewatit AF5 (LANXESS, Germany) and the feed in 
scenarios E and F was guaranteed using a syringe pump (Harvard Apparatus, Model 11 
Plus, Holliston, MA, USA) filled with pure BA (c.a. 6..66 M) (Appendix 6C). 
Table 6.3: Conditions for the different process options. i: BA was fed for 24.5 h, but reaction proceeded for 48 h in total; ii: 
BA was fed for 48 h, but reaction proceeded for 65 h in total, the recirculation through the column was made at a flow of 1.5 
ml/min. 
 Process strategies 
A B C D E F 
[BA] M 0.4 0.4 0.4 0.4 0.42 0.22 
[IPA] M 1 1 1 1 1 1 
Volume (mL) 2 2 2 2 2 4 
ISPR Resin (g/L) 0 100 100 100 250 250 
Reaction time (h) 48 48 48 48 48i 65ii 
Feed (μmol BA/h) - - - - 3.68E-02 1.93E-02 
In the end of the reaction, samples were taken from the aqueous phase, diluted and 
analysed by HPLC. The resins were recovered by removing the aqueous phase using a 
syringe. 4 mL of acetonitrile was added to each of the vials containing resin and mixed 
vigorously for 2 hours. Afterwards samples were taken from the liquid phase and once 
again analysed by HPLC. The liquid was again removed using a syringe and fresh 
acetonitrile was added and the elution process was repeated two more times. 
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 Process strategies featuring ion exchange resins and PYR removal 
In all the experiments, the resins were pre-washed with 1 mM HCl for 5 minutes and the 
liquid was removed afterwards. In order to re-set pH to 7, the resins were washed several 
times using 100 mM k-PBS, pH 7. The excess of liquid was removed afterwards using a 
syringe. 
6.4.2.2.1. Whole-cell catalysis 
The WC experiments were run using 1 M ALA and 30 mM APH as substrates in 2 mL scale. 
The PLP concentration was 2 mM in all the cases. The glucose concentration in the three 
scenarios was: 0 mM, 31.5 mM and 100 mM. The WC concentration was 10 g/L. Samples 
were taken over a period of 24 hours and analysed by HPLC. 
The PYR concentration was measured by HPLC using a Rezex ROA-Organic Acid H+ 
(300x7.8 mm) column (Phenomenex, Torrance, CA, USA) at a flow rate of 1 mL min-1 using 
an isocratic gradient flow of 0,025 M sulphuric acid. 
For the ISPR reaction involving WC, 400 g/L of resin was added to reaction mixture. 100 
In the end of reaction 100 μL sample was taken and diluted in 400 μL 1 M HCl. The 
remaining supernatant was discarded. The resin was washed multiple times with 2 mL 1 
M HCl. 
6.4.2.2.2. Process characterization assay 
The experiments G and H were carried out by Harrie Straatman at DSM Innovative 
Synthesis, Geleen, The Netherlands. The data and the following protocol was kindly 
supplied as result of the collaboration established with the company for means 
comparison. For all the reactions the temperature was kept at 30 ˚C and the pH at 7.5 by 
automatically controlling the supply of 1 M NaOH (pH-stat Tititrino plus, 877, Metrohm, 
Switzerland). The reaction volume was 10 mL and the CFE of (R)-ω-TAm (DSM) 
concentration was 47.4 g/L for reactions G and H and 40.02 g/L for I (immobilized on 9.1 
g of Sepabeads EC-EA/M with an equivalent immobilization yield of 84.4%). The PLP 
concentration was 1 mM. 
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The overall reaction conditions for each of the experiments (G-I) are summarized in Table 
6.4, where the ISPR resins refers to Lewatit MonoPlus SP 112 (LANXESS, Germany). The 
LDH was obtained from Codexis (California, USA) and GDH was obtained from DSM 
Innovative Synthesis (Geleen, The Netherlands). Homogenous samples (of 100 uL to 500 
uL) were taken during the reaction (at 0, 2, 4 and 6 hours), diluted with acetonitrile (in 
10 to 25 mL volumetric flasks) and analysed by HPLC. In the end of the reaction (24h) the 
pH of the reaction mixture was increased to 11 by adding 1 M NaOH in order to release 
the product from the resins and afterwards the entire content of the reactor was diluted 
in acetonitrile (500 mL) and vigorously mixed for 2 hours. Samples were taken from the 
resulting liquid phase and analysed by HPLC. 
Table 6.5 Conditions for the different process options using enzymatic cascades and ion exchange resins. 
 Process strategies 
G H I 
[BA] M 0.10 0.18 0.2 
[ALA] M 0.19 0.36 0.4 
Volume (mL) 10 10 10 
LDH/GDH (g/L) -/- 5/5 1/1 
NAD (g/L) -/- 5/5 1/1 
CFE (g/L) 47.4 47.4 40.02 
ISPR Resin (g/L) 0 100 100 
Reaction time (h) 24 24 24 
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The results are presented divided in two parts. In the first part it is presented the results 
for the screening of suitable polymeric resins for implementing ISPR and ISSS (section 
6.5.1), and in the second the suitable resins were used to implemented the different 
process strategies (section 6.5.2). 
6.5.1. Screening of polymeric resins for ISPR/ISSS 
 Screening of hydrophobic resins 
The nine resins composing the hydrophobic resins library (Table 6.2) were screened for 
their capacity to adsorb the substrates and products involved in the two model reactions 
system in study (production of MBA and APB using IPA as the amine donor). 
After 24 hours mixing the compounds in the presence of the different resins, it was 
expected that mass transfer equilibrium was achieved. The concentration of compounds 
in the aqueous phase was used to estimate the amount adsorbed onto the resins. The 
results are shown in Figure 6.5 A (for the amine products) and B (for the ketone 
substrates). 
   
Figure 6.5: Screening of hydrophobic resins based on their adsorption capacity towards MBA and APB (A) and APH and BA 
(B). Resin = 25 g/L; MBA = 0.3 M; APB = 0.04 M; APH = 0.05 M and BA = 0.01 M. 
Two resins (Lewatit AF5 and Dowex Optipore L493) were observed to have a superior 
capacity to adsorb both the amine products and the substrates better than all the other 
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resins. This is likely to be related to the superior surface area of these two resins in 
comparison to the others (Table 6.2).  
To select between these two resins, the amine donor (IPA) and the co-substrate (ACE) 
were evaluated for their affinity towards each of the resins. Ideally, only a small 
concentration of these compounds would be expected to have affinity towards the resins 
since they are fully miscible in aqueous phase with LogP values lower than 1 (Table 5.7). 
However, it was observed that both resins adsorbed some of these compounds (Figure 
6.6). This is in part due to the high concentrations these compounds that was used in this 
assay (2 M for both compounds). Nevertheless, a difference in affinity was observed. The 
resin Lewatit AF5 showed slightly a lower adsorptive capacity towards both IPA and ACE. 
 
Figure 6.6: Adsorption of IPA and ACE on the resins AF5 and L493. 
Resin = 25 g/L; IPA = ~2 M and ACE = ~2.1 M 
Considering these results, the resin Lewatit AF5 (Figure 6.7) was selected from the 
library and used in the next set of experiments where the different process strategies 
featuring this resin is tested. 
     
Figure 6.7: SEM pictures of Lewatit AF5 (A = 100 x magnification, B = 500x and C = 5000 x) 
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 Optimization of hydrophobic resin loading 
As demonstrate in Chapter 3, small concentrations of products caused severe inhibition 
to the enzyme. For this reason, in order to be effective, the ISPR strategy needs ensure 
low product concentrations in the media. As the results in the previous sections 
demonstrates, the hydrophobic resins also have great affinity towards the ketone 
substrates considering their hydrophobic characteristics (Table 5.7). This suggest a 
potential substrate-product separation issue, as discussed in Chapter 5. This can 
potentially make difficult to guarantee an efficient and complete removal of the product 
without compromising the availability of substrates.  
To better illustrate this, two resin loadings (100 g/L and 150 g/L) were used in the 
presence of approximately 0.4 M of each of the ketone substrates and amine products, 
and the results are shown in Figure 6.8.  
 
Figure 6.8 Adsorption of approximately 0.4 M of APB, MBA, APH and BA in function of resin (Lewatit AF5) loading after 24 
hours equilibration.  
As it can be observed, with a resin loading of 100 g/L, the aqueous concentration of the 
inhibitory products  are approximately 25 mM for both APB and MBA. Considering the 
results obtained in Chapter 3, it can extrapolated that at this product concentration the 
inhibition will affect 100% of the enzymes (lowering the reaction rate to zero). On the 
other hand, at this resin loading the substrates (APH and BA) concentration in the 
aqueous phase is ideal to guarantee maximum reaction rate. With a resin loading of 150 
g/L, the products concentration reduce to approximately 5 mM and 8 mM for APB and 
MBA respectively. However, also the substrates concentrations in aqueous phase 
decrease to concentrations that would limit the reaction rate.  
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This leads to a bottleneck where a compromise between the resin loading and the desired 
product concentration in the aqueous phase is difficult to achieve. A possible solution 
could be to use the highest resin loading, since it is important to keep the product 
concentration in aqueous phase low to prevent the inhibition issues, and supply the 
substrate either in a fed-batch mode or as a combined ISSS/ISPR strategy. These were 
tested and the results will be shown and discussed further in this chapter. 
 Screening of ion exchange resins 
The two ion exchange resins were screened based on their adsorptive capacity for the 
ketone substrate (APH) and the corresponding amine product (MBA). Both resins were 
similar in properties (matrix and particle size), thus it was expected that both would have 
similar adsorptive capacity towards these compounds. This is illustrated in Figure 6.9, 
where this can be observed.  
 
Figure 6.9: Adsorption of approximately 0.3 M of MBA and 0.04 M of APH onto the 25 g/L of resins. 
A major difference between this result and the one obtained for the hydrophobic resins, 
is that the ion exchange resins show lower adsorptive capacity. This is due to the lower 
surface area of these resins in comparison with the hydrophobic ones (c.a. 40 m2/g for 
Lewatit Mono Plus SP 112 in comparison with 1500 m2/g for Lewatit AF5) although their 
particle sizes are very similar. 
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Between the two ion exchange resins, the Lewatit Mono Plus SP 112 (Figure 6.10) was 
selected for further experiments, since it showed slightly higher adsorptive capacity and 
it has a slightly larger particle size which can be an advantage for separation. 
     
Figure 6.10 SEM pictures of Lewatit Mono Plus SP112 (A = 100 x magnification, B = 500x and C = 5000 x) 
 Optimization of ion exchange resin loading 
In order to understand the resin loading required to adsorb the products, a fixed 
concentration of products APB (c.a. 0.25 M) and MBA (c.a. 0.35 M) were mixed with 
increasing resins loading. The results are summarized in Figure 6.11 where it can be 
observed that a loading of about 800 gResin/L is requited to lower the product 
concentration to a value below 10 mM. Considering the space this resin loading might 
occupy in the reactor, a possible strategy would be use an external vessel for the resins 
(e.g. packed bed column or second tank) where the resins would be retained. 
 
Figure 6.11 Adsorption of c.a. 0.35 M of MBA and 0.25 M APB for increasing resin loading (Lewatit Mono Plus SP 112). 
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6.5.2. Characterization of process strategies  
In this section, it is presented the results regarding the different process strategies used 
to improve the productivity.  
Subsection 6.5.2.1 summarizes the results regarding ISPR, ISSS, IScPR and fed-batch 
strategies applied to the production of MBA using IPA as the amine donor. ISPR using the 
hydrophobic resins was implemented to control the product inhibition and ACE removal 
by means of nitrogen sweeping was applied in order to remove the formed ACE and help 
displacing the equilibrium. To avoid excessive evaporation of substrate (APH) which 
occurred when nitrogen sweeping was used, the feeding strategies ISSS and fed-batch 
were tested. 
In subsection 6.5.2.2, the results for ISPR using ion exchange resins are presented. The 
assay were carried out at 10 mL scale for the reaction system producing APB with ALA as 
amine donor. This was coupled with IScPR through cascade reactions using the LDH/GDH 
system. In addition, results regarding whole cell catalysis as a possible alternative for 
isolated enzymes are shown. This was done using the production of MBA and ALA as the 
amine donor. 
 Process strategies featuring hydrophobic resins and ACE removal 
6.5.2.1.1. Acetone removal assay  
As discussed in Chapter 5, the use of an inert gas such as nitrogen to remove the volatile 
co-substrate (ACE) is not selective resulting in the evaporation of the ketone substrate as 
well. This is illustrated in  Figure 6.12 where it can be seen that the reaction equipped 
with nitrogen sweeping strategy had most of the substrate (APH) evaporated in the first 
6 hours of the reaction. After 24 hours, only a residual concentration of the substrate was 
left in the reactor. Considering that the substrate disappearance did not correspond to 
product formation, it can be assumed that the loss occurred as result of evaporation. This 
clearly demonstrate the non-selective characteristic of this strategy and it seems to be 
even more critical when insoluble concentrations of the substrate are used. 
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Figure 6.12: Production of MBA over time for ATA 47 with ACE removal (circles) and without ACE removal (triangles). Whole 
cells (27.4 g/L) were added to 1 M IPA, 0.5 M APH, 2 mM PLP, and 0.1 M potassium phosphate buffer pH 7. The temperature 
was fixed at 30 ˚C. (dashed line) equilibrium conversion. 
In another work where water soluble concentration of APH (c.a. 30 mM) were used 
instead, it was observed that the degree of substrate lost was inferior (data not shown). 
This suggest that using a feeding strategy such as ISSS or fed-batch would help 
overcoming this issue and minimize substrate evaporation. 
6.5.2.1.2. Process characterization using hydrophobic resins 
The results for the rapid characterization of process strategies featuring hydrophobic 
resins are presented in Figure 6.13, where it can be seen that the control reaction (A) 
stopped at approximately 5 g/L of product concentration. Considering that this value is 
far from the theoretical equilibrium concentrations (c.a. 40 g/L), and based on results 
observed in Chapter 3, this low performance can be directly associated to inhibition 
caused by the product. The strategies B to D were carried out using 100 g/L of resins 
loading. However, this did not result in major improvements in final product 
concentration obtained. This is most likely due to the resin selectivity issues, as 
previously discussed. This was observed in strategy B (ISPR only) where large amount of 
substrate was removed from the aqueous phase upon addition of resin. After 48 hours of 
reaction, very small concentration of substrate was found left in the aqueous phase while 
a large amount was recovered from solid phase (data not shown).  
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Figure 6.13 Biocatalytic yield and product concentration achieved with different process strategies. (A) reaction without 
ISPR/ISSS/IScPR (control), (B) ISPR only, (C) ISPR combined with ISSS, (D) ISPR combined with Fed-batch, (E) ISPR combined 
with Fed-batch and IScPR (acetone removal), and (F) ISPR combined with Fed-batch and IScPR using immobilized enzymes . 
Approximately 5 g/L (s)-ω-TA CFE (ATA 47, c-LEcta, Germany), 1 M IPA and 0.4 APH, 150 g/L resins (B-D) and 250 g/L (E-F) 
(Lewatit AF 5). 
Loading the substrate onto the resin in advance and implementing the ISSS/ISPR 
combined strategy (C) helped in controlling the concentration of substrate in the aqueous 
phase, however, again due to the large amount of product that also accumulated in the 
aqueous phase, the conversion did not improve further. 
In strategy D, nitrogen sweeping was added to the ISSS/ISPR strategy to remove the 
formed acetone and therefore help shifting the equilibrium position.  A slight 
improvement was observed in comparison to options without nitrogen sweeping (A, B 
and C). However, the results obtained were still far from the equilibrium yields. Product 
inhibition and substrate evaporation prevented this strategy to yield better results. 
In strategies E and F, the substrate feeding was done using a syringe pump (fed-bath 
mode instead of ISSS). This allowed a better control of the substrate supply rate. When 
combined with acetone sweeping using nitrogen, it resulted in better performance. In 
both cases the product concentration obtained was 5 fold higher than the control (A). 
However, in case of E, the theoretical equilibrium was still not achieved. This could to be 
related to the feeding rate of BA which seemed to have been too fast for the reaction rate, 
resulting in the adsorption of the substrate to the resin. In strategy F, the feeding rate was 
decreased and immobilized enzymes were used in order to make possible the use of 
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external column to where the reaction media was re-circulated. This resulted in a better 
performance with the reaction reaching equilibrium yields, but not continuing further, 
which suggest inefficiency of the co-product (ACE) removal strategy.  
 Process strategies featuring ion exchange resins and PYR removal 
Ion exchange resins combined with cascade reactions were used in the reaction system 
featuring ALA as amine donor. As previously discussed, reactions featuring ALA as amine 
donor have a very low thermodynamic equilibrium in comparison with those featuring 
IPA.  On the other hand, the formed PYR can be selectively and completely removed using 
cascade reactions as introduced in section 5.1.2.4. This have been investigated using 
whole cells (WC) catalysis and isolated enzymes and the results are presented in the 
following sections. 
6.5.2.2.1. Whole-cell catalysis 
In order to investigate whether the use of WC allow removal of pyruvate, and how the 
initial concentration of glucose (Glu) influences the reaction efficiency, three assays were 
prepared: i) reaction without initial Glu, ii) with 31.5 mM and ii) with 100 mM. The results 
are shown in Figure 6.14. 
 
Figure 6.14 Yield of (S)-MBA over time for different initial concentrations of Glucose (0, 31.5 and 100 mM).  1 M ALA and 30 
mM APH as substrates; 10 g/L WC. 
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For all the three scenarios, the reaction proceeded beyond the equilibrium threshold, 
which suggest a functional mechanism for PYR removal. However, the results suggest that 
the reaction achieve higher yields when no Glu (0 mM) was added, contrasting with 
reactions where 31.5 and 100 mM of Glu were used. In order to better understand the 
reason behind this, the concentration of PYR was followed during the three reactions and 
the results presented are presented in Figure 6.15 where it can be seen that when the Glu 
was not added, the PYR was continuously removed throughout the 24 hours of reaction, 
contrasting with reactions where 31.5 and 100 mM of Glu was added causing PYR 
production after 6 hours of reaction.  
 
Figure 6.15: Pyruvate concentration over time for reactions using 10 g/L WC, 1 M ALA, 30 mM APH, and 
Glu concentrations of 0, 31.5 and 100 mM.  
Other studies showed before that the metabolism of living cells (Vibrio fluvialis) were able 
to remove pyruvate internally [33]. In this case, lyophilized resting E. coli cells were used 
and still these results suggest that they are metabolically active and therefore, able to 
remove the co-product PYR internally. The use of resting cells bring the advantage of 
avoiding biomass formation and potentially increase of product yields on carbon and 
energy sources [171].However, the results shown in Figure 6.15 also suggest that this 
cells were also able to undergo through other(s) pathways in the presence of Glu, causing 
formation of PYR, which affected the final yields as was observed in Figure 6.14. 
The cell growth was not measured as this was not expected considering that lyophilized 
cells were used in this study and the reaction media was not favourable for cell growth. 
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Lyophilized cells are thought to not be active due to the harsh process they are subjected 
to during the drying process [172]. If bacterial growth is occurring, it can be also possible 
that the amine group that is supplied by the amine donor is being used for formation of 
other metabolites instead. The product can also be degraded by the cells to form other 
intermediates. Cell growth of supposedly resting cells was also observed in other studies 
when glucose was added to the reaction medium [173]. 
An option to ensure that the desired cascade reaction system is predominately working 
in the cell, is to overexpress all of the enzymes involved in the cascade (LDH and GDH) 
alongside with ω-TAm. This approach was pursued by several groups [38, 39]. This can 
also be achieved by using isolated enzymes as it will be demonstrated in the following 
section. 
6.5.2.2.2. Process characterization using ion exchange resins 
In contrast with the reactions featuring IPA which are primarily affected by inhibition 
since the equilibrium is slightly more favourable, in the reactions where ALA is used as 
the amine donor, the equilibrium becomes the main issue. Without a strategy to displace 
it, the reaction will not even proceed to the point where inhibition becomes an issue. This 
can be observed in options G in Figure 6.16 where reaction without any process strategy 
was carried out. 
 
Figure 6.16: Process strategies using (R)-ω-TAm (DSM), LDH/GDH cascade and ion exchange resins. Reactions were run for 6 
hours using ~ 0.2 M BA (10 mL scale). G – control reaction; H – reaction with IScPR (LDH/GDH cascade); I – reaction with 
IScPR (LDH/GDH cascade) and ISPR (ion exchange resins)  
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On the other hand, when cascade reactions were used (H), higher product concentrations 
were obtained. However, the reaction did not proceed to completion, due to product 
inhibition. This was overcome when the ion exchange resins were introduced in the 
reaction, allowing the reaction to proceed to 100% yield in very short period of time 
(approximately 4 hours) (I). The production overtime for this assay can be seen in 
Appendix 6D. 
In addition, WC combined with resins were investigated. This was done using ALA as 
amine donor and APH as amine acceptor. The results are summarized in Figure 6.17 
where it can be observed that upon addition of 400 g/L of resins, the final yield is 
decreased in comparison to the reaction without resin. This result is unexpected since 
the addition of resin to the isolated enzymes assay showed excellent results. A possible 
explanation for this could be related to the shear forces caused by the resins to the cells, 
this could have damaged the cells and the relevant mechanism for PYR transportation 
and reaction, or other unknown experimental error that may have harmed the cells. 
The PYR concentration was measured and found to be 2.90± 0.38 mM, which is very 
similar to the final product concentration of 3.89 mM. This confirms that the mechanism 
to remove PYR was not functional, opposite to what was previously observed in absence 
of resins. The use of a more moderate stirring speed or an external column filled with the 
resins could be an option to overcome this issue. However, this was not investigated.  
 
Figure 6.17: Yield of MBA after 24 hours reaction using 1M ALA, 30 mM APH and 10 g/L L-WC 
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Process engineering strategies have a realistic potential to overcome many of the issues 
inherent to transaminase catalysed reactions. In this chapter these strategies were 
successfully demonstrated using polymeric resins to overcome inhibition and nitrogen 
sweeping or cascade reactions combine with amine donor excess to displace equilibrium. 
It was made clear that the selectivity of the technology is a very important parameter as 
it will dictate the efficiency of the implemented strategy. In order to guarantee the use of 
the right strategy, it is important to implement a smart but also rapid screening process.  
In this work, the polymeric resins were screened using mainly their loading capacity 
towards the compounds. This approach disregards the selectivity of these resins and 
their adsorptive/adsorptive kinetics, but on the other hand guarantees a very fast 
screening among a library of resins with similar properties.  
In the case of hydrophobic resins, the screening process is challenging since these resins 
has good affinity for both the ketone substrate and the amine product. This issue is also 
present in cases when organic solvents are used for ISSS and/or ISPR, although this also 
has the additional challenge of toxicity for the biocatalyst. 
The ion exchange resins combined with the use of ALA s the amine donor, guaranteed a 
better selectivity towards the products. The main disadvantage of using ALA is the 
unfavourable equilibrium which becomes critical. However, as it was here demonstrated, 
using cascade reactions to remove the co-product PYR through the use of LDH/GDH 
cascade system can solve this issue and make the reaction go even faster than some other 
reaction system with better thermodynamic equilibrium. 
From this work it also became clear how the choice of amine donor influences the process 
and the strategies needed to solve the several bottleneck inhered with transamination. 
For instance, when IPA is used as the amine donor, the equilibrium constant, which is still 
unfavourable towards the products, is however higher by ratio of 1.000-10.000 than the 
equilibrium constant when ALA is used as donor.  This difference causes a tremendous 
change in the driving bottleneck for the process. When ALA is used, the main driving 
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bottleneck is the equilibrium which prevents the reaction to even yield products 
concentration that can inhibit the reaction. On the other hand, when IPA is used as amine 
donor, the equilibrium ceases to be the main bottleneck giving place to the inhibition 
instead, which in turn forces the reaction to stop long before equilibrium yields are 
achieved. 
Nevertheless, in this work it has been demonstrated that ISPR and IScPR can play an 
important role. The use of excess of amine donor was used in every experiments here 
reported, however it is the removal of the products and co-products that have the major 
impact. 
Figure 6.18 A (reaction using IPA as amine donor and hydrophobic resins) and B 
(reaction using ALA as amine donor and ion exchange resins) summarizes the major 
enhancements obtained with the different strategies. The combination of product and co-
product removal allow obtaining higher product concentration, while the use of 
immobilized biocatalyst allow obtaining higher biocatalytic yield (considering the 
possible re-utilization of the biocatalyst). 
 
Figure 6.18: Summary of results obtained using the different strategies. (A) Control reaction (without ISPR/ISSS/IScPR); (B) 
ISPR only; (C) ISPR combined with ISSS; (D) ISSS/ISPR combined IScPR (acetone removal using nitrogen sweeping); (E) ISPR 
combined with Fed-batch and IScPR (acetone removal using nitrogen sweeping); and (F) ISPR combined with Fed-batch and 
IScPR (acetone removal using nitrogen sweeping) using immobilized enzymes. (G)  Control reaction (no IScPR/ISPR); (H) 
reaction with IScPR (LDH/GDH cascade); (I) reaction with IScPR (LDH/GDH cascade) and ISPR (ion exchange resins). 
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This work allows the conclusion that ISPR and IScPR tools are able to effectively improve 
productivity in transaminase catalysed reactions. The main challenge associated with 
these technologies is the need for screening and selection of a suitable auxiliary phase, 
which can be solid, liquid or gas. Two main criteria can be considered to be important in 
the screening process: the toxicity of the support towards the biocatalyst and the 
selectivity towards the product in detriment of the substrates. 
Ion exchange resins were found to be more suitable for ISPR in transaminase catalysed 
reactions when ALA was used as the amine donor, in comparison with the hydrophobic 
resins (used when IPA was employed as the amine donor). The former is more selective 
and allowed selective removal of the protonated product. Similarly, the use of cascades 
reactions to remove the co-product PYR when ALA is used as amine donor  was shown to 
be more selective and efficient than using nitrogen to remove the ACE when IPA was used 
as amine donor. 
The process engineering strategies here discussed are able to overcome the challenges 
associated with transamination catalysed by ω-TAm. The feeding of the substrate, 
product and co-product removal allow achieving higher product concentration (g/L) 
while the use of immobilized biocatalyst allowed obtaining higher biocatalytic yield 
(gproduct/gbiocatalyst).
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Biocatalysis offers a wide range of possibilities to access many interesting compounds 
with key function in the modern days. The technology has great potential as well as many 
open challenges that need to be addressed so that full advantage of its benefit can be seen. 
This thesis focused on the interesting case study of ω-transaminase catalysed reactions 
which is one of the most acclaimed processes in the past decade to asymmetrically access 
chiral amines. The enzyme allow access to enantiomerically active amines which are the 
important building blocks of many pharmaceutical intermediates. Throughout this thesis, 
an overview of the main challenges associated with the process development for this 
enzyme was made. Among these, product inhibition and the unfavourable 
thermodynamic equilibrium are to be highlighted. Each of these limitations prevent the 
maximum theoretical yield to be achieved and the combination of both directly translate 
in the process infeasibility. 
It was demonstrated in this thesis that these two limitations affected the enzyme at 
different degree, depending on the amine donor chosen for the process. For instance: 
x when isopropylamine was used as the amine donor the inhibition seemed to 
be the major issue, preventing the reaction to reach the theoretical equilibrium 
yields; 
x on the other hand, when alanine was used as the amine donor, the 
thermodynamic equilibrium constants drastically lowers (1000-10000 fold 
compared to when isopropylamine is used). Thus the reaction stop before product 
inhibition becomes an issue. 
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 A key finding in this thesis, was the difference in the inhibition level depending on the 
choice of the amine donor. Reactions featuring alanine was shown to be more severely 
affected by inhibition than those featuring isopropylamine. The reaction rate rapidly 
dropped to zero with small product concentrations. However, these results also suggest 
the need for further research on his matter as the equilibrium might as well be the 
responsible for this behaviour. 
Interestingly, the choice of amine donor also influences the type of technology that can 
be used to overcome these limitations. The use of isopropylamine prevents the use of the 
in situ product removal strategy using ion exchange resins, due to similar charge 
properties between the amine donor and the amine product. As alternative 
hydrophobicity can to be used to remove the product. However, also this option revealed 
to be inefficient due to selectivity issues between the ketone substrate and the chiral 
amine, since both are similar in terms of hydrophobicity. This issue can potentially be 
solved by employing a controlled feeding strategy, and synchronize this with the enzyme 
reaction rate, in order to ensure that the supplied substrate is converted into product 
before being adsorbed onto the resin. In order to this, it is important know the kinetic of 
the adsorption beforehand. This possibility is an open challenge that is part of future 
work. 
Another possibility, also demonstrated in this thesis, is to use alanine as the amine donor. 
Being alanine an amino-acid, it has two protonation levels which provide an isoelectric 
point of c.a. 6. This can be used to neutrally charge the compound, allowing the use of ion 
exchange resins for ISPR. This was demonstrated here with excellent results, although an 
optimization of the enzyme loading is required in order to increase the biocatalytic yield 
(gproduct/gbiocatalyst) which was slightly lower than those obtained in the experiments 
featuring hydrophobic resins. 
With the results here obtained it can be concluded that alanine is a better amine donor 
than isopropylamine as it allows the use of cascade reactions using LDH/GDH system to 
selectively remove the co-substrate pyruvate (IScPR) and also allow using ion exchange 
resins to selective remove the formed chiral amine product (ISPR). 
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It was demonstrated that the key factor for an efficient implementation of the product 
and co-product removal strategies is the selectivity of the technology used. This was 
evident specially when using acetone removal strategy (to shift equilibrium when 
isopropylamine was used as the amine donor). Although a substantial improvement in 
the yield and final product concentration was observed (for the combination of fed-
batch/ISPR/acetone removal), the process resulted in major loss of the ketone substrate 
by evaporation. On the other hand, the use of enzymatic cascade reactions represent a 
more efficient strategy. The major limitation of this technology can be the selection of 
suitable enzymes to remove the co-product and the need for co-factor regeneration, 
which often requires the use of extra enzymes, increasing the process costs. Therefore, it 
is important to balance the benefits with the costs. 
An options to overcome this issue, can be to immobilize the enzymes in the same support. 
This allow the possibility of re-using the biocatalysts for many cycles, as was 
demonstrated, which would help reducing the costs. A still open challenge in this topic 
relies on the co-immobilization of many enzymes in the same support. This can be crucial 
in order reduce the space the immobilized biocatalysts occupy in the rector. Co-
immobilization of the co-factors is also a possibility that can be explored to reduce the 
costs.  
In this thesis, ω-TAm enzymes have been immobilized using commercially available 
polymeric resins. It was possible to re-use the immobilized enzyme over 8 times which 
corresponds to more. 250 hours of operation in reaction condition with more than half of 
its initial activity left. More importantly, the outcome of this work opened the possibility 
to a more efficient process and allow a comprehensive step-wised carrier selection for 
immobilization of ω-TAm. The screening methodology used can be implemented for 
other enzymes and type of carriers. The properties identified in this work are believe to 
be equally suitable to other forms of this enzyme, from other microorganism. In 
summary, particles with diameter in the range of 0.2-06 mm or higher, with a pore 
diameter in the range of 40-60 nm and preferably with long chain functional 
groups should be suitable for other ω-TAm of similar molecular weight.
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Several open challenges and potential future works have become apparent during the 
writing of this thesis. These have not been pursued due to time limitation. 
x Characterization of the biocatalyst: During the comparison of the three ω-TAm 
mutants, the reaction rates were found to be very different for ATA 40, ATA 44 
and ATA 47. While the latter was demonstrated to have better tolerance towards 
substrate and products, it would have been useful to measure the protein content 
for each of these enzymes in order to understand if the difference in activity was 
anyhow related to a better expression of ω-TAm in ATA 47; 
x The same could have been done during the immobilization process, between the 
cycles. A protein quantification in the aqueous phase would have allowed 
understanding if the activity loss throughout the cycles were related with enzyme 
leaching or simply enzyme deactivation. 
x Also in the immobilization work, it would have been interesting to include 
covalent resins from other manufacturer in the study for better quality of this 
work. Another alternative that was not explored is the derivatization of the ionic 
exchange resins using glutaraldehyde. This would have allow covalent 
immobilization of the enzymes. 
x The co-immobilization of cascade enzymes (LDH and GDH) as well as the co-
factors was attempted, but never completed, remaining as an open challenge. 
x The screening methodology used to select resins for ISPR and ISSS, allowed a very 
quick selection a suitable resin. However, the addition of a step where further 
characterization of the selected resin were performed would have allowed a 
better understanding of the potential of this technology. For instance, isotherms 
could have been used to understand the adsorption/desorption kinetics. This 
would have been of great help during the process characterization step, where the 
lack of this information possibly resulted in the major adsorption of the substrates 
onto the hydrophobic resin. 
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x For reactions where fed-batch were approach were used, it is believed that further 
optimization of the substrate supply rate (matching this with the reaction rate for 
instance) would have resulted in a better performance of the system. 
x The experiments involving nitrogen sweeping could have been further optimized 
if the gas flow rate for instance have been investigated in order to find the most 
suitable for the scale used. 
x The results obtained using the ion exchange and the hydrophobic resin cannot be 
compared, considering that different biocatalysts and different reaction systems 
were used in each. The work successfully demonstrates the potential of each of 
these technologies and could have improved if all these technologies were 
implemented using both enzymes and both reaction systems. 
x The importance of selecting a suitable amine donor was made clear in this work. 
The results here obtained suggests the need for further investigation of the effect 
of each amine donor on inhibition.  
x Economic evaluation and scale up are very important part of the early stage 
process development. However, it was not possible to pursue any of these. The 
quality of this work would have been enhanced if the influence of each process 
strategy (tested in Chapter 6) on the economics would have been investigated.  
x Finally, the scale up of the most successful strategies (Fed-batch/ISPR/acetone 
removal for reactions using IPA and ISPR/cascade reactions for reaction using 
ALA) would have been useful to validate these strategies and further optimize 
them. 
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Figure 3A1: SDS-PAGE; S: Standard; 1: Total Protein; 2: Total Protein 10x Dilution; 3: Supernatant; 4: Supernatant 
10x Dilution 
Figure 3A2: MW Calibration Curve; Rf: Relative Mobility 
 
Figure 3A3: MW Calibration Curve in the desired range; Rf: Relative Mobility 
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Figure 3A4: Gel analysis of lane 1 
 
Figure 3A5: Gel analysis of lane 2 
 
Figure 3A6: Gel analysis of lane 3 
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Figure 3A7: Gel analysis of lane 4 
 
Figure 3A8: Gel analysis of lane 5 
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Table 3A1: Peak area analysis; MW: calibrated over whole range; MW cal: calibrated in desired range 
Lane Peak Rf Raw  Volume MW 
MW 
cal 
1. 1. 0.038 757 250 138 
1. 2. 0.085 887 150 119 
1. 3. 0.149 724 100 100 
1. 4. 0.225 2060 75 75 
1. 5. 0.359 2155 50 50 
1. 6. 0.466 985 37 37 
1. 7. 0.78 1331 25 14 
1. 8. 0.926 993 20 9 
1. 9. 0.979 695 15 7 
2. 1. 0.071 76 185 124 
2. 2. 0.143 172 108 99 
2. 3. 0.189 163 80 86 
2. 4. 0.23 309 63 76 
2. 5. 0.395 5830 34 45 
2. 6. 0.422 701 33 42 
2. 7. 0.509 975 29 32 
2. 8. 0.563 88 28 27 
2. 9. 0.619 271 27 23 
2. 10. 0.636 228 27 21 
2. 11. 0.664 170 27 20 
2. 12. 0.896 464 26 10 
2. 13. 0.916 326 26 9 
3. 1. 0.378 826 36 48 
3. 2. 0.505 114 29 32 
4. 1. 0.076 102 180 122 
4. 2. 0.142 236 109 100 
4. 3. 0.184 243 82 87 
4. 4. 0.226 386 65 77 
4. 5. 0.376 2205 36 48 
4. 6. 0.408 613 33 44 
4. 7. 0.502 743 29 33 
4. 8. 0.612 695 27 23 
4. 9. 0.886 240 26 10 
5. 1. 0.362 118 37 50 
5. 2. 0.493 54 30 33 
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Figure 3B1: Spectrum obtained by using a standard solution containing MBA, APB, APH and BA 
Different pH values were obtained by mixing the following mass of Boric acid (Mw: 61.83 
g.mol-1), Citric acid.H2O (Mw: 210.14 g.mol-1) and Na3PO4·12H2O (Mw: 380.13 g.mol-1) in 
water to a total volume of 50 mL: 
Table 3C1: Buffer composition 
 Volume of 
buffer 50 mL; 1M  
pH mBoric Acid [g] mCitric Acid [g] mNa3PO4 [g] 
2 2.4481 2.0801 0.1930 
3 2.3453 1.9927 0.9831 
4 2.2159 1.8828 1.9776 
5 2.0661 1.7555 3.1283 
6 1.9353 1.6443 4.1341 
7 1.7564 1.4924 5.5084 
8 1.6047 1.3635 6.6741 
9 1.4057 1.1944 8.2038 
10 1.1882 1.0096 9.8753 
11 1.0228 0.8690 11.1467 
12 0.4661 0.3961 15.4244 
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1/vo was plotted against 1/[S] according to the Lineweaver–Burk equation: 
ͳ
ݒ ൌ
ܭ݉
ܸ݉ܽݔ ൬
ͳ
ሾܣሿ൰ ൅
ͳ
ܸ݉ܽݔ 
Where the intercept with x-axis y(0) equals to െ ଵ௄௠ and the intercept with y-axis is equal 
to  
ଵ
௏௠௔௫  (using non-inhibitory concentrations – linear zone only) 
ATA 40: 
Table 3D1: Data for ATA 40 
APH (mM) 1/APH μmol/min.g 1/vo 
2 0.5 9.112254443 0.109742 
5 0.2 10.11412535 0.098872 
10 0.1 10.25724977 0.097492 
25 0.04 8.873713751 0.112692 
30 0.033333 7.394761459 0.135231 
Km = 0.34 mM, Vmax = 10.7 μmol/min.g                                   Figure 3D1: Lineweaver–Burk for ATA 40 
 
ATA 44 
Table 3D2: Data for ATA 44 
APH (mM) 1/APH μmol/min.g 1/vo 
0 1E+20 0 1E+20 
2 0.5 21.845 0.045777 
5 0.2 24.225 0.04128 
10 0.1 22.78 0.043898 
25 0.04 15.215 0.065725 
30 0.033333 12.495 0.080032 
Km = 0.39 mM, Vmax = 26.11 μmol/min.g                                   Figure 3D2: Lineweaver–Burk for ATA 44 
  
y = 0.0319x + 0.0935
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ATA 47 
Table 3D3: Data for ATA 47 
APH (mM) 1/APH μmol/min.g 1/vo 
0 1E+20 0 1E+20 
2 0.5 26.62412993 0.03756 
5 0.2 51.7099768 0.019339 
10 0.1 75.02088167 0.01333 
25 0.04 97.97679814 0.010206 
30 0.033333 105.0765661 0.009517 
Km = 7.99 mM, Vmax = 133.3 μmol/min.g                                   Figure 3D3: Lineweaver–Burk for ATA 47 
Table 3E1 – Enantiomeric excess for ATA 40, 44 and 47. 
 
 
 
 
 
Figure 3F1 – Solubility of APH in DMSO. Increasing concentration of APH was mixed with 
25 and 50% DMSO until formation of two a second was observed. 
y = 2.8004x + 38.605
R² = 0.9988
0
50
100
150
200
0 10 20 30 40 50 60
AP
H 
so
lu
bi
liz
ed
 (m
M
)
DMSO%
APH Solubility in DMSO
Data point
Linear (Data point)
 % ee 
MBA  
% ee  
APB 
[PEA]  
(g/L) 
Yield 
(%) 
ATA040 99.9 88.4 0.20 0.65 
ATA044 99.9 63.5 1.37 4.0 
ATA047 99.9 99.9 4.70 18 
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Table 4A1 – water content in pure and saturated organic solvents  
 % water Pure % water in saturated 
Toluene 0.0094 0.1602 
IPAc 0.0929 1.6869 
Cyclohexane 0.000 0.0137 
 
 
      
Figure 4A1 and 4A2 – Immobilization yield for S-TAm and R-TAm, respectively.  
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Table 4C-1-: Resins prices. Calculated from 5 and 10 Kg packages obtained from the supplier homepage 
(http://www.resindion.com) 
Structure and 
functional group 
Resin 
ID 
Resin 
name 
Cost 
(€/kg 
 
B-s Relizyme OD403/s 668 
B-m Relizyme OD403/m 576 
C-s Sepabeads EC-OD/s 549 
C-m Sepabeads EC-OD/m 474 
 
D-s Relizyme EP403/s 232 
D-m Relizyme EP403 /m 199 
E-s Sepabeads EC-EP /s 194 
E-m Sepabeads EC-EP/m 167 
 
F-s Relizyme HFA403 /s 722 
F-m Relizyme HFA403/m 625 
G-s Sepabeads EC-HFA/s 603 
G-m Sepabeads EC-HFA/m 522 
 
H-s Relizyme EA403/s 258 
H-m Relizyme EA403/m 221 
I-s Sepabeads EC-EA/s 215 
I-m Sepabeads EC-EA/m 183 
 
J-s Relizyme HA403/s 258 
J-m Relizyme HA403/m 221 
K-s Sepabeads EC-HA/s 215 
K-m Sepabeads EC-HA/s 183 
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Figure 6A1: Biocompatibility plotted against partition of MBA. The numbers between brackets are 
LogP values. 
   
 
Figure 6A2: Biocompatibility plotted against partition of APH.  The numbers between brackets are 
LogP values. 
Biocompatibility was measured by preparing about 40 mg WC (ATA 44, C-LEcta GmbH, 
Germany) in 750 μL of water and vigorously mix this with equal volume of different 
solvents for 1 hours and 30 °C. Afterwards cells were separated from solvent by mean of 
centrifugation (20 min at 10.000 rpm) at room temperature and the pellet were 
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resuspended in 500 μL buffer (pH 7) and tested for activity (1 M IPA, 5 mM APH, 2 mM 
PLP and 100 mM k-PBS pH 7). Results are based in initial rate measurements. 
The partition was measured by vigorously mixing 1 mL of 150 mM of MBA or APH 
prepared in 100 mM k-PBS pH 7 with equal volume of different solvent for 20 hours at 
30 °C. Samples were taken from the water phase and analysed by HPLC. 
 
Figure 5B1: Still of a continuous liquid-liquid separator.   
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Figure 6B2: Continuous liquid-liquid separator.   
 
 
Figure 6B2: Schematic overview of a potential liquid-liquid ISPR/ISSS.   
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Figure 6C1: Setup for process characterization featuring ACE removal and hydrophobic resins.  
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Figure 6D1: Reaction over time for scenario without cascade and ISPR (G), with cascade but 
without ISPR (H) and with cascade and ISPR (I). 
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